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"Does the body rule the mind or does the mind rule the body? 
 I dunno.” 
       -Morrissey 
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ABSTRACT 
 
   Nuclear receptors (NRs) are essential transcription factors that participate in a 
diverse number of cellular functions. Operating as sensors of both endogenous and 
exogenous ligands they are able to direct gene expression in both a positive and negative 
manner. Many NRs exhibit attractive chemotherapeutic potential due to their ability to 
govern key pathways of cellular differentiation, growth arrest and programmed cell 
death. Interestingly, there are numerous examples of NR signaling becoming disrupted in 
human malignancies including the prostate. Mechanisms that give rise to impaired 
receptor signalling are investigated herein; these include pre-receptor regulation of NR 
ligand availability and epigenetically mediated hypoacetylation of N-terminal histone 
tails. This work attempts to overcome or circumvent their transcriptional disruption and 
also unveils the molecular mechanisms behind NR transcriptional potency in prostate 
cancer.  
Prereceptor ligand metabolism has been previously demonstrated as an important 
factor in the regulation of nuclear receptor activity. During progression, CaP cells acquire 
the ability to upregulate the formation of AKR1C3, this enzyme may be responsible for 
conversion of prostaglandin intermediates. This study attempted to restore the actions of 
the anti-tumourigenic nuclear receptor PPARγ through reduction in the levels of 
AKR1C3. This may increase the levels of the ligand PGJ2 available for PPARγ activation. 
From these studies it was identified found that reducing the levels of AKR1C3 and co-
treatment with PGD2 and SAHA was unable to restore activation of this NR. This is in 
opposition to studies in leukaemic cells and suggests a distinct molecular mechanism of 
PPARγ activation by prostaglandins in human prostate cancer.  
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In additional studies, one member of the NR family was chosen for further 
analysis, namely the vitamin D receptor (VDR). This thesis consistent with previous 
investigations describes malignant metastatic PC-3 prostate tumour cell lines to be 
selectively insensitive to the biologically active form of vitamin D. Several of the genes 
regulated by VDR in immortalized non-transformed RWPE-1 cells become unresponsive 
when challenged with active vitamin D in the PC-3 malignant cell line. Furthermore, the 
disruption was also shown to be present in the isogenic RWPE-2 cell line suggesting NR 
deregulation is acquired prior to androgen deprivation therapy resistance (ADT-R).  
Nuclear receptor insensitivity is shown in Chapter 5 of this work with PC-3 and 
RWPE-2 cells selectively deregulating the VDR. In accordance with this finding studies 
of the VDR basal levels of expression in PC-3 cells become altered. Thus, levels of VDR 
expression are lost in correlation to its target genes and this reflects the ability of VDR to 
exert its anti-proliferative actions prostate cancer. 
Furthermore, the networks of gene targets within VDR signaling motifs also 
become skewed in prostate cancer. The incoherent feedforward response observed within 
VDR-MCM7 signalling contains a microRNA (MiR106b) whose activity was shown in 
this work to become disrupted in cancer. Not only does the proliferative MCM7 protein 
become upregulated but also the miR106b that targets CDKN1A transcript for 
degradation becomes upregulated. Therefore, the hypothesis proposed was that MiR106b 
is a proto-oncogene capable of indicating the VDR resistant/responsive status of CaP 
cases. To continue this work it was suggested that the serum analysis of human patients 
with various stages of prostate disease should be analysed and compared alongside 
control groups to determine a risk stratification profile for prostate cancer patients.  
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The vitamin D receptor and its target gene CDKN1A were then examined for 
recruitment of VDR, nuclear corepressor (NCOR1) and RNA p-polymerase II to response 
elements. Using the non-malignant prostate epithelial cell line RWPE-1, and PC-3 
prostate cancer cell line, to represent stages of prostate disease progression, the spatio-
temporal binding characteristics in response to ligand were measured. These findings 
identified aberrant nuclear corepressor recruitment to the transcription start site of 
CDKN1A in the malignant disease model cell line. Taken together, these investigations 
serve to enhance the understanding of nuclear receptor activity within prostate cancer 
with a particular focus on the VDR. 
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1.1 The Prostate  
1.1.1 Prostate Malignancy 
 The prostate forms part of the male reproductive system, and is situated beneath 
the bladder. Post-embryonic growth occurs principally during puberty and the organ 
develops to encapsulate the urethra. Activity of the prostate tissue is regulated through 
androgens such as testosterone, which also control its rate of proliferation. The prostate’s 
primary function is to regulate the semen, ensuring a suitable environment in which the 
sperm can survive.  
The first stage of prostate cancer (CaP) tumourigenesis is thought to be prostatic 
intraepithelial neoplasia (PIN) in luminal cells (Figure 1.1), occurring in either a low or 
high grade manner. Reviewed in Abate-Shen & Shen [1], high grade PIN has been shown 
to be a precursor of CaP with cells losing expression of important differentiation markers 
such as E-cadherin. Furthermore, development from PIN leads to loss of the basal lamina 
contributing to an invasive carcinoma that can escape the confines of the prostate capsule. 
However, a recent study has demonstrated that basal cells are also able to stimulate 
growth of benign prostate tissue [2]. This finding suggests that immunohistochemical 
studies of prostate cancers can be misleading, thus emphasizing the importance that 
molecular studies are conducted in parallel when investigating cell origins. 
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Figure	  1.1	  Progression	  of	  human	  prostate	  cancer	  (CaP).	  The	  multistage	  process	  of	   cancer	   begins	   with	   an	   abnormal	   proliferation	   of	   luminal	   cells	   disrupting	   the	  regular	  structure	  of	  the	  epithelium.	  This	  develops	  and	  obtains	  invasive	  qualities	  that	  lead	  to	  further	  malignant	  characteristics	  like	  metastasis	  and	  angiogeneisis.	  Adapted	  from	  Abate-­‐Shen	  and	  Shen	  [1].	  
1.1.2 Epidemiology of prostate cancer 
 CaP is one of the most common forms of malignancy in men in the Western 
world. Currently, there are approximately 200,000 new cases and it is responsible for the 
deaths of 30,000 men in the USA every year [3]. The United Kingdom has a similarly 
proportional rate with CaP being the second most common cause of cancer death in males 
[4]. Therefore, substantial resources are aimed at treating this hormonally initiated 
disease. Contributing factors are numerous, with ethnicity, diet, lifestyle and genetic 
background all having high influence in development of the disease [5]. There are also 
significant geographical differences observed in the level of CaP incidence. For example 
South East Asia has a far lower incidence, but when individuals migrate to Western 
Europe and the USA their incidence increases [6]. Therefore, it is probable that there is 
interplay of all of these different factors that interact with contributing genetic 
components. 
The evidence that dietary interactions can provide a protective relationship against 
CaP (such as various fruit and vegetable consumption) is compelling and detailed by 
Mills et al 1989 [7]. In this cohort study of 14,000 Seventh-day Adventist men (this 
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group have a history of low CaP occurrence and live on a strict vegetarian diet) it was 
found that in particular vegetables and dried fruit were cancer protective. However, the 
impact of such dietary factors will depend also upon the individual’s hormone and 
metabolic enzyme levels, and their intake of compounds such as the heterocyclic amines. 
As the majority of people in the Western hemisphere have an omnivorous diet the actions 
of heterocyclic amines cannot be ignored. These have a strong association with both 
genotoxic and non-genotoxic effects [8]. Accordingly, levels of CaP show correlation 
with geographical areas where red meats are a major component of the diet [9]. 
Conversely, countries such as Japan with a high intake of fish and lower intake of red 
meat have a lower incidence rate of CaP [9]. However this finding may be more 
reflective of the anti-tumour effects of either ω−3 fatty acids or vitamin D that are present 
at high levels in fish [10, 11].  
The prostate is highly responsive to hormonal signals and CaP development is 
hormonally driven. Physiological androgens such as testosterone increase the growth rate 
of cells, and the prostate is highly efficient at converting hormonal precursors into active 
testosterone and dihydrotestosterone by 5-α reductase type II. These are then able to bind 
to the androgen receptor (AR) and activate a battery of pro-growth target genes 
associated with an increased rate of cell division. Concordant with this, androgen ablation 
results in 80% of patients showing partial or complete response [12]. However, remission 
only lasts approximately 12 to 18 months before tumours then become Androgen 
Deprivation Therapy-Recurrent (ADT-R) [13].  
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Therefore, despite the impressive initial response rate to androgen deprivation and 
sustained prostate specific antigen (PSA) monitoring there is need for improvement. This 
is particularly vital when considering the success of long term treatment as the 10 year 
survival rate of prostate cancer is currently 60% in England [14]. 
The full extent and interaction between each of these factors remains largely 
unknown and so are subject to constant research efforts. For example, emerging large-
scale prospective epidemiological studies such as the EPIC (European Prospective 
Investigation into Cancer) in the EU [15] will evaluate which of these interactions are 
important. Going forward it is likely that these findings will be integrated with Genome 
Wide Association studies (GWAs) [16] to illuminate true cancer risk factors. 
 
1.1.3 Vitamin D in Prostate Cancer 
 The inverse proportionality between skin cancer and prostate cancer was revealed 
with the collection, unification and comparison of worldwide cancer statistics in the 
1970s. Only then was it discovered that the incidence of CaP in Caucasian populations 
throughout Europe and the United States increased with geographical latitude [17, 18]. In 
addition, it was also found that development of skin cancer was associated with a 
significantly decreased likelihood of CaP occurrence [19, 20]. The evidence therefore 
suggested that exposure to UV sunlight produced a protective response, delaying the 
transformation of cells in the prostate. Therefore, it was hypothesised that a UV mediated 
effect influenced growth decisions made by the prostate, slowing or preventing prostate 
cancer initiation or progression.  
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The biologically active isoform of vitamin D (1α,25(OH)2D3) is formed in the 
presence of UV sunlight and therefore it became heavily correlated with cancer protective 
processes [21]. This original finding was linked with colon cancer but statistics for CaP 
showed a similar level of significance, and therefore 1α,25(OH)2D3 activity was for the 
first time linked to prostate anti-cancer response. This was further supported with the 
identification that an increase of 25nmol/lit in plasma 25,(OH)D3 levels resulted in a 29% 
reduction in colon cancer related deaths and a 17% decrease in the number of cases [22]. 
   
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  1.2	  Formation	  of	  vitamin	  D.	  7-­dehydrocholesterol	  is	  converted	  to	  pre-­
vitamin	   D3	   in	   response	   to	   sunlight.	   Vitamin	   D3	   binds	   to	   vitamin	   D-­‐binding	  protein	   (DBP)	   in	   the	   bloodstream,	   and	   is	   transported	   to	   the	   liver.	   This	   is	   then	  hyroxylated	  by	  25-­‐hydroxylase	  producing	  25-­‐hydroxycholecalciferol.	  Upon	  reaching	  the	   kidney	   25(OH)D3	   is	   1α-­‐hydroxylated	   1α,25(OH)2D3.	   The	   rate	   of	   synthesis	   is	  positively	   regulated	   by	   parathyroid	   hormone	   levels	   and	   negativley	   regulated	   by	  Ca2+,	   Pi	   and	   	   1α,25(OH)2D3.	   The	   main	   effects	   of	   vitamin	   D	   upon	   the	   main	   target	  tissues	  are	  depicted.	  Adapted	  from	  Deeb	  et	  al	  [23].	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 The human body is unable to synthesize the precursor form of vitamin D 
(25(OH)2D3) and relies on the dietary intake of vitamin D, obtained from foods such as 
dairy products and fish (Figure 1.2). These are high in 7-dehydrocholesterol, the pro-
vitamin whose conversion to 25(OH)2D3 (pre-vitamin D3) occurs in epidermal cells upon 
exposure to UV B radiation. This provides enough energy to cleave the 9-10 bond in the 
B ring of the circulating 7-dehydrocholesterol to produce 25(OH)2D3 which is then 
isomerized to yield the physiologically active 1α,25(OH)2D3 [24].  
Conversion and metabolism of the various forms of vitamin D occurs through the 
action of the cytochrome P450 superfamily of haem-containing mono-oxygenases. 
CYP24A1 encodes the main metabolic enzyme responsible for the hydroxylation of 
1α,25(OH)2D3 to a biologically less active molecule [25]. Over the past 30 years research 
has investigated the risks of 1α,25(OH)2D3 deficiency and its relationship with  disease 
including malignancy of the prostate [26, 27]. 
 
1.2 Cell and animal models of the prostate  
1.2.1 Non-malignant prostate cell lines 
To understand the processes in the development of CaP, cell line models are used 
to represent specific stages of tumourigenesis. Human cells are a highly desirable model 
with which to study cancer as extrapolation towards in vivo conditions is more 
comparable. All human cancer cell lines used for in vitro work have become 
immortalized during disease progression. However, models of normal epithelial cells are 
not transformed and therefore require transfection with viral genetic components able to 
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overcome normal senescence. This gives a robust and maintainable source of cells that 
retain the properties of non-malignant cells.  
The RWPE-1 cell line was selected for this study as a model of the normal non-
malignant prostate epithelium. These cells originated from the prostate of a Caucasian 
male without CaP undergoing cystoprostatectomy. Immortalisation of the extracted cells 
was conducted by introduction of a psHPV-18 m plasmid containing the complete HPV-
18 gene. Transfection with this gene has been demonstrated in other cell lines and leads 
to retention of characteristics of growth and differentiation control [28, 29]. RWPE-1 
cells have been shown to have an epithelial morphology with functional PSA and AR 
status, and stain positively for p53 [30]. Specifically, these cells are androgen responsive 
and cultured in the presence of the epidermal growth factor (EGF). The RWPE-1 cells are 
thought to be a luminal-basal intermediate of the prostate that are partially differentiated. 
They express prostatic cytokeratins 8 and 18 and are not invasive so unable to form 
tumours when injected in nude mice. These data further supports their use as a suitable 
and reproducible model of non-malignant prostate epithelial cells. 
1.2.2 Prostate cancer cell lines 
The use of isogenic cell lines within comparative studies is often a way of 
controlling biological and experimental variation. Analysis of cell lines with the same 
genetic background may reduce inherent differences between cells derived from different 
individuals. To address this, transformed isogenic cell lines of RWPE-1, called RWPE-2 
were also used in the current study. RWPE-2 cells contain the same HPV 18 adenovirus 
transfection as the RWPE-1 cells. Additionally they have v-Ki-RAS introduced, which 
activates production of the v-Ki-RAS oncogene, that found to be mutated in 25% of 
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human CaP [31]. As a result RWPE-2 cells are able to manifest tumour growth when 
injected in nude mice and show a moderate invasive profile in vitro [30]. Therefore, the 
RWPE-2 cell lines represent human CaP at an early stage of transformation. 
More aggressive CaP cell lines such as PC-3, DU 145 and LNCaP were derived 
from different primary tumours [32]. PC-3 cells were derived from a prostatic lumbar 
vertebra metastasis [33], and are classed as poorly differentiated prostate 
adenocarcinoma. Upon analysis they were found to express elevated levels of the 
proliferative protein EGF-R [34]. PC-3 cells represent advanced grade CaP that is ADT-
R, a classification which makes them similar to DU 145 cells. These cells were derived 
from a metastatic tumour in the central nervous system of a 69-year-old Caucasian male 
[35]. LNCaP cells were derived from the lymph node metastasis of a 50-year-old 
Caucasian male. They are moderately differentiated and represent metastasis with a lower 
proliferative rate than that of PC-3 or DU 145 cells. As with PC-3 and DU 145 cells they 
are able to form tumours when injected into nude mice, but LNCaP cells retain some 
degree of androgen responsiveness [36]. Also similar to the RWPE-1 cells, LNCaP cells 
have an isogenic variant that is used to assess the acquisition of ADT-R phenotype. The 
LNCaP C4-2 cells were produced by co-injection of LNCaP and human bone 
osteosarcoma cell line MS into castrated nude mice. This produced development of the 
ADT-R sub-line of cells capable of forming tumours [37]. Characterisation of the 
tumours confirmed they were able to induce angiogenesis and vascularisation. Together, 
these cell lines provide key investigational models for spectrum of cancer states.   
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1.2.3 TRAMP mouse as a prostate cancer model 
This work utilizes the TRansgeneic Adenocarcinoma of the Mouse Prostate 
(TRAMP) murine model. The TRAMP mouse was produced with a prostate epithelium 
specific transgene SV40 (linked with the probasin promoter) [38]. This gene is induced in 
the adolescent animal under the control of the AR receptor producing a progressive form 
of prostate neoplasia recapitulating human disease. TRAMP mice exhibit mild 
hyperplasia by 10 weeks and invasive adenocarcinoma at approximately 18 weeks. As 
the development of the tumour is dependent upon physiological androgens, castration of 
the mice at 12 weeks of age is partially curative with a success rate of 20% (the 
remaining 80% develop an ADT-R CaP). Among the advantages of the TRAMP model, 
there is 100% incidence of CaP and the histologic analysis of progression from PIN to 
invasive carcinoma is reflective of the human form of disease. Shown in Figure 1.3 is a 
time line illustration of the TRAMP model stages of progression. 
  
 
 
 
 
	  
	  
	  
Figure	  1.3	  Illustration	  of	  the	  TRAMP	  murine	  model	  development.	  The	  probasin	  gene	  begins	  expression	  between	  4	  and	  6	  weeks	  of	  age,	  leading	  to	  hyperplasia	  by	  12	  weeks	   and	   poorly	   differentiated	   adenocarcinoma	   by	   24	   weeks.	   All	   TRAMP	   mice	  develop	  CaP.	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1.3 Nuclear Receptor (NR) functions 
1.3.1 Nuclear receptor structure and function  
There are 48 different types of nuclear receptors making them the largest family 
of transcription factors in humans [39]. NR superfamily members include the steroid 
hormone receptors (thyroid hormone receptor (TR), oestrogen receptor (ER) and 
glucocorticoid receptor (GR)) and the non-steroidal binding NRs such as the retinoic acid 
receptor (RAR) and the vitamin D receptor (VDR). As with other transcription factors, 
NRs have various functional domains encoded into their genomic sequences. Each of 
these regions is responsible for encoding a motif that exerts a specified molecular action, 
such as precise DNA binding, ligand binding recognition and cofactor interactions 
(Figure 1.4).  
NRs bind to DNA as homodimers or heterodimers, with other members of the 
nuclear receptor family (for example VDR and RARs bind with RXR (Retinoid X 
Receptor to form a heterodimer [40])). Therefore, NR target gene specificity arises in part 
from the ability to recognise specific nucleotide sequences within promoter and enhancer 
regions. Using their ability to select these sites of binding, each NR activates and 
represses cohorts of genes. This allows regulation of essential biological responses 
including reactions to intrinsic hormonal signals (such as oestrogen and testosterone) and 
extrinsic stimuli such as dietary derived vitamin D, retinoic acid and xenobiotics. Thus, 
NRs have combined roles of both receptors, in their ability to detect and respond to 
ligand, and transcription factors in their gene regulatory effects. 
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Figure	   1.4	   Basic	   NR	   structure	   and	   DNA	   binding.	   A)	   All	   NRs	   contain	   a	  ligand/hormone	  binding	  domain	  (LBD)	  and	  a	  DNA	  binding	  domain	  (DBD).	  The	  LBD	  contains	   helical	   motifs	   that	   undergo	   conformational	   change	   in	   the	   presence	   of	  ligand.	  The	  DBD	  contains	  two	  zinc	  finger	  motifs	  whose	  sequence	  varies	  dependent	  upon	  the	  NR.	  This	  helps	   to	  dictate	  binding	  sequence	  specificty.	  B)	  NRs	  bind	  to	   the	  DNA	  as	  a	  dimer.	  This	  example	  shows	  a	  response	  element	  containing	  two	  AGGTCA	  in	  a	  direct	  repeat	  separated	  by	  a	  spacer	  sequence.	  Taken	  from	  Privalsky	  [41].	  
 
However, the response of each NR is integrated within multiple networks of 
signalling pathways. Thus, important cellular processes including the cell cycle and 
inflammation are governed through networks that integrate signals to mediate NR 
activity. Therefore, the crosstalk with other pathways produces a highly intricate level of 
control over their transcriptional targets. Examples are shown in Figure 1.5 whereby 
multiple growth factors using transition of phosphoryl groups as a means of transmitting 
signals and can phosphorylate the ligand binding domain (LBD) of retinoic acid receptor 
(RAR) [42]. This alters the activation potential of the NR increasing its likelihood of 
association with the core co-integrator CBP/P300 and subsequently the transcriptional 
machinery complexes leading to gene activation.  Additional to these signals ubiquitin 
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protein groups can be added to the NRs and their bound components. These are recycling 
flags that mark proteins for degradation by large proteosomal complexes. Thus, marking 
the various cofactors of NR mediated transcription with ubiquitin groups leads to their 
removal and subsequent breakdown.  
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
Figure	  1.5	  Signalling	  pathways	  provide	  a	  network	  of	  feedback	  influencing	  NR	  
mediated	   transcription	   of	   target	   genes.	   Fluctuation	   in	   the	   NRs	   transcriptional	  output	   is	  produced	  by	  numerous	   signal	   transduction	  pathways,	  G-­‐Protein	   coupled	  receptors	  (GPCRs),	  and	  growth	  factors.	  These	  signals	  occur	  in	  a	  cell	  cycle	  dependent	  nature	   to	   temporaly	   influence	   the	   proliferative	   rate.	   The	   Retinoic	   acid	   receptor	  (RAR)	  Retinoid	  X	   receptor	   (RXR)	  heterodimer	   is	   shown	  here	  as	  an	  example	  of	  NR	  functioning.	  Coregulator	  proteins	  such	  as	  NCOR1,	  NCOR2/SMRT	  and	  the	  CBP/P300	  complexes	  are	  shown.	  These	  bind	  to	  the	  NR	  mediating	  recruitment	  of	  activation	  or	  repressive	   complexes.	   Addition	   of	   phosphorylation	   marks	   to	   proteins	   that	   are	  involved	  in	  NR	  target	  gene	  transcription	  alters	  their	  activity.	  Placement	  of	  ubiquitin	  marks	   upon	   proteins	   flags	   them	   for	   removal	   and	   breakdown	   by	   the	   proteosome.	  Taken	  from	  [43].	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Therefore, the NRs utilise a wide number of cellular inputs to carry out their 
sigalling potency. Furthermore, there are additional protein complexes within the nucleus 
that modify their functioning. These provide an important element of flexibility into their 
response allowing increasingly complex transcriptional outputs.   
Essential to their regulatory activity, the NRs rely upon the presence of supporting 
proteins collectively named coregulators. These coregulators mediate the transcriptional 
activation or repression of target genes produced in the presence of NR ligand. This leads 
to the central dogma behind NR gene regulation; ligand binding induces conformational 
change lowering NR affinity for corepressors (CoRs). This has the effect of promoting 
NR binding of coactivators (CoAs). Release of the CoR from the DNA bound NR 
induces the recruitment of a number of different CoAs.  
Many CoA proteins exist in large multi-protein complexes with distinct activity. 
For example; histone tail modifying enzymes that modify the surrounding chromatin, 
placing post-translational modifications (PTMs) such as methylation and acetylation 
marks on histone amino acid residues. ATP dependent chromatin remodeling machinery: 
as the name indicates these require ATP for their activity and are responsible for the 
dismantling and repositioning of the nucleosome subunits. Mediator complex, this acts as 
a bridge attached to the activator complexes and recruiting the transcriptional machinery 
to the gene. Additionally, there are numerous other proteins found in the CoA complexes 
with roles that are as yet undefined. However, it is suggested these may be concerned 
with the placement, reading, and removal of PTMs to the histone tails.   
CoRs act in opposition to CoA and repress transcription genes. The two major 
CoRs that bind to NRs were identified as the silencing mediator of retinoic acid and 
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thyroid hormone receptor (NCOR2/SMRT) and nuclear corepressor (NCOR1) proteins 
[44]. These are very similar in structure and contain an N-terminal section with various 
repression domains and a C-terminus that allows NR interaction of the CoRs (Figure 1.6). 
Individual knockout murine models of NCOR1 [45]	   and NCOR2/SMRT [46] show 
embryonic lethality at different timepoints. This suggests they have distinct and essential 
roles in development that cannot be replaced. Therefore, although the two corepressors 
are shown to have some functional redundancy they also have some highly specific roles. 
In accordance with this certain NRs exert a preference for either NCOR1 or 
NCOR2/SMRT.  
 
  
 
 
 
 
 
	  
	  
	  
	  
	  
	  
Figure	   1.6	   The	   two	   main	   corepressors	   of	   NR	   activity	   (NCOR2/SMRT	   and	  
NCOR1).	   The	   splice	   variants	   of	   the	   two	   CoRs	   are	   shown	   containing	   truncationed	  isoforms.	   These	   CoRs	   contain	   repressive	   and	   receptor	   interacting	   regions.	   The	   C-­‐terminal	   domain	   binds	   to	   NR	   and	   the	   N-­‐terminal	   contains	   various	   repression	  domains	   responsible	   for	   recruiting	   chromatin	   remodelling	   machinery.	   Thus	   the	  CoRs	  act	  as	  a	  platform,	  attaching	   to	  NRs	  and	  mediating	  epigenetic	  modifcations	   in	  the	  local	  chromatin	  environment.	  Taken	  from	  Privalsky	  [41].	  
 
Chapter 1    General Introduction 
 
 
31 
For example RARs bind with NCOR2/SMRT in preference to NCOR1, and TR 
recruits NCOR1 in preference to NCOR2/SMRT [47, 48] (a dependency that may relate 
to the lethality of murine knockouts as RARs are indispensable for embryonic 
development). The repression domains contained in the CoRs enforce suppression of a 
genes activity. This is produced by histone modifying enzymes bound to the CoRs such 
as the histone deacetylase 3 (HDAC3) [49]. NCOR1, NCOR2/SMRT have been 
demonstrated to bind allosterically to HDAC3 and few if any, other HDAC members 
[50]. This suggests the HDAC3 enzyme is integral for the biological effect of NCOR1 
and NCOR2/SMRT upon NR mediated transcription. The relationship that CoAs and 
CoRs have with NRs makes them key regulators of biological pathways.  
1.3.2 Key NRs within the prostate 
• Androgen Receptor (AR) 
The AR is centrally linked with prostatic tumourigenesis, reviewed in [51].  
Endogenous AR ligands are all cholesterol-derived steroids. It has been demonstrated that 
the biosynthesis pathways responsible for steroidogenesis are upregulated in CaP tissues 
[52]. It is the availability of androgens that drive the activity of the AR target genes. 
These in turn act to stimulate the proliferative pathways such as AKT and cMYC [53]. 
Therefore, the main therapeutic intervention has been to block the ARs activity by 
minimising the concentration of ligand to interact with or blocking the receptors from 
binding DNA. Late stage CaP cells are able to alter their requirements for proliferation, 
becoming self sufficient in growth signals. This results in the AR becoming constitutively 
active in the absence of ligand [54].  
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• Peroxisome Proliferator Activated Receptor-γ  (PPARγ) 
PPARγ has been associated with many anti-tumourigenic actions [55-57]. In 
particular it has been demonstrated to have pro-differentiating [58] and anti-proliferative 
[59] responses in murine and human prostate cancer cell lines. In conflict with this, the 
anti-cancer potential of PPARγ is confounded by publications detailing pro-tumourgenic 
properties of activation and overexpression in some cancers [60, 61]. However, strong 
evidence remains for therapy using PPARγ targeting, such as xenograft models of colon 
cancer in rodents decreasing in cancer development to troglitazone treatment [62]. The 
agonist Troglitazone is able to reduce the occurrence of colitus [63], an inflammatory 
condition associated with colon cancer in many mammals including humans. 
 In parallel with these observations, many PPARγ target genes are linked with cell 
cycle arrest and inhibition of the E2F transcription factor [64]. PPARγ stimulation also 
decreases the phosphorylation status of retinoblastoma (Rb), limiting cell cycle 
progression. Additionally, PPARγ increases the expression of cyclin dependent kinase 
inhibitors like p21(waf/cip) [65], inducing a G1 growth arrest and suggesting NRs have 
important anti-tumourgenic actions.  
• Retinoic Acid Receptors (RARs) 
Retinoic acids are signaling molecules that are have been demonstrated to be 
essential for embryonic development and cellular differentiation (Reviewed in [66]).  
Of the three isoforms of RAR (α, β and γ) RARβ has been shown in previous 
studies to inhibit the growth of prostate cancer when used in combination with 
1α,25(OH)2D3 [67, 68]. Co-treatment of 9cRA with 1α,25(OH)2D3 induced cell cycle 
arrest in LNCaP cells through the altered expression of p21(waf1/cip1)and p27(kip1) [69]. A 
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further study was also conducted in CaP using PC-3 cells. This revealed that 
combinatorial treatment of 9cRA and 1α,25(OH)2D3 is able to reduced the growth of 
cells in culture and when injected into nude mice [70]. Therefore, targeting of the retinoic 
acid receptors is emerging as an efficient anticancer strategy.  	    
• Vitamin D Receptor (VDR) 
The VDR was first cloned in humans in 1988 [71]. Located on chromosome 12, it 
is composed of 11 exons that encode the functional protein. The translated protein 
contains various elements permitting hormone binding and DNA binding activity 
(reviewed by [72]). The VDR recognises and binds to VDRE’s within the genome. These 
are usually two hexonucleotides that are repeats and spaced by a varying number of base 
pairs. Occupation of the response element by the heterodimer requires VDR to attach to 
the 5’ and RXR on the 3’ end. Though it must be stated that the composition and binding 
ability of the response elements varies greatly.  
        Amongst many VDR targets is the CDKN1A gene, which encodes the p21(waf1/cip1) 
protein. p21(waf1/cip1)  is a member of the Cip family of proteins and plays a key regulatory 
role in the control of the cell cycle by activating the G1 phase block. The role of 
p21(waf1/cip1) as a potent tumour suppressor gene is not only linked to the p53 protein. The 
effects of p21(waf1/cip1) have been demonstrated to activate numerous anti-proliferative and 
pro-differentiation pathways independently of p53 [73-76].  
 p21(waf1/cip1) exerts its action via the binding and inhibition of the cyclin dependent 
kinases CDKs (Figure 1.7), and blocks the cell cycle progression. In addition, p21(waf1/cip1) 
inhibits the PCNA dependent DNA polymerase responsible for DNA replication required 
during S-phase. Inactivation of the CDKs by p21(waf1/cip1) occurs by prevention of its 
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phosphorylation activity. A motif contained within the protein permits the binding of 
CDK subunits, deregulating the interaction between CDK and its substrate CDK-cyclin.  
 
 
 
 
 
 
 
 
 
	  
	  
	  
	  
Figure	   1.7	   The	   role	   of	   p21(waf1/cip1)	   in	   cell	   growth	   regulation.	   	   Specific	   stimuli	  (DNA	  damage,	   oxidative	   stress	   etc…)	   are	   able	   to	   induce	   the	   activation	   of	  CDKN1A	  gene	  transcription	  and	  translation	  into	  protein.	  The	  primary	  role	  is	  in	  the	  inhibition	  of	  the	  cyclin	  dependent	  kinases	  (CDKs)	  and	  inhibiton	  of	  the	  proliferating	  cell	  nuclear	  antigen	  (PCNA).	  Some	  of	  the	  anti-­‐proliferative	  actions	  of	  p21	  are	  mediated	  through	  its	   protein-­‐protein	   interactions	   and	   its	   effect	   on	   transcriptional	   activity	   are	  generally	   inhibitory.	  Both	  of	   these	   factors	   are	   required	   to	  be	   active	   for	   the	   cell	   to	  commence	  S	  Phase	  replication.	  Thus	  by	  their	  inhibiton	  CDKN1A	  exibits	  a	  G1	  Phase	  arrest	  upon	  activation.	  Taken	  from	  Abbas	  and	  Dutta	  [77].	  	  
 
This mechanism generates considerable potential for p21(waf1/cip1) to inhibit tumour 
growth and inflict significant anti-proliferative, apoptotic damage. However, in addition 
to these effects there are also emerging data suggesting p21(waf1/cip1) holds anti-apoptotic 
actions. For instance, p21(waf1/cip1) has been shown to inhibit the CDKs in response to 
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ionising radiation, resulting in a reduced level of apoptosis in cell populations [78]. In 
addition there are several additional pathways that support the anti-apoptotic response of 
p21(waf1/cip1). These include the binding of p21(waf1/cip1) to the apoptotic proteins pro-
caspase 3 [79], caspase 8 and 10 [80] inhibiting their activity. Therefore, whilst the 
consequences of p21(waf1/cip1) activation are largely anti-tumourigenic, there are pro-
survival pathways that require p21(waf1/cip1) for their activity.  
1.4 Disruption of NR signalling 
1.4.1 Altered CoR activity restricts transcription 
 
In accordance with these findings new technology has enhanced our 
understanding of NR actions. Genome wide ChIP-ChiP and ChIP-Seq assays have shown 
there to be a variety of NR responses [81, 82]. The distortion of the ARs transcriptome 
has been shown to occur in prostate malignancy with an enhanced transcription of 
proliferative target genes and downregulation of anti-proliferative genes [83]. An 
example of which is the TMPRSS2/ETS fusion gene becoming constitutively active by 
distorted AR signalling in CaP [84]. The restoration of homeostatic NR activity has 
become an important therapeutic target. Therefore, restoration of appropriate NR 
signalling within malignancy may produce growth restrictive outcomes slowing or 
halting disease progression. 
Current research suggests the abilities of NRs become ‘selectively filtered’ in 
malignancy. Transcriptional programs are skewed toward pro-growth target genes and 
downregulation of growth inhibition genes.  
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Furthermore, CoRs have been heavily implicated in many human cancers such as 
leukaemias (reviewed in [85]). Mechanistic examples of CoR dysfunction in disease 
include genetic translocations producing a fusion protein that results in aberrant NCOR1 
and NCOR2/SMRT binding. 	  	  	  	  	  	  	  	  	  
Figure	  1.8	  CoR	  deregulation	  through	  PML/RAR	  fusion	  protein	  in	  APL.	  In	  acute	  promyelocytic	  leukaemia	  (APL)	  the	  PML/RaR	  fusion	  protein	  binds	  to	  CoRs	  which	  in	  turn	   recruit	   HDACs.	   The	   PML/RAR	   then	   recruits	   chromatin	  modifiers	   such	   as	   the	  DNA	   methyltransferases	   DNMT1	   and	   DNMT3.	   The	   resulting	   modified	   chromatin	  then	  acts	  as	  a	  binding	  site	  for	  acessory	  componants	  that	  are	  able	  to	  bind	  methylated	  DNA	   including	   MBD1.	   In	   addition	   the	   methylated	   histones	   are	   bound	   by	   the	  heterochromatin	   associated	   protein	   1	   (AP1)	   ‘compacting’	   the	   histones	  conformation.	   Consequently,	   pro-­‐differentiation	   genes	   are	   deactivated	   ehancing	  proliferation	  of	  the	  leukaemia.	  Taken	  from	  Pelicci	  et	  al	  [86].	  
 
A common illustration is the PML/RARα	   fusion	   protein.	   Acute	   promyeloid	  leukaemia	   (APL)	   is	   a	   subtype	  of	   acute	  myelogenous	   leukaemia	   (AML).	   It	   develops	  when	  the	  RARα	  gene	   found	  on	  chromosome	  17	  becomes	  reciprocally	   translocated	  to	   the	  promyelocytic	   gene	   (PML)	   located	  on	   chromosome	  15	   resulting	   in	   a	   fusion	  gene	  and	  protein	  [87].	  This	  fusion	  is	  remarkably	  consistent	  in	  the	  manifestation	  of	  disease	  with	  97%	  of	  APL	  patients	   [88].	   The	   oncogeneic	   actions	   of	   the	  PML/RARα	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fusion	   protein	   have	   been	  widely	   studied	   and	   its	  mode	   of	   action	   is	   in	   part	   due	   to	  PMLs	  dimerisation	  domain.	  This	  is	  potent	  and	  induces	  the	  formation	  of	  very	  stable	  heterodimers.	   Heterodimers	   of	   PML/RARα	   are	   able	   to	   recruit	   and	   maintain	   the	  stablisation	  of	  CoR	  complexes	  (Figure	  1.8).	  This	  has	  the	  effect	  of	  silencing	  the	  anti-­‐proliferative	  and	  pro-­‐differentiation	   target	  genes	  of	  RARα	   [89].	  However,	  APL	  can	  now	  be	  effectively	  treated	  by	  combining	  chemotherapy	  with	  All	  Trans-­‐Retanoic	  Acid	  (ATRA)	  treatment	  and	  is	  a	  success	  story	  of	  modern	  medicine.	  Therapeutic	  doses	  of	  ATRA	  are	  able	  to	  bind	  the	  PML/RARα	   fusion	  proteins	   ligand-­‐binding	  domain.	  This	  induces	   the	   release	   of	   corepressor	   complexes	   that	   have	   been	   inappropriately	  recruited	   and	   stabilized.	   This	   beneficial	   effect	   is	   improved	   further	  with	   additional	  HDAC	  inhibitor	  treatment.	  	  
1.4.2 Epigenetic regulation and deregulation of NR transcription. 
In addition to these actions the DNA itself can be methylated. DNA methylation 
occurs on cytosine bases of CpG dinucleotides. Placement of methyl groups is conducted 
by one of three DNA methyltransferases (DNMTs) that are essential for embryonic 
development (reviewed by [90]). Methylation of the DNA remains one of the major 
mechanisms the cell uses to induce inheritable transcriptional silencing of genes. The 
best-known example of which is X-chromosome inactivation, used to give long term 
silencing of one copy of the X- chromosome in females.    
The ability of chromatin to modulate changes in gene transcription is also 
mediated through DNA methylation of local CpG islands. Previous studies have shown 
that unmethylated DNA is wrapped around nucleosomes that were found to have largely 
acetylated histone tails [91, 92]. In conjunction with these findings, methylation levels of 
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DNA correlate with nucleosomes containing non-acetylated histone tails and more 
compact chromatin conformation [93]. The consequences of DNA methylation have also 
been observed upon specific histone modifications as well as general overall changes. For 
example methylation of DNA has been shown to produce H3K9 methylation, responsible 
for gene silencing and inhibition of H3K4 methylation [94]. Genes silenced by DNA-
methylation can also be re-expressed with the application of de-methylating compounds 
such as 5-azacytidine and 5-aza-2’-deoxycytodine. These have been shown to have 
clinically relevant effects at low doses and they are now being used as treatments for 
leukaemia [95].  
 The histone code hypothesis suggests that gene regulatory process extend to the 
post-translational modifications (PTMs) placed upon the histone amino acid subunits. It 
is thought these influence transcription of genes recruiting downstream ‘reader’ and 
‘effector’ proteins [96]. One of the most commonly investigated PTMs thought to 
regulate transcription is the histone 3 lysine 4 (H3K4) methylation mark. This residue is 
able to be mono, di or tri methylated [97]. Furthermore, the presence of these 
modifications in the promoter of a gene impacts upon likelihood of the genes expression. 
As mentioned H3K4me3 is strongly linked with actively transcribed genes. In addition it 
is enriched at the Transcription Start Site (TSS) of active genes in comparison to 
surrounding regions. Methylation of specific histone amino acid subunits has been also 
observed to occur in correlation with the methylation of DNA. Addition of tri-
methylation marks to histone 3 lysine 4 (H3K4) is associated with active genes and has 
been shown to be present at CpG poor promoters only when the gene is transcribed [98]. 
However, areas high with CpG’s are constitutively methylated at H3K4 regardless of the 
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transcriptional activity of the gene [99]. This demonstrates that the features contained 
within the DNA are able to establish an epigenetic state. This then directly influences the 
accessibility of transcription factors and machinery to the DNA. Furthermore, in the 
absence (or low levels) of CpG sequences the cells use histone modifications to influence 
gene activity.  
 DNA methylation is central to epigenetic control of gene expression in cancer and 
CpG methylation has been used as a marker of both disease predisposition [100] and 
progression [101].  
 
 
 
 
 
 
Figure	  1.9	  Epigenetic	  corruption	  of	  gene	  expression.	  A)	  Gene	  X	  has	  low	  levels	  of	  DNA	   methylation	   (brown	   circles)	   and	   is	   transcriptionally	   active.	   It	   has	   an	   open	  chromatin	   conformation,	   accordingly,	   many	   transcriptional	   complexes	   are	   bound	  (green	   circles).	   H3K9	   acetylation	   and	   H3K4	   methylation	   marks	   are	   also	   present.	  	  Gene	  Y	  is	   inactive,	  and	  contains	  high	  CpG	  methylation	  and	  inactivating	  marks	  such	  as	   H3K27me3	   (pink	   circles)	   and	   repressive	   protein	   complexes	   (red	   circles).	   B)	  Transformed	   cells	   alter	   gene	   expression	   through	   silencing	   normally	   active	   genes	  and	   activating	   normally	   silent	   genes.	   Using	   the	   aberrant	   placement	   of	   histone	  modifications	   and	   changes	   recruitment	   of	   protein	   complexes	   (activating	   or	  repressing)	   epigenetic	   corruption	   of	   the	   transcriptome	   can	   be	   achieved.	   	   Adapted	  from	  Feinberg	  [94].	  	  
	  
A B 
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There are very few studies examining direct effects of DNA methylation upon NR 
signalling and the present evidence suggests DNA methylation status maybe able to 
influence local NR activity. However, the LXR nuclear receptor has been demonstrated 
to have areas of hypermethylation across its promoter in murine models [102]. Also the 
gene encoding the ER-a nuclear receptor (ESR1) shows a strong correlation of promoter 
methylation and prostate cancer progression. In particular, this study found that the 
higher the gleason grade of prostate cancer the higher the extent of ESR-1 promoter DNA 
methylation [103].  
Epigenetic maintenance of gene repression is also mediated through the 
H3K27me3 mark [104]. This is also known as the polycomb repression mark placed by 
polycomb repressive complex 2 (PRC2). However, the presence of both H3K4me3 and 
H3K27me3 at a promoter leads to an activating and a repressive mark being in place at 
the same time. This is known as ‘bivalency’ and its purpose is not clear but may play 
some role in regulating genes important for differentiation [105]. Although it may also 
serve as an additional mechanism by which the cell uses to reduce transcriptional noise of 
genes.  
 Specific amino acids can also be subject to different changes, for example 
H3K9me2 holds a repressive influence where as H3K9ac is a mark associated with gene 
transcription. In support the activation effect of H3K9ac a genome wide study of human 
tissues often found both H3K9ac and H3K4me3 to occupy the promoters of most genes 
alongside RNA polymerase II [106]. This indicates that they are hallmarks of 
transcriptionally active genes.      
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In opposition to this the H3K27me3 mark is often found to be at silenced genes 
([107]). Thus, the distribution of both activating and repressive marks can influence 
genes activity. Therefore, NRs ability to recruit and remove certain histone PTMs will 
provide alterations in target gene transcription. Furthermore, changes in PTMs have been 
found to be associated with different malignancies [108]. This leads to the conjecture of 
there being a strong epigenetic component to the pathology of cancer.  
 In order to exert their activity the H3K4me3 relies upon the binding of proteins 
with a particular domain known as the plant homeodomain fingers (PHD fingers). 
Proteins (such as P300, CBP and nucleosome remodeling factor (NURF)) with this 
domain are able to ‘read’ the chromatin and the H3K4me3 mark provides the ‘ligand’ for 
their ‘activation’[109]. Such factors upon binding to H3K4me3 are able to recruit 
transcriptional machinery often found associated with RNA polymerase II. Thus the 
previous finding of elevated H3K4me3 at promoter regions of genes is thought to anchor 
protein complexes important for transcriptional activation processes.  
 This gives the H3K4me3 mark a high degree of importance, one that is 
emphasised with evidence of its deregulation being contributory to prostate 
tumourigenesis (reviewed in [110]). Furthermore, there are proteins with other chromatin 
binding properties that indicate a deregulation between the reading, placement and effects 
of the histone marks can impact upon CaP development. Alterations in histone marks 
produced by aberrant NR binding patterns may provide a causative mechanism for 
propagation of an aberrant transcriptome.  
 Such mechanisms are already being identified and again leukaemia provides a 
pertinent example. The MLL gene has been demonstrated to be a prominent H3K4 
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specific methyltransferase. Its activity is shown to induce gene transcription through the 
placement of this mark. However, in Acute Myelogenous Leukaemia MLL gene 
rearrangements are commonly reported [111]. One such study investigated the MLL-PTD 
duplication (MLL exon 4 to 11 or 4 to 12 duplication). Using a mouse knock-in model it 
was shown that MLL-PTD produces an elevation in the levels of H3K4me2 at HOXA 
genes. Furthermore, this was found to be in conjunction with histone acetylation at the 
same cluster. An elevation in the expression levels of these genes is shown to induce 
leukaemia indicating aberrant histone methylation influencing tumourigenesis [112].  
 Another example of a corruption in the placement of histone marks occurs with 
the H3K27me3 specific methyltransferase named enhancer of zeste homolog 2 (EZH2). 
This enzyme has often found to be upregulated in cancers including the prostate [113]. 
Concordantly, reduction in its levels attenuated the growth of prostate xenograft tumour 
models [114]. It has also been demonstrated the mutation of a single amino acid in the 
EZH2 protein nullifies its H3K27 trimethylation activity [115]. These findings emphasise 
the ease with which the placement of PTMs can be perturbed, leading to epigenetic 
corruption of a genes activity.  
 Alongside the errors in PTM placement, their inappropriate removal is also a 
mechanism by which transcription can be influenced. Aberrant histone demethylase 
(HDM) activity has particular pertinence at the H3K4 and H3K27 amino acids. A recent 
discovery, the presence of HDMs such as LSD1 has provided and extra pathway of 
regulation. LSD1 was demonstrated to be a stable element within HDAC containing 
CoRs [116]. Excessive removal of the methyl marks at H3K4 by elevation of LSD1 was 
shown to produce anti-tumourigeneic actions in breast cancer. Conversely, reduction in 
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LSD1 increased the invasiveness of malignant cells [117]. However, the anti-/pro-
tumourigenic nature of this activity depends upon the gene at which it is located. For 
example LSD1 is able to remove methylation of H3K4 at the AR providing 
transcriptional activation of the AR target genes within CaP [118].   
1.4.3 NR and CoR interactions in transcription. 
 Bound coregulator complexes also govern the activity of all NRs. These induce 
the changes in chromatin remodelling and previously described placement of histone 
PTMs to activate genes. In comparison to CoAs the CoRs activities and roles in gene 
expression are less well understood.  
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  1.10	  NR	  interacting	  motifs	  in	  CoR	  and	  CoA.	  In	  the	  absence	  of	  ligand	  the	  
NRs	   (shown	   examples	   here	   are	   RXR	   and	   TR)	   are	   bound	   to	   the	   CoRs.	   These	  coregulators	   contain	   an	   extended	  CoRNR	  box	  motif	   (LxxH/IIxxxI/L)	   that	   occupies	  the	  hydrophobic	  pocket	  with	  the	  NR.	  Ligand	  binding	  induces	  confirmational	  shift	  of	  helix	  12	   re-­‐shaping	   the	  hydrophobic	  pocket.	   This	   induces	   the	   rejection	  of	  CoR	   for	  association	  with	   the	  CoA	   (example	  here	   is	   the	   steroid	   receptor	   coactivator	   (SRC))	  containing	  both	  a	  CBP	  interacting	  domain	  and	  the	  shorter	  LXXLL	  motif	  able	  to	  bind	  the	  hydrophobic	  pocket.	  Taken	  from	  Rosenfeld	  [43].	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Initially formed upon the identification of interacting regions within their 
sequence is the conventional model of CoR release during transcriptional activation. Here 
an activating ligand binds to an already CoR bound receptor occupying a specific DNA 
sequence.  
Ligand presence induces release of CoR and recruitment of CoA and in turn 
histone acetyltransferase (HAT) enzymes. The mechanism behind this is focussed upon 
structural differences between the CoAs and CoRs. A motif contained within the CoRs 
called the Corepressor nuclear receptor (CoRNR) box, interacts with the hydrophobic 
groove of the NRs structure. Ligand binding to the NR displaces the bound CoR through 
conformational changes in the helix 12 positioning (found in the AF-2 region) (shown in 
Figure 1.10). As the CoRNR box is an elongated motif containing an LxxH/IIxxxI/L 
sequence it is too large to occupy the NRs newly configured hydrophobic pocket. 
These changes allow selective binding of only CoA proteins, as they contain the 
LxxLL binding motif that is a shorter sequence compared to the CoRNR box. This 
alternation between coregulators in association with the NR allows recruitment of histone 
acetyltransferases (HATs). Thus producing activation of chromatin remodelling and 
histone PTMs that activate gene transcription.  
However, more recent findings have shown the classical view of CoR and CoA 
exchange inducing gene transcription to be over simplified. Using the ERα as a model 
previous work has shown numerous interactions between coregulators and NRs. 
Furthermore, these occurred in response to ligand treatment over a timeframe of several 
minutes [119]. As part of this study a panel of transcription factors, histone modifying 
enzymes, and chromatin remodeling complexes were all screened for their promoter 
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presence. Using these data it was demonstrated that there were reoccurring fluctuations in 
histone methylation and acetylation. This suggested there were repeating recruitment and 
release patterns of CoAs and CoRs at the ERα bound response element. Furthermore, 
changes in these levels related to the recruitment and loss of the various chromatin 
modification enzymes [120]. This not only supported the histone code hypothesis (that 
gene activation required and induces changes in the PTMs on histone tail amino acids 
[121-123]) but also revealed that transcription is a highly dynamic process with frequent 
exchanges at the genomic template as well as the different coregulator proteins.  
Therefore, this was one of the first studies to show that NR mediated gene 
transcription is a cyclical procedure. In addition, it requires both activating and repressive 
events to occur on a genetic and epigenetic level. The changes in associated complexes 
were mediated by the NR undergoing repeatable clearance and recruitment patterns of the 
coregulators.  
The same group revealed the fluidity involved in NRs mediated gene regulation, 
they found that both unbound and ligand bound ERα can bind to target gene promoters in 
a cyclical manner [124]. It is conjectured that unliganded NR binding to the DNA may 
enforce repression of genes preventing unnecessary activation. In addition it may assure a 
rapid mRNA response to the detection of ligand.  
Together, these investigations indicate that gene activation required sequential 
recruitment and release of coregulators that exhibits cyclical qualities (Figure 1.11). 
Furthermore, such cyclical turnover of complexes bound to NRs may serve as a sampling 
process. The cell may use this to measure the concentration of ligand available, therefore, 
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detecting change. This in turn allows the fine-tuning of mRNA output to suit 
environmental requirements. 
However, observations of other NR models although they suggest similar cyclical 
release and recruitment it is shown to occur on a differing temporal scale. The previously 
described investigations with the ERα detailed above demonstrate cycles occurring 
within minutes of ligand exposure. In contrast, experiments in CaP using the AR binding 
to the PSA promoter as a model show that this has a prolonged cyclical nature lasting 
approximately 16 hours [125]. Therefore, it is clear in terms of NR specificity there are 
many differing gene targets, the transcriptional regulation varies between tissues and 
NRs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	  1.11	  Cyclical	  recruitment	  and	  release	  of	  coregulators.	  There	  are	  a	  huge	  number	  of	  coregulatory	  complexes	  (activators	  in	  green	  and	  repressors	  in	  red)	  that	  interact	   with	   NR	   to	   modulate	   transcription.	   The	   NR	   passes	   through	   cycles	   of	  association	  with	  each	  type	  of	  coregulator	  during	  transcription	   in	  order	  to	  produce	  specific	  mRNA	  kinetics.	  Taken	  from	  [43].	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Spatio-temporal studies of the VDR demonstrate that, similar to the ERα and AR, 
it is also able to undergo re-occurring recruitment to promoters. This also suggests there 
is cyclical recruitment and loss of both CoA and CoR at VDREs. For example a previous 
study determined that there were three active VDREs encoded within the CDKN1A gene 
(encodes p21(waf1/cip1)). These were shown to bind VDR upon ligand activation displaying 
varied kinetics [75]. This study continued further by using ChIP experiments showing 
recruitment of the CBP protein to the VDR bound VDRE. Furthermore, the presence of 
these factors varied overtime in response to 1α,25(OH)2D3 as did their accumulation at 
each response element.  
Additional work linked the VDR mediated events with histone PTMs within the 
local chromatin environment [126]. As a result it was discovered during each cycle the 
loss of CoR NCOR1 was followed by an accumulation of H3K9 acetylation mark at the 
transcription start site (TSS) of CDKN1A. At the same timepoints they were able to show 
enrichment of the activating CBP HAT. This work also reveals the importance of CoRs 
and their associated proteins, as knockout of either NCOR-1 or HDAC3 perturbed the 
mRNA kinetics of the gene. Interestingly, however, knockout of CBP had no effect upon 
transcriptional outcome.  
Therefore, VDR target gene activation appears to undergo repeated ‘programmes’ 
to enable sampling of the environment and assess ligand concentration. These changes 
vary in rapidity dependent upon the NR being observed. Also these ‘programmes’ place 
specific histone modifications that change in parallel with fluctuations in mRNA 
expression.  
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Oscillations in the mRNA levels of target genes can be of critical importance to 
homeostasis and development (Reviewed in [127]). These changes are in part mediated 
through accumulation patterns of many CoA and CoR at their promoters [119, 128] 
(described above). However, malignancy renders cells unable to mediate the anti-
proliferative actions of many NRs (such as RAR, PPARs and VDR). Concordantly, many 
of the NR target genes have been shown to become transcriptionally unresponsive or 
resistant.  
Investigations into the mechanisms of this resistance within bladder cancer cells 
have revealed the importance and continuity of corepressors in transcriptional regulation. 
Bladder cancer tissues overexpress NCOR1, this in turn increased the growth rate of cells 
and mediated insensitivity to VDR and PPARγ ligands [129]. By using siRNA this work 
demonstrated reducing NCOR1 in combination with HDACi treatment (Suberoylanilide 
hydroxamic acid, SAHA) treatment enhanced the cells response to ligand. Significantly, 
this was shown by a measurable biological phenotype using proliferation rate in 
comparison to single treatments. Furthermore, it was identified that a reduction in levels 
of NCOR1 produced a similar level of proliferation as HDAC inhibition alone. Therefore, 
these data strongly suggest the importance of NCOR1 as a mediator of HDAC activity. 
Also it shows an aberrant increase of NCOR1 in cancer may contribute to transcriptional 
repression through epigenetic changes at NR target genes. These previous works indicate 
the potential significance of using HDAC inhibition as a therapeutic strategy.  
Analysis using other malignant cell models supported the significance of these 
findings. Co-treatment of 1α,25(OH)2D3 with the HDACi Trichostatin A (TSA) has been 
found to overcome the gene repression exerted by NCOR1 and HADC3 in breast cancer 
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cells [130, 131]. This suggests the mechanistic nature of NR mis-regulation share some 
similarity between cancers of originating from different tissues.  
 In addition prostate malignancy demonstrates a similar response. Using a range 
of CaP cell lines it was revealed that HDAC inhibition with NaB (Sodium butyrate) or 
TSA in co-treatment with 1α,25(OH)2D3 increased the sensitivity of CaP cell lines (DU 
145, PC-3 and LNCaP) [132]. As in bladder and breast malignancy the proliferative rate 
of these cells was attenuated in comparison to the single treatment conditions. Using 
primary human prostate tissues additional work showed that NCOR2/SMRT was elevated 
in cancer compared to normal controls [133]. Upon further examination with CaP cells it 
was demonstrated that a reduction in NCOR2/SMRT levels increased expression of cell 
cycle arrest genes such as GADD45α. These findings all support there being an 
imbalance in corepressor levels in malignant cells. Furthermore, this selectively distorts 
the actions of NRs (in this case VDR) through elevated HDAC recruitment and 
hypoacetylation of local chromatin.  
Alternative models of prostate malignancy provided additional support to this 
hypothesis. A study using CWR22 xenograft models examined the proliferative actions in 
response to VDR stimulation. It was shown that NCOR1 and NCOR2/SMRT were 
elevated in cells insensitive to VDR stimulation and their activity was vital to repress 
VDR target genes [134]. The investigation showed that down-regulating either NCOR1 
or NCOR2/SMRT was sufficient to restore VDR activated gene expression. In addition 
this study revealed important knowledge regarding 1,25(OH)2D3 properties within the 
cell. They demonstrated that the expression of vitamin D transporters and ligand binding 
affinities were similar in resistant and responsive cells.  
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Therefore, these studies supported the hypothesis that NR insensitivity is not 
caused by alterations in the NR itself. Alternatively, the data show corruption of 
epigenetic mechanisms being responsible for the deregulation of NR target genes. 
Moreover, the activity of CoRs and HDACs were heavily implicated in this role.  
Thus, aberrant CoR levels emerged as a pivotal factor in cancer development by 
controlling the transcriptional actions of NRs. Investigations into non-malignant and 
malignant cells show that in cancer NRs have a restricted ability to activate genes. For the 
majority of cases in non-malignant cells, unliganded NRs do not activate gene expression 
and exist bound to coregulators. It is the elevated CoR configuration of these complexes 
that can contribute to the differential amplitude of transcriptional response (Figure 1.12).  
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	   1.12	   Model	   for	   corruption	   of	   co-­repressor	   activity	   in	   malignacy.	   (a)	  Non-­‐malignant	   cells	   use	   a	   balance	   of	   co-­‐activators	   and	   co-­‐repressors	   to	   mediate	  dynamic	  gene	  transcription	  (right).	  (b)	  Increases	  in	  co-­‐reppressor	  activity	  occuring	  during	   transformation	   produce	   a	   prodominatly	   repressed	   response.	   (c)	   Sustained	  overexpression	   of	   co-­‐repressors	   produces	   a	   repressed	   chromatin	   environment	  enhancing	  the	  presence	  of	  inheritable	  epigenetic	  changes	  (CpG	  methylation).	  Taken	  from	  Battaglia	  et	  al	  [85].	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However, the importance of cell type specific effects cannot be overlooked. All of 
the studies examining NR and coregulator exchange described above use malignant cell 
models. As yet unaddressed is the nature of these dynamics within the non-malignant 
environment. Whilst there has been identification of aberrant CoR and HDAC levels in 
comparison to normal cells, there has been no study into the transcriptional kinetics 
within these systems.  
Therefore, investigations are needed that examine the recruitment and loss of co-
repressors at NR target genes in non-transformed cells. In addition to this, a comparative 
analysis of recruitment in malignancy is required. Such experiments may reveal a deeper 
understanding of aberrant CoR interactions within normal physiology and malignant 
disease. 
1.4.4 Prereceptor regulation of nuclear receptor activity  
Pre-receptor regulation of NRs involves the control of ligand availability through 
metabolic enzymes. Pre-receptor ligand metabolism has now been shown to occur in a 
number of NRs including the AR and GR [135, 136]. Therefore, aberrant activity or 
altered level of enzymes may exert ligand regulation to impair NRs target gene 
expression. 
Upregulation of androgen converting enzymes in CaP tissue and cells has been 
widely reported [137]. In particular, it has been shown that Aldoketoreductase 1C3 
(AKR1C3) is overexpressed in prostate cancer tissue samples and cell lines [138]. 
AKR1C3 is also referred to as type 2 3α-HSD or 17-beta-hydroxysteroid dehydrogenase 
type 5 and is involved in the conversion of androstenedione to testosterone [139]. In 
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correlation with this ADT-R CaP cells have been shown to overexpress AKR1C3 protein 
and lack its primary substrate 5α-dihydrotestosterone [140] (Figure 1.13).  
The prostaglandin catabolic pathway in untransformed cells produces the 
PPARγ ligand 15ΔPGJ2. However, in malignancy it is hypothesized that excess AKR1C3 
may utilise PGD2, converting it into the 9α,11β prostaglandin F2, that has proliferative 
actions [141].  
Figure	  1.13	  Elevated	   level	  of	  AKR1C3	   found	   in	   cancers	  diverts	   conversion	  of	  
PGJ2	  into	  PGF2.	  Non-­‐malignant	  cell	  lines	  do	  not	  have	  elevated	  AKR1C3,	  and	  PGJ2	  is	  non-­‐enzymatically	  converted	   in	  to	  15ΔPGJ2,	  a	   ligand	  for	  PPARγ	   inducing	  activation	  of	   anti-­‐tumourgenic	   target	   genes.	   An	   inappropriate	   conversion	   to	   PGF2	   increases	  cellular	   cascades	   inducing	   pro-­‐tumourgenic	   actions.	   Adapted	   from	   Campbell	   et	   al	  	  [142].	  
 
Through this mechanism AKR1C3 may deprive the PPARγ of activating ligand. 
In the absence of elevated AKR1C3 represented in normal tissue PGD2 is non-
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enzymatically converted into a PPARγ ligand inducing anti-growth response genes. 
Therefore, inhibition of AKR1C3 levels in CaP may restore previously lost 
PPARγ activation. 
1.4.5 Sirtuin activity induces aberrant NR activity. 
The action of HDACs has been long studied, and among the many groups of 
HDAC enzymes are the Sirtuin family. HDACs are classified into four families (Class I, 
II, III, IV) named in regard to their similarity to yeast derivatives. Sirtuins fall into the 
Class III nicotinamide adenine dinucleotide (NAD)-dependent deacetylases. Indeed the 
activity of many transcription factors (including nuclear receptors) can be significantly 
altered by acetylation through HATs or deactylation by HDACs [143, 144] (Figure 1.14). 
All mammals have seven variants of Sirtuins, and various studies have shown that the 
HDAC activity of Sirtuin family can become deregulated in cancer [145, 146].  
This family of proteins has wide reaching actions and understanding the activity 
of the Sirtuins in cancer may provide important insight into the consequences of their 
upregulation. It was in 1914 Peyton Rous (whom a few years earlier had been the first 
person to boldly hypothesise cancer could be transmitted by a virus [147]), discovered 
that rats on a calorie controlled diet showed reduced tumour sizes and decreased 
morbidity [148]. The biological mechanism behind the observation eluded both Rous and 
the entire scientific community for decades to come. However, the benefits of a calorie 
restrictive diet continued to be measured in many organisms ranging from yeast to higher 
apes. A significant finding came with the discovery in yeast [149] and mice [150] that the 
increased life span effect produced by calorie reduced diet was nullified with Sirtuin 
knockout models.  
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CaP incidence increases with age suggesting factors effecting lifespan may be 
associated with development. Accordingly, changes in global histone acetylation and 
methylation status have been used to predict CaP recurrence in patients [151].  
Figure	   1.14	   Cellular	   localisation	   and	   actions	   of	   Sirutins.	   SIRT1	   is	   involved	   in	  nutrient	   sensing	   and	   promoting	   cell	   survial.	   SIRT2	   is	   able	   to	   cross	   the	   nuclear	  membrane	   and	   deacetlyate	   histone	   tails	   to	   prevent	   advancement	   through	   the	   cell	  cycle	   in	   presence	   of	   DNA	   damage.	   SIRT3,	   4	   and	   5	   are	   found	   exclusively	   in	  mitchondria.	  SIRT	  3	  activates	  acetyl-­‐CoA	  sythetase	  to	  increase	  actly-­‐CoA	  production.	  SIRT	  4	  represses	  glutamate	  dehydrogenases	  repressing	  insulin	  signaling	  pathways.	  The	  actions	  of	  SIRT5	  are	  yet	  to	  be	  identified.	  SIRT6	  activates	  upon	  genomic	  damage	  and	  promotes	  DNA	  repair,	   through	  unidentified	  target	  genes.	  SIRT7	  mediates	  Pol	  I	  transcription	  of	  rRNA	  genes.	  Taken	  from	  Saunders	  and	  Verdin	  [156].	  
 
Studies in mouse and human CaP have shown that SIRT1 is overexpressed [152], 
and so Sirtuins may have an integral role in disease development. Specific effects of 
SIRT1 on NRs in CaP have also been published with conflicting results. Studies have 
found SIRT1 inhibition to decrease the growth of ADT-R CaP cells [153], but contrasting 
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work on SIRT1 has demonstrated deacetylation of the AR act as an additional 
corepressor [154, 155]. 
Therefore, SIRT1 has been associated with both pro and anti-tumourgenic actions 
in CaP. In addition to this Sirtuins have also been shown to directly regulate the activity 
of NRs and in particular the PPARs through modification of histones [157], thus 
influencing their signaling ability. As such targeting the aberrant activity of Sirtuins in 
cancer through inhibition may restore NR mediated actions. Combining their inhibition 
with exogenously added ligands targeting PPARγ may produce anti-proliferative, pro-
differentiating effects.   
1.5 VDR regulated epigenetic events 
1.5.1 CDKN1A Regulation in RWPE-1 cells. 
NR target gene expression has been frequently studied with particular focus upon 
the receptor binding to DNA response elements. The changes in NR binding have been 
shown to produce mRNA fluctuations that vary in their magnitude and timing dependent 
upon the NR being studied. However, all of these previous studies use models of 
malignancy to test their hypothesis.  
Therefore, there is a need for an investigation of NR mediated events that lead to 
transcription within non-malignant cells. This will establish a ‘baseline’ of normal 
untransformed cell functioning reflective of in vivo NR activity.  
 
 
 
 
Chapter 1    General Introduction 
 
 
56 
 
	  
Figure	   1.15	   Functional	   VDREs	   within	   the	   CDKN1A	   promoter.	   Analysis	   of	   the	  human	  CDKN1A	   promoter	   revealed	   three	   responsive	   VDREs	  within	   the	   first	   10kb	  upstream	  of	  the	  TSS.	  Response	  element	  positions	  relative	  to	  the	  transcription	  start	  site.	  Adapted	  from	  Samaraki	  et	  al	  [75].	  
The CDKN1A gene as shown in this work and also by other groups [126, 158] is a 
VDR regulated gene. Multiple response elements have been identified within the 
CDKN1A and these include numerous binding sites for p53 amongst other transcription 
factors. Screening of the gene found it to contain numerous putative VDRE binding sites 
that hold the consensus sequence RGKTCA (R = A or G, K = G or T) and variants of this 
configuration (Direct Repeats (DR3, DR4), Inverted repeats (IR3) or Everted Repeats 
(ER9)). Previous findings by this laboratory include identification of the mRNA kinetics 
of VDR target genes in response to 1α,25(OH)2 D3 (100nm) exposure [76]. This study 
used the non-malignant RWPE-1 cell line to represent the normal untransformed prostate 
epithelial condition.  
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Figure	   1.16	   CDKN1A	   response	   in	  RWPE-­1	   cells	  with	   1α25,(OH)2D3	   (100nm).	  RWPE-­‐1	   cells	  were	   treated	  with	   1α,25(OH)2D3	   (100	   nM)	   or	   EtOH	   and	  mRNA	  was	  extracted	   at	   the	   indicated	   time	   points,	   and	   accumulation	   of	   indicated	   genes	  measured	  by	  TaqMan	  Q-­‐RT–PCR.	  Each	  data	  point	  represents	  the	  mean	  of	  triplicate	  experiments	   in	   triplicate	   wells	   ±SEM	   (*P<0.05,	   **P<0.01,	   ***P<0.001).	   All	  measurements	   performed	   in	   technical	   and	   biological	   triplicate.	   (B)	   Total	   cell	  proteins	   were	   isolated	   from	   cells	   treated	   as	   above	   at	   the	   indicated	   time	   points	  (1α,25(OH)2D3	  (100nm))	  and	  subjected	  to	  western	  immunoblotting.	  Representative	  blots	   are	   shown	   for	   p21(waf1/cip1).	   β-­‐Actin	   used	   as	   a	   loading	   control.	   Adapted	   from	  Thorne	  et	  al	  [76].	  
 
From the data shown in Figure 1.16 20 at 30 minutes post exposure to 
1α,25(OH)2D3 (100nm) there is a statistically significant (p-value<0.05) rise in CDKN1A 
mRNA. This early peak is followed by an mRNA profile that fluctuates between 
significant changes compared to the vehicle only treatment. These data demonstrate that 
the cyclical changes in VDR mediated CDKN1A accumulation are productive, and 
transcriptional events contributed to changes at the protein level. This maybe a 
A 
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consequence of the mRNA accumulation measured at 1 and 2 hours. Eight hours post 
ligand addition there is detectable p21(waf1/cip1) at an increasing rate, at these later stages 
changes in protein abundance mediated by secondary interactions cannot be excluded. 
From the above data is it clear that cyclical accumulations of p21(waf1/cip1) message and 
protein occurs in response to VDR activation. 
Previous work in our laboratory studied four histone modifications that were 
chosen for analysis at the regions of the CDKN1A gene shown in Figure 1.15. These 
time-resolved quantitative ChIP approaches at the described VDREs revealed that histone 
modifications regulate CDKN1A expression [76]. Histone modifications investigated 
were associated with gene maintenance, H3K4me3 (the trithorax mark) [159] and the 
H3K27me3 (the polycomb mark) [160].  
 
 
 
 
 
 
 
 
Figure	   1.17	   VDR-­regulated	   epigenetic	   events	   on	   the	   promoter	   of	   CDKN1A.	  Changes	   to	   histone	  modifications	   (H3K9me2	   and	  H3K9ac)	  were	   assayed	   using	  N-­‐ChIP	   and	   normalized	   using	   bound	   over	   unbound	   DNA	   pulled	   down	   with	   specific	  ChIP	   grade	   antibodies.	   Enrichment	   was	   measured	   by	   Q-­‐PCR	   as	   above.	   Each	   data	  point	   represents	   the	   mean	   of	   triplicate	   experiments	   in	   triplicate	   wells	   ±SEM	  (*P<0.05)	  Adapted	  from	  Thorne	  et	  al	  [76].	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In addition H3K9ac and H3K9me2 were also examined. This investigation found 
enrichment of the activating H3K9ac and loss of repressive H3K9me2 0.5 hours post 
treatment at VDRE-2 (Figure 1.17). This exchange of marks at H3K9 was also reversed 
after 1 hour indicating a deactivation signal. This suggests a highly dynamic and tightly 
regulated epigenetic mechanism of gene transcription.  
Previous work focusing upon the NCOR1 corepressor has suggested that it may 
play a significant role in the acquisition of methylation at H3K9. It was found that 
NCOR1 but not NCOR2/SMRT was able to bind a protein called Kaiso. Upon binding of 
the Kaiso/NCOR1 complex to promoters there was deacetylation and methylation of the 
H3K9 subunits [161]. Additionally Kaiso is a methyl CpG binding protein indicating that 
it can contribute to inheritable repression of genes as well as transcriptional repression 
through NCOR1 presence.  
Therefore, elevated NCOR1 containing Kaiso protein may be responsible for 
contributing to epigenetic changes in H3K9. The imposed PTMs may then influence 
changes in transcriptional response to ligand.  
Additional work in this group show that the DNA helicase and replication factor 
minichromosome maintenance complex 7 (MCM7) is emerging as a VDR regulated gene. 
This exhibits an mRNA expression profile in response to 1α,25(OH)2D3 (100nm) that has 
similar dynamics to CDKN1A expression. MCM7 has a strong correlation between the 
level of expression of this gene and the level of DNA replication conducted by the cell. In 
conjunction with this studies have found increased MCM7 expression to be associated 
with malignancy in many tissues including the prostate [162-165].  Supplemental to this 
the MCM7 gene encodes in its 3’UTR the sequence for a microRNA subfamily [166]. 
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MiR106B is contained within this sequence and its upregulation has been measurement in 
response to 1α,25(OH)2D3 using real-time PCR. These data have shown a similar 
response transcriptional to MCM7 and CDKN1A. Analysis of mRNA expression over the 
first hour post treatment shows that the MCM7 and MiR106B production rise in their 
levels, these exhibit an ‘early’ peak of mRNA that precedes the CDKN1A peak observed 
in RWPE-1 cells.  
MiR106B is able to target the CDKN1A mRNA for degradation, it is therefore 
hypothesised that 1α,25(OH2)D3 is able to initiate through MCM7 activation transcription 
of the microRNA MiR106B. MiR106B then marks the CDKN1A mRNA for degradation. 
Thus contributing to the mRNA dynamics observed in response to 1α,25(OH)2D3 
providing and additional layer of transcriptional regulation.   
 
 
 
 
 
 
 
Figure	  1.18	  mRNA	  expression	  of	  CDKN1A,	  MCM7	  and	  MiR106B	  in	  response	  to	  
1α25,(OH)2D3	  (100nm).	  RWPE-­‐1	  and	  PC-­‐3	  cells	  were	  treated	  with	  1α,25(OH)2D3	  (100nM)	   or	   EtOH	   and	   mRNA	   was	   extracted	   at	   the	   indicated	   time	   points,	   and	  accumulation	  of	   indicated	  genes	  measured	  by	  TaqMan	  Q-­‐RT–PCR.	  Each	  data	  point	  represents	   the	   mean	   of	   triplicate	   experiments	   in	   triplicate	   wells	   ±SEM	   (*P<0.05,	  **P<0.01,	   ***P<0.001).	   All	   measurements	   performed	   in	   technical	   and	   biological	  triplicate.	  Conducted	  by	  Dr.	  Orla	  Maguire.	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 Upon activation by VDR the MCM7 gene shows detectable rises in mRNA after 
15 minutes this appears 15 minutes prior to the early peak in CDKN1A suggesting that 
MCM7 mRNA is activated first. Further, the sequence for MiR106B can be detected at an 
increased level after 20 minutes and is situated in-between CDKN1A and MCM7. All of 
the early peaks observed are lost by 1 hour treatment.  Investigation in the malignant cell 
line PC-3 shows that although mRNA inducibility is lost in response to VDR, the 
expression profile of MCM7 and MiR106B is maintained although its potency is 
decreased in comparison to RWPE-1 (Figure 1.18). 
Therefore, there is a selective distortion of the feedforward loop (FFL) in CaP. 
This is biased in favour of silencing the anti-proliferative target genes, whilst minimizing 
disruption of the proliferative genes.  
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Hypothesis 
Nuclear receptors mediate a wide range of growth control events. However, 
during malignancy their activity becomes distorted. Therefore, the overarching 
hypothesis of this thesis is that inappropriate overexpression of CoRs NCOR-1 and 
NCOR2/SMRT contribute to transcriptional silencing in prostate cancer. Elucidation of 
this may allow identification of new therapeutic targets, which can be exploited to restore 
NR sensitivity.  
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Study aims  
Experiments designed to test the hypothesis of this thesis were broken down into three 
specific aims.  
  
1. To investigate the ability of AKR1C3 to regulate PPARγ at a pre-receptor level. 
Decreasing the levels of AKR1C3 in CaP may restore endogenous PPARγ ligand 
concentrations producing a decreased proliferation rate.  
2. To examine if the transcriptional actions of VDR vary in prostate cell lines 
representing non-malignant disease. All previous studies of NR and coregulator 
binding have been performed in malignant cell lines. Therefore, to investigate 
how VDR regulated epigenetic events influence gene expression RWPE-1 non-
malignant cell lines were utilised.  
3. To test for differential VDR and cofactor binding in CaP models. Comparison of 
RWPE-1 binding kinetics to malignant cell lines will reveal the true level of 
epigenetic mis-regulation giving rise to NR target gene insensitivity.  
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Chapter 2: Materials and Methods 
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2.1 Materials and Methods 
2.1.1 Cell Culture 
 
Human prostate cell lines used in this work (RWPE-1, RWPE-2, PC-3, LNCaP 
and DU 145) were purchased from American Type Cell Culture (ATCC) Manassas, 
Virginia USA. The LNCaP-C42 cells were taken from a stock storage at Roswell Park 
Cancer Institute, Buffalo, New York, USA. RWPE-1 and RWPE-2 cells were maintained 
within Keratinocyte serum free medium (K-SFM) (Invitrogen GIBCO). This was 
combined with the supplements of bovine pituitary extract (0.05mg/ml) (BPE) and 
human recombinant epidermal growth factor (5ng/ml) (EGF) (Invitrogen GIBCO).  
LNCaP, LNCaP C-42, PC-3 and DU 145 cells were maintained in RPMI medium (Sigma 
Aldrich) containing 10% fetal bovine serum (FBS) (Invitrogen) and 2mM L-Glutamine.  
To minimise chances of infection all cell lines were maintained in 100 units/ml Penicillin 
and 100µg/ml Streptomycin. All cells were kept in at 37oC in air 95% and 5% CO2. 
Confluent cells were washed in sterile PBS, split using Trypsin-EDTA (Sigma Aldrich) 
and seeded into new flasks containing fresh media. Different cell lines were spilt with 
differing frequency dependent upon growth characteristics for example; RWPE-1 cells 
were split at 1:4 ratio bi-weekly. Faster dividing LNCaP, LNCaP C-42, PC-3 and DU 145 
cells were split four times weekly at a 1:8 dilution. RWPE-2 cells were maintained within 
the KSF complete medium and split at a 1:5 ratio three times weekly.  
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2.1.2 Compounds 
 
• 1α,25(OH)2D3 (BioXell) was stored in a 10mM stock solution in ethanol, 
protected from sunlight and stored at -20oC. 
 
• Bezafibrate (Sigma Aldrich) was stored in a 1mM stock ethanol solution, 
protected from sunlight and stored at -20oC. 
 
• Suberoylanilide hydroxamic acid (SAHA) was a kind gift from Merck and stored 
in a 1mM ethanol solution at -20oC. 
 
• GW9662 (Sigma Aldrich) was stored in a 1mM DMSO stock solution and 
protected from sunlight by storage at -20oC. 
 
• Sirtinol (Sigma Aldrich) was stored in a 4M stock solution in acetonitrile, 
protected from the sunlight and stored at -20oC. 	  
For experimental dilutions all compounds were diluted in the corresponding diluent 
control and treatment commenced alongside vehicle only controls.  
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2.1.3 Proliferation assays 
Principle 
Rate of cell division was measured using the ViaLight Plus Kit for high 
sensitivity cell proliferation (Lonza Rockland Inc.). This used detection of ATP levels 
within cells to extrapolate their rate of growth. Cells producing ATP were measured 
using the enzyme luciferase, this catalysed the formation of light using ATP, luciferin 
and O2. Under these conditions the below reaction took place. The level of light emitted 
from each well was directly proportional to the concentration of ATP in the well. 
 
ATP + luciferin + O2      
luciferase         oxyluciferin + AMP + PPi + CO2 + LIGHT 
Procedure 
Cells were seeded at differing densities in relation to their inherent differences in 
proliferation rate. RWPE-1 cells (4x103) were loaded per well in 96 well plate, PC-3 and 
DU 145 (2x103) cells were loaded per well in white walled 96 well plate (Costar). Cells 
were left to attach to the bottom of well overnight at 37oc in air 95% and 5% CO2. 
Addition of treatment took place the following day and again 48 hours later. Thus the 
exposure to compound(s) was 72 hours, before the plate was read by the microplate 
luminometer (Berthold Id Detection System, Fisher Scientific Ltd, UK). Cell lysis 
reagent (50µl) was added in each well using a multichannel pipette and left at room 
temperature for 10 minutes. ATP monitoring reagent (100µl) was added and the plate 
was left for 2 minutes covered with tin foil to exclude sunlight. ATP levels were recorded 
in Relative Luciferase Units (RLU) with a read time set to 1 second as recommended by 
the kit manufacturer. Inhibition of proliferation was expressed as a percentage relative to 
Chapter 2                                                                                                                    Materials and Methods 
 
68 
vehicle treated control. All final results were the result of at least three independent 
biological experiments performed in triplicate wells. Values were plotted using mean data 
± Standard Error of the Mean (SEM) and statistical significance was assessed using 
Students unpaired t-test where *=p-value <0.05, **=p-value <0.01 and ***=p-value 
<0.001. 
2.1.4 Fluorescence Activated Cell Sorting (FACS) for cell cycle 
analysis 
Principle 
As eukaryotic cells grow towards division it passes through specific periods or 
phases, each phase has a specific role and name. There are four phases to the cell cycle 
(G1, G2, S and M) although a senescence phase, that precedes G1 called G0, is often 
omitted. Throughout each phase the growing cell contains a different amount of DNA. 
Thus each phase can be detecting by determining the relative amount of DNA in cells by 
using propidium iodide (Roche). This is intercalating dye binds any present double 
stranded DNA. As propidium iodide cannot permeate the cell membrane populations 
must first be lysed and nuclear DNA exposed. This can be performed by exposure to 
detergents and salt concentrations able to induce swelling and bursting of cellular 
membranes. The propidium iodide in the stained nuclei is excited by light with a 
wavelength of 488 nm resulting in fluorescence that can be measured by the flow 
cytometer.  
Between G1 phase where there is one copy of the genome and G2 phase that has 
two copies of the genome is the S phase. This normally lasts 10–12 hours and duplicates 
the DNA contained within the cell. Therefore, those cells in G2 and M phase should 
produce greater signal intensity as they have duplicate copies of DNA. S phase cells are 
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undergoing duplication and so will yield a greater level of florescence than G1 
populations but not as great as G2 populations.  
Procedure 
         T75 cell bind flasks were seeded with sub-confluent, exponentially proliferating 
cells and allowed to settle overnight. Cells were treated with 1α,25(OH)2D3 (10nm and 
100nm) for 24 hours. Cells were harvested by trypsinisation and pelleted by 
centrifugation at 12,000g for 5mins. Cells were resuspended in 1ml PBS (stored at 4ºc) 
and transferred to flow cytometry tubes (Falcon). Cells were washed in PBS (1ml) and 
resuspended in 500µl cell cycle buffer (1 % sodium citrate, 0.1 % Triton X-100, 0.1mM 
sodium chloride) and 10µg/ml propidium iodide (Sigma Aldrich) protected from light 
and stored at 4ºC. Samples were vortexed and incubated on ice in the dark for at least 
40mins before flow cytometry analysis.  	  
	  	  
	  
Figure	  2.1	  An	  example	  of	  FACS	  analysis	  cell	  cycle	  profile	  in	  untreated	  cells.	  On	  the	  x	  axis	  is	  the	  intensity	  of	  the	  fluorescent	  signal	  and	  the	  y-­‐axis	  shows	  the	  number	  of	   events	   measured.	   Cell	   cycle	   distribution	   was	   determined	   using	   a	   Becton-­‐Dickinson	  Flow	  Cytometer	  and	  CellFIT	  Cell-­‐Cycle	  Analysis	  software.	  Analyses	  were	  carried	  out	  on	  10,000	  nuclei	  per	  sample	  and	  each	  condition	  was	  examined	  in	  at	  least	  three	  independent	  experiments.	  
	  	  	  	  
 
Cell	  Cycle	  Phase	   %	  Cells	  G1	   71.61	  S	   9.50	  G2/M	   18.89	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2.1.5 RNA extraction 
Principle  
Isolation of pure, good quality RNA can be critical for accurate quantitative 
analysis in molecular biology. RNA molecules are weak structures that rely on 5’ capping 
and 3’ polyadenylation to maintain their conformation. However, RNA molecules are 
still susceptible to attack by ribonucleases or RNAse and so the quality of samples can 
degrade rapidly. The following methodology utilised is that detailed by Chomczynski, P. 
and Sacchi, N. in 1987 [167] whom developed the Guanidinium thiocyanate-phenol-
chloroform extraction procedure. Guanidinium thiocyanate-phenol-chloroform is able to 
preserve to stability of RNA by denaturing the ribonucleases. In addition it degrades 
tissue and cellular components yielding total RNA whilst maintaining integrity. Addition 
of chloroform to the Guanidinium thiocyanate-phenol mix allows the separation of 
phases. Bottom is a red phenol-chloroform phase, an interphase containing DNA and an 
aqueous phase at the top that contains the total RNA extract. Removal of the aqueous 
phase and ethanol precipitation of the hydrophillic nucleic acids allows for isolation and 
resuspension in nuclease free water.  
Procedure 
1ml of Guanidinium thiocyanate-phenol (Trizol (Invitrogen)) per 5 million cells 
was added to the well in use. The reagent was then pipetted up and down on the well to 
maximise lysis of cells and exposure to all areas of the well. The cellular contents now 
suspended in the Trizol were transferred to an Eppendorf (1.5ml) and left at room 
temperature for 5 minutes to equilibrate. After 5 minutes, chloroform (200ul) per ml of 
Trizol added and the samples were then vortexed for 10 seconds then left to incubate at 
room temperature for 5 minutes. The sample was then centrifuged at 12,000g for 5 
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minutes at 4oC. The top layer (an aqueous phase containing the RNA) was removed and 
dispensed into a new Eppendorf (1.5ml) to which isopropanol (propan-2-ol) 500ul (per 
1ml of Trizol used) was added. This was then inverted 5 times to mix and kept at -20oc 
for at least 30 minutes to ensure precipitation of RNA. The sample was then centrifuged 
for 10 minutes at 12,000g at 4oc to collect a nucleic acid pellet at the bottom of the 
Eppendorf. The isopropanol was then removed and the pellet was then resuspended in 
75% ethanol and centrifuged further for 5 minutes at 12,000g at 4oc to wash the sample. 
The 75% ethanol was then removed and the sample resuspended in nuclease free water 
(50ul) and stored at -80oc.   
RNA was quantified using the NanoDrop (ND100, Labtech International, UK).  
Quantification of 2µl of RNA sample was measured through absorbance at 260nm and 
280nm with the ratio of 260nm/280nm being an indicator of the purity of RNA sample. 
Ratios <1.6 indicates partially degraded RNA or a high level of non-nucleic acid present 
and so was discarded and not used.  
2.1.6 Reverse Transcription  
Principle 
Quantification of isolated mRNA first required conversion of the mRNA into 
cDNA as RNA is unstable and will degrade rapidly under thermocycling conditions. 
Therefore, the RNA must be converted to complementary DNA (cDNA) that is stable and 
receptive to polymerase chain reaction (PCR) conditions. Conversion to cDNA is 
performed using a commercial cDNA synthesis kit i-script (Biorad). This kit utilises the 
RNase H1 reverse transcriptase enzyme in a cocktail containing RNase inhibitor, oligo 
dT and random primers. RNase H1 reverse transcriptase is able to copy the mRNA 
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sequence whilst degrading the RNA template upon completion. The reverse transcriptase 
enzyme requires initiation through the binding of oligo dT or random primers. These are 
able to detect the polyadenylated tail of mRNA or any sequences of oligonucletides 
respectively.  This ensures all present mRNA is converted into cDNA.  
Procedure 
Previously purified, isolated and quantified RNA was diluted to yield 1µ of RNA 
in 10µ of nuclease free water (Ambion) per sample. Added to this was the i-Script 
cocktail and reverse transcriptase in the following volumes:  
Components Volume per reaction (µ l) 
5x i-Script Reaction Mix 4 
i-Script Reverse Transcriptase 1 
Nuclease Free Water 5 
RNA Template (1µg Total RNA) 10 
TOTAL REACTION VOLUME 20 
Table	  2.1	  Reverse	  transcriptase	  master	  mix	  components	  and	  volumes	  	  
 
Reaction Protocol  
The mix was incubated at the following conditions:  
 
Time (minutes) Temperature (oc) 
5 25 
30 42 
5 85 
∞ 4 
Table	  2.2	  Reverse	  transcriptase	  reaction	  thermal	  conditions.	  	  
 
Resulting cDNA was stored at -20oc. 
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 2.1.7 Quantitative Real-Time Polymerase Chain Reaction (Q-RT-
PCR) 
Principle 
This technique allows accurate detection and quantification of cDNA produced 
during each PCR amplification cycle. It is an advancement of the traditional polymerase 
chain reaction procedure. There are three stages in the PCR procedure; denaturation, 
annealing and extension. Denaturation of the DNA occurs at high temperatures (95oC) 
and the double stranded DNA unwinds and separates into single strands. The temperature 
of the reaction mix must then reduce to approximately 40oC below that of the template 
primers used, this allows them to bind to the single stranded cDNA. In the presence of 
thermophillic DNA polymerases (Taq) the bound primer and induces ‘extension’ which 
is the copying of the primer bound template by the polymerase. This produces an 
identical strand of DNA, the cycle is then repeated 40 times. In this way the amount of 
product exponentially increases every cycle. Importantly the primers used must be 
predesigned to be complimentary to an intron-exon boundary thus preventing any 
genomic DNA interfering with measurement. The product after 30–40 cycles can then be 
ran on an agarose gel (1-3%) containing the fluorescent DNA interacting ethidium 
bromide (0.5µg/ml) and viewed under UV light conditions. However, as this process is 
exponential and only the end product is viewed it is not an accurate method of measuring 
abundance and only regarded to be semi-quantitative.  
Therefore Q-RT-PCR was developed. This uses an amplicon specific fluorescent 
probe that is detected upon the specific product being formed. Cleavage of the probe by 
the DNA polymerase during the extension step of PCR allows detection and extrapolation 
of fluorescence into a quantifiable value. The probe is also linked to a quencher 
preventing inappropriate detection, only when the DNA cleaves the probe from the 
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quencher is its fluorescence detected. This technique allows quantification of amplified 
product at the end of every cycle of denaturation, annealing and extension. Therefore, the 
earlier cycle a transcript is detected the more copies of the gene are present in the sample 
i.e. gene X appearing at cycle 19 is present at a higher level than gene Y which appears at 
cycle 23. Thus there are more copies of gene X in the sample of isolated cDNA than gene 
Y.  
 
Figure	  2.2	  Real	  Time	  PCR	  detection	  using	  primer	  and	  probe	  combination.	  The	  probe	  oligonucleotide	  is	  modified	  with	  a	  fluorescent	  reporter	  dye	  (FAM)	  and	  with	  a	  quencher	   (TAMRA).	  While	   the	  probe	   is	   intact	   the	  dye	   is	  proximal	   to	   the	  quencher	  and	  prevents	  fluorescence	  emission.	  During	  the	  extension	  phase	  of	  the	  PCR,	  the	  taq	  polymerase	   (has	   5’	   to	   3’	   exonuclease	   activity)	   digests	   any	   annealed	   probe.	   This	  induces	   separation	   of	   the	   reporter	   dye	   from	   the	   quencher	   enabling	   fluorescence	  detection.	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To give individual samples an internal robustness that allows them to be 
compared to each other there must be an endogenous control. This is quantified within 
each reaction to account for differences in cDNA amounts between samples. 18s is a 
ribosomal RNA that is constitutively expressed in all cells in high concentrations. Its 
expression is consistent between different cell types and changes in levels remain 
undetectable in exposure to compounds. Comparison of the gene of interest to the 18s 
internal control gene first then allows direct comparison to samples between treatments.   
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  2.3	  An	  example	  of	  the	  amplification	  curve	  of	  1α,25(OH)2D3	  treated	  and	  
untreated	  RWPE-­1	  cells.	  Cycle	  thresholds	  (Cts)	  are	  related	  to	  the	  internal	  control	  18s	  rRNA	  Cts	  and	  ddct	  are	  calculated	  by	  comparing	  the	  amplification	  curve.	  In	  this	  example	  of	  1α,25(OH)2D3	  treatment	  upregulated	  the	  levels	  of	  CYP24A1	  mRNA,	  this	  was	   shown	   by	   a	   shift	   in	   the	   amplification	   curve	   to	   the	   left	   in	   comparison	   to	   the	  untreated	  sample.	  	  	  
 
Chapter 2                                                                                                                    Materials and Methods 
 
76 
As already stated the amplification process is exponential. The cycle at which a 
determined level of fluorescence occurs is termed the cycle threshold (Ct) and 
quantification occurs at the exponential phase of amplification. The Cycle threshold or Ct 
of the internal control gene can be subtracted from the Ct of the gene of interest. This 
allows normalisation of the sample termed delta Ct (dCt). Using the delta Ct an untreated 
control cell can be compared to that of a ligand treated cell. The subtraction of the 
untreated delta Ct from the treated delta Ct yields the delta delta Ct (ddCt). Conversion of 
the Ct value into relative fold change by the 2^-ddCt calculation is then performed. The 
use of 2^ (POWER) is an approximate and hypothetical value used to account for primer 
amplification efficiency.   
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Primers and probes used for qRT-PCR were as follows: 
Accession 
Number Primer Name Primer Sequence (5’-3’) 
CYP24A1 Forward CAAACCGTGGAAGGCCTATC 
CYP24A1 Reverse ACTTCTTCCCCTTCCAGGATCA 
NM_ 
000782 
CYP24A1 Probe ACTACCGCAAAGAAGGCTACGGGCTG 
CDKN1A Forward GCAGACCAGCATGACAGATTTC 
CDKN1A Reverse GGATTAGGGCTTCCTCTTGGA 
NM_ 
000389 
CDKN1A Probe CCACTCCAAACGCCGGCTGATCTT 
NCOR1 Forward TGAAGGTCTTGGCCCAAAAG 
NCOR1 Reverse TTTGTCTTGATGTTCTCATGGTA 
NM_ 
006311 
NCOR1 Probe CTGCCACTGTATAACCAGCCATCAGATACCA 
GADD45α Forward AAGACCGAAAGGATGGATAAGGT 
GADD45α Reverse GTGATCGTGCGCTGACTCA 
NM_ 
001924 
GADD45α Probe TGCTGAGCACTTCCTCCAGGGCAT 
VDR Forward CACCCGGCAGTATCATGAGA 
VDR Reverse CGAGCGTGATTCCTCCTCTT 
NM_ 
000376 
VDR Probe CTTCCGCATCGCCTGGTTTATT 
PTGS2 Forward GAATCATTCACCAGGCAAATTG 
PTGS2 Reverse TCTGTACTGCGGGTGGAACA 
NM_ 
000963 
PTGS2 Probe TGGCAGGGTTGCTGGTGGTAGGA 
G0S2 Forward CAGAGAAACCGCTGACATCTAGAA 
G0S2 Reverse GCAGCAAAACTCAATNMCCCAAA 
NM_ 
015714 
G0S2 Probe TGACCTACCACAAGCATCCACCAAAGG 
ERα Forward GGGAAGCTACTGTTTGCTCCTAAC 
ERα Reverse AAGATCTCCACCATGCCCTCTA NM_ 000125 
ERα Probe TGCTCTTGGACAGGAACCAGGGAAAAT 
MAPK4 Forward GCTGATGGCCGCTAACCA 
MAPK4 Reverse GGCTCACAGGGTACCTGGAA NM_ 002747 
MPAK4 Probe TGACCTACCACAAGCATCCACCAAAGG 
MCM7 Forward CGGTGCTGGTAGAAGGAGAG 
MCM7 Reverse AAACCCTGTACCACCTGTCG 
NM_ 
005916 
MCM7 Probe GCCAATCCTGCGCACTGGGT 
AKR1C3 Forward GGGATCTCAACGAGACAAACG 
AKR1C3 Reverse AAAGGACTGGGTCCTCCAAGA 
NM_ 
003739 
AKR1C3 Probe TGGACCCGAACTCCCCCGGTG 
Table	   2.3	   Primer	   and	   probe	   sequences	   for	   Taqman	   real	   time	   RT-­PCR.	   All	  
probes	   have	   the	   fluorescent	   dye	   called	   Fam,	   attached	   to	   the	   5’	   end	   and	   the	  
quencher	  Tamra,	  bonded	  to	   the	  3’	  end,	  only	  upon	  release	  of	   the	  quencher	   is	  
the	  fluorescence	  detected.	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Gene Bank 
Accession 
Number 
Gene name Product code 
NM_000698 5-Lipoxygenase Hs00167536_m1 
NM_030593.1 SIRT2 Hs01560288_m1 
NM_016539.1 SIRT6 Hs00213036_m1 
Table	  2.4	  Assay	  on	  demand	  primer	  and	  probe	  mix	  used	  in	  this	  thesis	  (Applied	  
Biosystems).	  Listed	   above	   are	   the	   accession	   numbers	   and	   product	   code	   used	   for	  each	  assay	  on	  demand	  gene.	  	  
 
Primers and probes used previously by the group had been calibrated to guarantee 
linearity of amplification. Primer efficiency experiments were carried out in order to 
ensure reliability on mRNA detection. This optimization step was undertaken to ensure a 
linear relationship between template concentration and Ct values when undertaking a 
multiplex reaction with both housekeeping genes and target genes. G0S2 primer probes 
had to be designed using Primer 3 program and ordered from Sigma Aldrich as they were 
not previously in use. These were tested by using a range of 10 fold cDNA dilutions to 
examine amplification and multiplex efficiency of primer sequences. The data obtained 
from this validation is depicted in Figure 2.4. Primer and probe combinations for the 
ALOX-5 gene were unable to produce a satisfactory efficiency in either singleplex or 
multiplex conditions. Therefore, an Assay on DemandTM (Applied Biosystems) product 
was used see Table 2.4 for manufacturers code. 
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Figure	  2.4	  An	  example	  of	  multiplex	  efficiency	   curves	   for	  RT-­PCR	  primer	  and	  
probe	  sets	  displaying	  the	  relationship	  between	  G0S2	  and	  18s.	  Efficiency	  values	  were	   measured	   using	   the	   CT	   slope	   method.	   This	   method	   involves	   generating	   a	  dilution	  series	  of	  the	  target	  template	  and	  determining	  the	  CT	  value	  for	  each	  dilution.	  A	  plot	  of	  CT	  versus	  log	  cDNA	  concentration	  is	  constructed.	  
 
Procedure. 
 cDNA was amplified in a 20µl reaction containing 1x TaqMan PCR MasterMix 
(Sensimix dT - QT6T3, Quantace, UK), 125nM FAM-TAMRA labeled probe (Sigma 
Aldrich) and 1µM of primers (Sigma Aldrich). All reactions were multiplexed with 1x 
VIC-TAMRA 18s (Applied Biosystems). An ABI 7500 fast real time PCR system was 
used under the following cycle conditions:  
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Time	   Temperature	  (oC)	   Cycles	  2	  minutes	   50	   1	  10	  minutes	   95	   1	  15	  seconds	   95	   40	  1	  minute	   60	   40	  30	  seconds	   72	   40	  
Table	  2.5	  Thermocycling	  profile	  used	  in	  the	  Q-­Real-­Time	  PCR.	  
	  
Final measurements were an average of at least three independent experiments, in 
triplicate wells for each condition. Assessment of statistical significance was preformed 
using fold changes of gene expression and was conducted by applying the unpaired t-test.  
2.1.8 Microfluidic gene card (Q-RT-PCRm) 
Principle 
Developed and sold by Applied Biosystems the microfluidic gene card is a 384-
well custom array that allows detection of 384 simultaneous quantitative real time PCR 
reactions. Each card contains the custom ordered genes already pre-loaded into the well 
and present in duplicate, arranged in 96 wells (96x2x2=384). Therefore, 96 genes can be 
observed and measured in duplicate per card. The plate is run on an ABI 7900H 
thermocycler (Applied Biosystems) containing a 96-well plate heating block and 
analysed as a normal real time PCR reaction.	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Figure 2.5 Diagrammatic representation of the genes included on the microfluidic 
card. Included on the card were genes that could be ascribed in to various grouped 
pertinent to the prostate nuclear receptor network. The picture not only shows their 
function but also their sub-cellular location. Produced by Dr. James Thorne. Full list in 
Appendix section.	  
 
Procedure 
RNA concentrations of each sample were measured using the NanoDrop and 
diluted accordingly to the lowest within the samples to be analysed. One-step reaction 
Master-Mix (Qiagen) (200µl) was added to the diluted RNA together with RT mix (4µl) 
(Qiagen), 100µls of reaction mix were then dispensed per every two rows in the card. 
This was then centrifuged twice at 10,000g for 2 minutes to distribute sample into each 
well. The plate was then sealed and run on the ABI 7900 machine under the following 
cycle conditions:  
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Time	   Temperature	  (oC)	   Cycles	  30	  seconds	   50	   1	  15	  minutes	   95	   1	  45	  seconds	   95	   40	  45	  seconds	   60	   40	  45	  seconds	   76	   40	  
Table	   2.6	   Thermocycling	   profile	   used	   in	   the	   microfluidic	   gene	   card	   q-­Real-­
Time	  PCR.	  
 
2.1.9 Western Immunoblotting  
Principle 
               The extraction, purification and quantification of different proteins is an 
important part of molecular biology, allowing comparative levels of expression. As many 
proteins have different molecular sizes exploiting their inherent charge differences allows 
their separation through electrophoresis. Western immunoblotting uses electrophoresis on 
a polyacrylamide gel (PAGE). Using this background allows the proteins to move 
through the pores in the gel. Pore size is determined by the levels of acrylamide within 
the gel and decreases as the concentration of acrylamide increases. Therefore, the 
combination of protein size, charge, and gel pore size regulates the speed of a protein’s 
migration through the gel. Increasing the acrylamide concentration of a gel will produce a 
smaller pore size giving a higher resolution of separation between proteins of a smaller 
molecular weight. In addition the gel is ran under denaturing conditions with 1% Sodium 
Dodecyl Sulphate (SDS). This has a high negative charge and upon heating with the 
protein lysates attaches to them increasing the negativity exhibited. An additional benefit 
of the heating in the presence of SDS and β-mercaptoethanol presence is the reducing of 
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tertiary and secondary structures producing a linear confirmation. These products when 
ran on an acrylamide gel form an anionic system with the negatively charged SDS coated 
proteins migrating from the cathode down through the gel towards the positive anode. 
Boiled SDS coated protein lysates are loaded into a gel made up of two segments a 
stacking (or loading) gel and a resolving gel. The stacking gel has a low concentration of 
buffers and allows the proteins to migrate as a thin band when a current is applied to 
them. Application of constant voltage to the gel initiates migration of the lysates with the 
lower molecular weight proteins moving faster through the gel. Upon completion of this 
stage there will be a separation of the proteins by the molecular weight (kDa) and the 
contents of the gel is ready for the transfer stage to a protein binding membrane. 
Polyvinylidene Fluoride (PVDF) is an inert fluoropolymer that has high protein retention. 
On contact with the acrylamide gel containing the proteins in the presence of a voltage 
PVDF can hold the proteins that migrate off the gel. Once bound to the surface of the 
PVDF membrane the proteins are washed in 5% non-fat milk, this blocks nonspecific low 
affinity interactions of antibody-protein. Following this incubation with specific antibody 
allows recognition and stable binding. Primary antibody is then recognised and bound by 
a secondary antibody used for detection purposes. Secondary antibodies are conjugated to 
a moiety, commonly Horseradish Peroxidase (HRP) that upon application of a chemical 
substrate (ECL, Amersham) will produce light. The light emitted by the reaction at the 
site of the protein of interest can be visualised as a band present when impressed on a 
sheet of auto-radiographic film in a dark room. 
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Procedure 
 Exponentially growing cells maintained in normal cell culture conditions were 
trypsinised and pelleted in a Falcon tube (10ml) by centrifugation at 1,300 g. Cells were 
then washed in ice cold phosphate buffered saline (PBS) and respun. To the resulting 
pellet RIPA buffer was added to lyse the cells, a flask containing 5x106 cells required 
100µl RIPA buffer. Lower cell amounts were treated accordingly, and protease inhibitor 
(Sigma Aldrich) was added at a volume of 1µl per million cells. The tube was then 
vortexed for 10 seconds to increase the extent of cell lysis and stored at -20oc for 30 
minutes, this was then repeated four times to enhance the protein yield. Upon completion 
the protein lysates were centrifuged at 12,000g for 10 minutes at 4oc and supernatant was 
transferred into a new 1.5ml Eppendorf tube and stored at -80oc. 
 Quantification of proteins was required to ensure equal amounts were loaded 
between samples, unequal loading would influence interpretation of the resulting bands 
density. Using the Bio-Rad Protein Assay kit (Reagent A 500-0113, Reagent B 500-
01114, Biorad) the concentration of proteins in a sample can be obtained. This process 
used the shift in colour change that was proportional to protein content within the 
reaction mix. Presence of the reaction shifts absorbance from 465nm to 595nm in 
conjunction with the stabilisation of the dye. This produced a visible colour change from 
yellow to blue. A standard solution containing Bovine serum albumin (BSA) in RIPA 
was produced at 10µg/µl and serial dilutions were performed in RIPA creating a standard 
curve. A volume of 5µl was loaded into duplicate wells of a clear bottom plastic 96-well 
plate (Costar), in addition 5µl of protein extracts were also added in duplicate. To each 
well Bradford reagent A (25ul) and Bradford reagent B (200µl) was added and the plate 
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left at room temperature for 10 minutes. The plate was then read using 1420 Multilabel 
Counter (Perkin Elmer) and resulting data transferred to a spreadsheet of the Excel 
program, determination of protein concentration occurred by the following method: 
 
y = absorbance of well 
a = slope of standard curve 
x = concentration of sample 
b = intercept 
y = ax + b 
Rearranging the equation gives x = (y-b)/a 
 
 
 
 
 
 
	  
Figure	  2.6	  Linear	  regression	  curve	  obtained	   from	  running	  protein	  standards	  
of	  BSA.	  This	  was	  used	  to	  calculate	  the	  protein	  concentration	  of	  the	  collected	  protein	  lysate	  samples.	  Absorbance	  is	  indicated	  along	  the	  y	  axis	  and	  protein	  concentration	  is	  along	  the	  x	  axis.	  	  
 
            With the protein concentrations calculated, equal amounts (generally 30-40µg) 
were diluted into ddH20 and 2x Laemelli buffer (4% SDS, 10% β-mercaptoethanol, 20% 
Glycerol, 0.004% Bromophenol Blue & 0.125M Tris-HCL pH 6.8) to an equal volume. 
These were then boiled at 98oc for 5 minutes to reduce secondary and tertiary structures 
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and coat the proteins in negatively charged SDS. Gels were cast with 12.5% acrylamide 
content using the following recipe:  
Resolving gel: 
Compound Volume 
Ammonium Persulphate (Sigma Aldrich) Spatula tip 
ddH2O 1.9ml 
Stock 2* 10ml 
30% Bis-Acrylamide (Gene Flow) 8.1ml 
Tetramethylethylenediamine (TEMED) 
(Sigma Aldrich) 6.2µl 
* STOCK2: (500ml) - 0.75M TRIS 45.5g, 0.2% SDS 1g, pH 8.8, made up with ddH2O 
Table	   2.7	   Reagents	   and	   quantities	   used	   in	   the	  making	   of	   a	   resolving	   gel	   for	  
western	  immunoblots.	  
	  
Stacking (or loading) gel: 
Compound Volume 
Ammonium Persulphate (Sigma Aldrich) Spatula tip 
ddH2O 3.7ml 
Stock 1* 5ml 
30% Bis-Acrylamide (Gene Flow) 1.3ml 
Tetramethylethylenediamine (TEMED) 
(Sigma Aldrich) 3.4µl 
*STOCK1: (500ml) - 0.2 M TRIS 15.15 g, 0.2%SDS 1 g, pH 6.8, made up with dH2O 
Table	   2.8	   Reagents	   and	   quantities	   used	   in	   the	   making	   of	   a	   stacking	   gel	   for	  
western	  immunoblots.	  
 
 The thickness of gels used was 1.5mm prepared by using 1.5mm plates (Biorad) 
and 1.5mm combs (Biorad) containing 10 wells. Once set gels were loaded into gel tanks 
(Biorad) and combs removed. Samples were loaded into the wells alongside a running 
ladder made up of marker proteins of a known molecular weight (Dual Colour Precision 
Ladder (Biorad)).  
             Gel tanks were filled with 1 litre 1X running buffer (1litre 10X: Glycine 141.1g 
(Sigma Aldrich), TRIS 30g (Sigma Aldrich), SDS 10g (Sigma Aldrich), made up 1L 
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dH2O running buffer, the gels were run at a constant 120v for approximately 90 minutes 
or until the dye front passed through the bottom of the gel. Upon completion the 
apparatus was dismantled and gel removed for transfer to the PVDF (Millipore) 
membrane. This was prepared by immersion in methanol for 10 seconds to activate it, 
then placed in ddH2O for 1 minute and then left to equilibrate in 1 litre 1X transfer buffer 
(1litre 10X: TRIS 30.28g, Glycine 144g, SDS 1g, made up 1L dH2O – 1X: 100 ml 10X 
buffer, 700 ml dH2O, 200 ml methanol) for 5 minutes. Using the appropriate apparatus 
(Biorad) the gel and PVDF membrane were set up between sponge and filter paper in the 
following order: 
Figure	  2.7	  Arrangement	  of	  wet	  transfer	  protocol	  for	  protein	  transfer	  to	  PVDF	  
membrane.	  
	  	  
To ensure no air bubbles impeded protein transfer efficiency the sandwich was 
assembled in transfer buffer and each layer was rolled with a pipette to exclude air 
bubbles. The sandwich was enclosed in a cassette, immersed in transfer buffer containing 
an ice block and ran for 60 minutes at 80V at room temperature.  
Upon completion the sandwich was removed and the PVDF membrane was 
stained with Ponceau S solution (Sigma Aldrich) for 5 minutes, this was then removed 
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and membrane washed in ddH2O. Ponceau S stained present proteins and allowed visual 
assessment of the success of the transfer, successful transfers were then left in 5% milk 
dissolved in TBS-T (1litre	   10X:	   50	   ml	   1M	   Tris-­‐HCl	   pH	   7.6,	   NaCl	   20g,	   Tween-­‐80	  0.625ml,	   dH2O	   2449.4	  ml).	  Milk	   interacted	   and	   bound	   to	   the	   surface	   of	   the	   PVDF	  inhibiting	   any	   low	   affinity	   interactions	   with	   antibody,	   thus	   reducing	   non-­‐specific	  binding	  signals.	  Blocking	  was	  conducted	  at	  room	  temperature	  on	  a	  rocking	  platform	  for	  at	  least	  60	  minutes.	  Upon	  completion	  the	  membrane	  was	  washed	  three	  times	  for	  10	  minutes	  in	  TBS-­‐T	  to	  remove	  excess	  milk.	  Primary	  antibody	  was	  next	  added	  to	  a	  solution	   of	   5%	   milk	   in	   TBS-­‐T.	   Concentration	   of	   antibody	   used	   varies	   depending	  upon	   their	  efficiency.	  The	  membrane	  and	  antibody	  were	   incubated	  overnight	  on	  a	  rocking	  platform	  at	  4oc.	  The	  loading	  standard	  used	  in	  all	  western	  blots	  was	  for	  the	  β-­‐actin	  gene	  and	  this	  was	  incubated	  at	  room	  temperature	  for	  60	  minutes.	  Below	  is	  a	  list	  of	  antibodies	  used	  in	  this	  work	  and	  their	  catalog	  number. 
Antibody Species Catalogue number 
VDR Anti-Rabbit Abcam Ab3508 
COX-2 Anti-Rabbit Cayman 160107 
ALOX-5 Anti-Rabbit Cayman 160402 
MCM7 Anti-Mouse Santa Cruz SC-9966 
P21(waf1/cip1) Anti-Mouse Abcam Ab-7960 
β-actin Anti-Rabbit Abcam Ab-1801 
AKR1C3 Anti-Mouse Sigma Aldrich A6229 
Table	  2.9	  List	  of	  primary	  antibodies	  used	  in	  Western	  immunoblotting.	  	  	  
	  
The day after primary antibody incubation the membrane was washed three times 
for 15 minutes at room temperature. Secondary HRP linked antibody was added to the 
membrane diluted in 5% milk TBS-T and incubated for 60 minutes at room temperature 
on a rocking platform. The origin of the primary antibody specifies the secondary to be 
used and upon completion of the incubation stage it was washed four times for 15 
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minutes in TBS-T. Visualisation occurred using chemoluminesence (Pierce Super Signal 
Picostain). Equal volumes of solutions A and B were mixed and pipetted onto the PVDF 
membrane and left to incubate for 5 minutes. The excess was then removed from the 
membrane and the membrane was carefully wrapped in cling film and placed into a 
developing cassette. Exposure took place in a dark room using Kodak autoradiography 
film and was placed into a developer (Kodak) the exposure times varied depending upon 
the signal achieved after 1 minute.  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  2.8	  An	  image	  taken	  from	  Western	  immunoblot	  analysis	  probed	  for	  VDR	  
and	  β-­actin.	   The	   top	   section	   depicts	   bands	   obtained	  when	  probing	  with	   the	  VDR	  antibody	  and	  the	  lower	  picture	  shows	  bands	  from	  β-­‐actin	  to	  show	  levels	  of	  protein	  loading.	  
 
 2.1.10 Cross-linked Chromatin Immunoprecipitation (xChIP) 
Principle 
 
Chromatin immunoprecipitation has become a widely applied method used to 
detect the presence of proteins at specifically identified genomic loci.. Cells were fixed 
with formaldehyde, this compound is able to cross-link the protein-protein and even 
DNA-protein interactions. This created a stable but reversible bond between them. After 
fixation the cells were lysed and the genomic template sheared to render access to 
crosslinked DNA-protein. In addition the sheared DNA has to be of a suitable size for 
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interpretation and PCR analysis. The general chromatin size suggested is a shearing size 
of 100 to 1000bp (average 500bp). After shearing to a suitable size the soluble chromatin 
is aliquoted and subject to immunoprecipitation. Protein specific for the antibody is 
selected (along with bound crosslinked DNA) and washing the immunocomplexes in 
solutions of increasing salinity reduced unbound DNA impurities.  
 
 
Figure 2.9 Chromatin immunoprecipitation for determining the association of 
proteins with specific genome sequences in vivo. Protein-DNA interactions are fixed 
with formaldehyde exposure. Cells are then lysed and soluble DNA sonicated. Specific 
antibody for the protein of interest is immunoprecipitated and pulled-down with agarose 
beads. Immunocomplexes are then removed and crosslinks are reversed by heating. 
Extracted DNA is isolated and used for PCR of specific genomic fragments.  
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The remaining antibody-Protein-DNA was then eluted to remove antibody. 
Reversal of the formaldehyde cross-links was conducted through heating and DNA 
phenol-chloroform extracted and ethanol precipitated.  
 
Procedure 
 
RWPE-1 and PC-3 cells were seeded and left overnight to adhere to the surface of 
the flasks. At approximately 60% confluence the cells were treated with 1α,25(OH)2D3 
(100nm) or ethanol vehicle control. Upon cessation of the timecourse formaldehyde 
(Sigma Aldrich) was added to each flask to a concentration of 1% for 10 minutes at room 
temperature. To stop the crosslinking process glycine was added to a final concentration 
of 0.125M and left for 5 minutes at room temperature. Medium was poured out of the 
flasks and the cells were washed twice with ice cold PBS (5mls) containing protease 
inhibitor cocktail (Sigma Aldrich) (1µl per ml). Cells were scraped and harvested into 
5mls ice cold PBS (containing protease inhibitor) and then spun at 1,200 g for 5 minutes 
at 4oc. The resulting cell pellet was then suspended into SDS lysis buffer and left at room 
temperature for 5 minutes. Sonication was performed using a Diagenode Bioruptor 
specifically produced for chromatin shearing. Lysates were sonicated in ice cold water on 
a medium setting for 30 seconds on and 30 seconds off repeated with 5 cycles. Cellular 
debris was then removed by centrifugation at 12,000g for 10 minutes at 4oc, and the 
supernatant containing the soluble chromatin fraction was transferred to new Eppendorfs. 
Aliquots of chromatin (200µl) were diluted to 500µl using dilution buffer (0.01%SDS, 
1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl pH 8.1 and 167mM NaCl) and 
antibody added. This was then incubated on an end over end rotator (25 rotations per 
minute) overnight at 4oc. 
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Figure	   2.10	   Chromatin	   fragments	   with	   an	   average	   shear	   size	   of	   500bp.	  Chromatin	  has	  been	  sheared	  using	  the	  Bioruptor	  Sonicator.	  The	  sheared	  chromatin	  is	  analyzed	  on	  a	  1.5%	  agarose	  gel.	  	  
 
 
Antibody Catalogue number 
VDR Ab3508 
p-POL II Ab5131 
NCOR1 Ab24552 
NCOR-2/SMRT Ab24551 
Table	   2.10	   Antibodies	   used	   in	   the	   ChIP	   procedure	   and	   their	   respective	  
catalogue	  numbers.	  	  
 
 The following day protein A/G agarose slurry (Millipore) (60µls) was added to 
the sample and left to rotate for 1 hour. This collected the immunocomplexes formed 
over the previous night. Protein A (IgG binding protein) agarose beads have a porous 
sponge like structure that binds the antibodies immobilizing the protein-DNA bound 
fragments. The agarose pellets were spun 100g for 1 minute and washed sequentially on 
an end over end rotator with the following solutions: Low salt immune complex wash 
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buffer (0.1% SDS, 1%Triton X-100, 2mM EDTA, 20mM Tris-HCl pH8.1 and 150mM 
NaCl), high salt immune complex wash buffer (0.1% SDS, 1%Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl pH 8.1 and 500mM NaCl), LiCl immune complex wash buffer 
(0.25M LiCl, 1% NP40, 1% sodium deoxycholate, 10mM Tris-HCl pH 8.1 and 1mM 
EDTA) and twice with TE buffer (10mM Tris-HCl pH 8.0 and 1mM EDTA). Elution of 
immunocomplexes occurred within elution buffer (250µls) rotating for 30 minutes at 
room temperature. During this time Protein-DNA bound fragments were released from 
the agarose. This was repeated yielding 500µl of protein-DNA solution. Collected 
protein-DNA fragments present in the supernatant were subjected to 65oc heating and 
NaCl (200mM) overnight to reverse the formaldehyde crosslinks. The following day 
proteinase K (40µg/µl) (Invitrogen) was added to the samples and incubated at 42oc for at 
least 1 hour to digest proteins. This was conducted alongside a 200µl sample of stock 
chromatin made up to 500µl with dilution buffer (0.01%SDS, 1.1% Triton X-100, 1.2mM 
EDTA, 16.7mM Tris-HCl pH 8.1 and 167mM NaCl). This produced the input samples 
representing total DNA within the cell. DNA extraction, with the addition of 
phenol/chloroform/isoamyl alcohol (25:24:1) (500µl) (Ambion), was mixed well using a 
vortex mixer and spun for 5 minutes at 12,000g. This produced three phases and the clear 
top phase was collected taking care not to collect the intermediate white protein phase. 
The supernatant was re-extracted with chloroform (500µl) to remove excess phenol and 
mixed well before centrifugation at 12,000g for 5 minutes. Then clear supernatant was 
removed and added to ice-cold ethanol (1ml), glycogen (20µg/µl) (1µl) and sodium 
acetate (120µl) 3M pH5.2 and stored at -20oc for at least 1 hour. The tubes were then 
spun for 15 minutes at 12,000g at 4oc and the supernatant removed with care taken not to 
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disturb the DNA pellet. This was then washed with 70% ethanol and spun at 12,000g for 
5 minutes and air dried before resuspension in nuclease free water (50µl). The resulting 
DNA is then stable for an indefinite period of time and stored at -20oc. DNA obtained 
from the chromatin immunoprecipitation (alongside the input samples of sonicated 
chromatin) was then be examined by PCR using primers design to amplify specific 
genomic regions the result of which is demonstrated below. 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  2.11	  Example	  of	   semi-­quantitative	  PCR	   from	  a	  ChIP	  experiment	  using	  
the	  described	  protocol.	  The	  oestrogen	  receptor	  antibody	  (Santa	  Cruz)	  was	  used	  to	  pulldown	  crosslinked	  and	  sonicated	  chromatin	  in	  breast	  cancer	  cell	  line	  MCF-­‐7	  cells.	  This	   identified	   an	   ERα	   response	   element	   located	   proximal	   to	   the	   PBF	   gene	   and	  published	  in	  Watkins	  et	  al	  2010	  [168].	  NTC=	  No	  template	  control.	  	  
 
 However, as stated previously this process was semi-quantitative. Therefore, 
quantitative PCR analysis in real time with the double stranded DNA dye SYBR Green 
was preferred. This had a number of advantages over analysis by gel electrophoresis, not 
least was the high throughput approach increasing the number of samples used. Firstly, 
the product of PCR was quantified in the linear range and not an endpoint reaction. In 
addition to this reactions can be easily ran in triplicate wells preventing the drawing of 
conclusions from a single PCR reaction. SYBR Green is an intercalating dye able to 
ERα   
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occupy double stranded DNA and was a financially viable alternative to using expensive 
FAM-TAMARA dyes used in q-RT-PCR reactions. The dyes level of fluorescence was 
measured at the annealing stage of each cycle allowing the PCR reaction to be visualized 
and quantified. The read out given was an amplification curve plotted on a graph of cycle 
time (Ct) and log10 fluorescence. As there was no specific probe used and SYBR Green 
was not selective all double stranded DNA will emit a fluorescent signal. A dissociation 
curve stage was carried out at the end of each PCR to ensure that the primers have 
formed a single product. Final measurements were an average of at least three 
independent experiments performed in triplicate wells for each timepoint. As with regular 
amplification of genomic DNA PCR with ChIP DNA used oligonucleotides 
approximately 20-22 bases in length with melting temperature of approximately 60oc. 
However, in addition to these requirements primers for amplification of ChIP’ed DNA 
should yield a product no greater than 146 base pairs (the length of DNA wrapped around 
one nucleosome). To exclude binding non-specific target amplification and maintain 
primer efficiency sequences were validated for their optimum concentration and melting 
temperatures are shown below in Figure 2.12.  
 
 
	  
	  
	  
Figure	   2.12	   An	   example	   of	   a	   gradient	   PCR	   result	   examining	   optimum	  
annealing	   temperatures	   for	   primer	   pairs.	   The	   above	   image	   demonstrates	   that	  primer	  pair	  VDRE-­‐2	  can	  be	  used	  with	  an	  annealing	  temperature	  between	  56.4oC	  and	  60.0oC.	  
56.4 57.6 60.0 61.5 62.1 
Annealing Temperature (oC) 
VDRE-2 
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Each primer set was subject to PCR reactions using a gradient PCR of five different 
annealing temperatures, products were then run on a 1.5% agarose gel containing 
ethidium bromide and visualised. 
Region 
Genomic 
location 
5’ – 3’ 
Forward Reverse Annealing Temp 
TSS -20 to +50 TATATCAGGGCCGCGCTG GGCTCCACAAGGAACTGACTTC 60
oC 
VDRE1 -2146 to -2129 GAGGAAGGGGATGGTAGGAG CTGGCAGATCACATACCCTGT 60
oC 
VDRE2 -4505 to -4489 TAGAGATGCTCAGGCTGCTG AGAGCTTCACCGACATAGCC 60
oC 
VDRE3 -7056 to -7036 AGCAGCACTGAAGCCTAACC GAGAGGCCTACCAGCTTCAG 60
oC 
Table	  2.11	  Forward	  and	  reverse	  primers	  used	  for	  p21(waf1/cip1)	  amplification	  in	  
ChIP	  experiments,	  annealing	  temperature	  used	  and	  genomic	  location.	  
 
 
Reagent	   Volume	  (µl)	  	  	  PCR	  Master	  Mix	  dt	  (Quantace)	   5.000	  SYBR	  Green	  (Quantace)	   0.200	  Forward	  Primer	  (100µM)	   0.125	  Reverse	  Primer	  (100µM)	   0.125	  Nuclease	  Free	  Water	   2.800	  DNA	   2.000	  
Table	  2.12	  Master	  mix	  reagents	  and	  volumes	  used	  for	  the	  q-­RT	  PCR	  analysis	  of	  
ChIP	  samples	  using	  SYBR	  Green.	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For analysis of ChIP recovered DNA Q-RT PCR was performed using the following 
program.  
Time	   Temperature	  (oC)	   Cycles	  30	  seconds	   50	   1	  15	  minutes	   95	   1	  45	  seconds	   95	   40	  45	  seconds	   60	   40	  45	  seconds	   76	   40	  
Table	  2.13	  PCR	  program	  for	  q-­PCR	  analysis	  of	  ChIP	  recovered	  DNA.	  
SYBR Green is a nonspecific intercalating fluorescent dye it will emit a light 
signal upon interaction with double strand DNA. Therefore, it is important a dissociation 
study be performed on every PCR plate run. Triplicate wells were then examined for their 
dissociation curve, a single curve confirms that there is one specific product formed in 
the PCR well. Dissociation curves with more than one peak were excluded from the 
triplicate set (Figure 2.13).  
Calculation for ChIP enrichment were as follows:  
dCt (normalised ChIP)= (Ct(ChIP) - (Ct(input) - LOG2 (3.322*))  
 
% Input = 2(-dCt(normalised ChIP)) 
*= Fraction of Input chromatin saved (1%) 
 
Time	   Temperature	  (oc)	   Cycles	  15	  seconds	   95	   1	  1	  minute	   60	   1	  15	  seconds	   95	   1	  
Table	   2.14	   Dissociation	   curve	   program	   required	   to	   confirm	   single	   PCR	  
product	  is	  formed	  within	  each	  wells	  reaction.	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Figure	   2.13	   Image	   showing	   a	   dissociation	   curve	   peak	   and	   ChIP	   sample	  
amplification	   curves	   demonstrating	   a	   single	   product	   formed	   in	   a	   PCR	  
triplicate.	  Appearance	  of	  more	  than	  one	  peak	  indicates	  that	  non-­‐specific	  product	  is	  also	  being	  formed	  and	  such	  wells	  are	  excluded	  from	  the	  analysis.	  q-­‐Real-­‐Time	  PCR	  amplification	   curves	   (right)	   from	   ChIP	   experiments.	   The	   IP	   sample	   produces	   a	   Ct	  higher	  than	  the	  Input	  chromatin	  and	  a	  Ct	  lower	  than	  that	  of	  the	  IgG	  negative	  control	  immunoprecipitation.	  An	  additional	  no	  template	  control	  well	  is	  depicted	  that	  arises	  above	  35	  cycles	  and	  therefore	  is	  discounted	  as	  it	  is	  due	  to	  fluorescence	  from	  primer	  dimers	  formed	  in	  the	  absence	  of	  DNA	  template.	  	  
 
 
 
 
	  
Figure	  2.14	  Image	  showing	  q-­RT-­PCR	  products	  from	  xChIP	  experiments	  using	  
NCOR1	   specific	   antibody	   ran	   out	   on	   a	   1.5%	   agarose	   gel	   alongside	   Input	  
samples.	  Crosslinked	  ChIP	  was	  conducted	  as	  described	  above.	  Recovered	  DNA	  was	  extracted	  and	  subject	  to	  Q-­‐RT-­‐PCR,	  upon	  completion	  the	  PCR	  product	  was	  removed	  from	  the	  well	  and	  ran	  on	  an	  ethidium	  bromide	  agarose	  gel	  at	  100volts.	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 2.1.11 Re-ChIP 
Re-ChIP was conducted as per xChIP with the addition of a further 
immunoprecipitation step. This is performed to examine the extent of co-occupancy of 
two proteins at the same genomic location. During the cross linking process protein-
protein binding was fixed as well as protein-DNA binding. This means by performing 
Re-ChIP the relationship between two proteins can be observed. The experiments 
performed in this thesis investigated the levels of co-occupancy between VDR and 
NCOR1 and VDR and NCOR-2/SMRT. Therefore, the following antibodies were used: 
Re-ChIP First IP Second IP 
VDR-NCOR1 VDR (Ab3508) NCOR1(Ab24552) 
VDR-NCOR-2/SMRT VDR (Ab3508) NCOR-2/SMRT (Ab24551) 
Table	  2.15	  Order	  of	  Re-­ChIP	  antibody	  and	  their	  product	  identification.	  	  
	  
Re-chip was performed as per the xChIP protocol with the addition of an 
incubation step in dilution buffer containing Dithiothreitol (DTT) (10mM) for 1hour. 
This is a strong reducing agent able to elute the first immunoprecipitant antibody (due to 
the high affinity for disulphide bonds) whilst leaving the formaldehyde crosslinks 
unaffected. The second round of immunoprecipitation took place and was washed as 
described in the xChIP procedure. Elution and extraction of immunoprecipitated DNA 
was performed as per above and q-RT PCR carried out using specific primers for the 
genomic region of interest.  
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2.1.12 Native chromatin Immunoprecipitation (nChIP) 
 Native chromatin immunoprecipitation is used for the analysis of histone 
modifications at specific genomic loci. The DNA from all nChIP samples used in this 
thesis were produced by Dr. James Thorne and used to examine the VDREs contained 
within the p21(waf1/cip1) promoter region in chapter 5. In addition to this the author of this 
thesis performed Q-RT-PCR for the following regions used the remaining DNA material 
from these samples:  
	  
Region 
Genomic 
location 
5’ – 3’ 
Forward Reverse Annealing Temp 
G0S2 
TSS 
+65 to  
-45 GGGGCCGCTTATATCTTTC TTTTCCCCTCCTCTTCTTCC 60
oC 
ALOX5 
TSS 
+55 to   
-102 GCGTGAAGAGTGGGAGAGAA CCAGGTGTCCGCATCTAGC 60
oC 
PTGS2 
TSS 
-22 to 
+58 GGAAGGTTCTCTCGGTTAGC CTGCTGAGGAGTTCCTGGAC 60
oC 
	  
Table	   2.16	   Forward	   and	   reverse	   primer	   sequences	   used	   for	   analysis	   of	  
transcription	  start	  sites	  (TSS)	  using	  nChIP	  samples.	  
 
 
	  
	  
	  
	  
	  
Figure	  2.15	  	  q-­RT-­PCR	  product	  performed	  on	  nChIP	  samples	  ran	  on	  an	  agarose	  
gel	   (1.5%).	   Soluble	   chromatin	   was	   digested	   using	   micrococcal	   nuclease	   and	  immunoprecipitated	  with	  antibodies	  specific	  to	  histone	  tail	  modifications	  described	  above.	  Recovered	  DNA	  was	  extracted	  and	  subject	  to	  q-­‐RT-­‐PCR.	  Upon	  completion	  the	  PCR	  product	  was	  removed	  from	  the	  well	  and	  ran	  on	  an	  ethidium	  bromide	  agarose	  gel	  at	  100volts.	  	  
 
Calculation for nChIP enrichment were as follows:  
Normalised Fold Enrichment = LOG2(Bound-Unbound) 
 
PTGS-2 TSS 
Chapter 2                                                                                                                    Materials and Methods 
 
101 
2.1.13 Short hairpin RNA knockdown (ShRNA) 
Principle 
 RNA interference is a naturally occurring mechanism used by cells to regulate 
translation of genes. In this way a gene can be transcribed but the genes active product 
(protein) is never formed. Responsible for the identification and breakdown of the gene 
transcript are short sequences of RNA approximately 22 nucleotides in length named 
small interfering RNAs (siRNA). These are made up of specific sequences 
complimentary to segments of the target genes mRNA. This gives siRNAs the ability to 
detect and bind to their corresponding targets marking them for degradation, and 
resulting in the functional protein not being translated. The first identification of this 
short sequences was found in plants and since has been identified in yeast all the way up 
to higher eukaryotes. This process has been utilized by molecular biology with the 
transfection of sequences into a cells genome able to produce siRNA effects. However, 
the transfection of siRNA into mammalian cells is not stable. As the cells divide it is lost 
due to a lack of the required RNA polymerases needed for their propagation. Therefore, 
molecular biology has had to develop a new technique specific for shRNA transfection 
stable across successive generations. Using a vector based system not only allows the 
incorporation of the polymerases required but also the sense and antisense sequences 
required to produce knockdown of a specific mRNA sequence. Furthermore, the vector 
also contains a resistance sequence (often to an antibiotic) producing drug resistance. 
This allows the use of a selective agent (such as Neomycin) that permits only cells 
expressing resistance to grow and those that do not carry the vector will die.  
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Procedure 
 
To produce shRNA targeting AKR1C3 oligos containing the short hairpin sequence 
(Sigma Aldrich) were annealed and inserted in a pcDNA3.1 vector (Invitrogen). This has 
had the original CMV promoter substituted with the human H1 promoter. Both this and 
the establishment of the stable ShAKR1C3 cells was performed by Dr. Farhat Kahnim 
(University of Birmingham).  Briefly, PC-3 cells were transfected with 2µg plasmid 
DNA and 6µl of lipofectamine 2000 transfection reagent. Transfection was ceased after 
24 hours and RNA was extracted and subjected to reverse transcription and Q-RT-PCR 
using primers specific for 18s and AKR1C3.  
 
 
 
 
 
 
 
 
 
 
Figure 2.16 Validatory confirmation of scrambled control versus vector only and 
ShAKR1C3 sequences. PC-3 cells were seeded with of 5x105 per well in a 6 well plate 
and left to adhere overnight. Cells were transfected with plasmid DNA and 
Lipofectamine 2000 for 24 hours. The following day mRNA was extracted, reverse 
transcribed and Q-RT-PCR performed. Each data point represents the mean of three 
separate mRNA isolates amplified in duplicate wells ±SEM. Statistical significance 
assessed using t-test ( **=p-value <0.01). 
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2.1.14 MicroRNA isolation and extraction from TRAMP model 
serum samples 
Principle 
MicroRNAs are 19-24 base pairs in length and are highly abundant, currently 
there are approximately 800 microRNAs in observed in human cells [169]. However, the 
list has been rapidly expanding and their deregulation has also become apparent in many 
different cancers (reviewed in [170]) . However, more recent investigations demonstrated 
that serum and plasma samples are able to reflect levels of deregulated microRNAs found 
in disease states. This has propelled serum analysis for microRNAs to the forefront of 
diagnostic biomarker research.  
Procedure 
TRAMP mouse serum samples were collected from Roswell Park Cancer Institute 
Core Resource and extracted using the following protocol. Serum samples (100µl) were 
mixed with Trizol LS (300µl) (Invitrogen) and left to equilibrate at room temperature for 
5 minutes. This allowed RNA extraction from a smaller number of cells or a sample that 
may have a low concentration of RNA such as serum. Chloroform (100µl) was added to 
the tube and vortexed for 10 seconds before leaving at room temperature for 10 minutes. 
The tubes were then centrifuged for 15 minutes at 12,000g. To the supernatant 
isopropanol (propan-2-ol) (200µl) was added and the tube inverted 5 times and kept at -
20oc for 30 minutes to ensure precipitation of RNA. The sample was then centrifuged for 
10 minutes at 12,000g at 4oc to collect a nucleic acid pellet at the bottom of the 
Eppendorf. The isopropanol was then removed and the pellet resuspended in 75% ethanol 
and centrifuged for 5 minutes at 12,000g at 4oc. The 75% ethanol was then removed and 
the sample resuspended in nuclease free water (50µl) and stored at -80oc. Reverse 
transcription of microRNA used an Applied Biosystems Reverse Transcription 
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microRNA kit. A master mix was produced for the specific microRNA of interest, 
alongside a second master mix. This second master mix was usedfor reverse transcription 
of the internal control used in the q-RT PCR reaction. The control most often used when 
investigating microRNAs in murine samples is snoRNA202, shown to be highly 
abundant in mouse tissue and so most commonly used. Therefore, two reverse 
transcription master mixes were produced. Upon completion of the reverse transcription 
protocol the samples are stored in -20oc. 
 
Component (n=1) per 15 µ l reaction 
dNTP 0.15µl 
RNase Inhibitor 0.19µl 
Reverse Transcriptase enzyme 1.00µl 
10x RT Buffer 1.50µl 
Nuclease Free Water (NFW) 4.16µl 
5x RT MiR106b Primers 3.00µl 
RNA 10ng 
Table	   2.17	   Components	   of	   the	   reverse	   transcription	   reaction	   required	   for	  
miR106B.	  
	  
	  
	  
	  
	  
	  
	  
Component (n=1) per 15 µ l reaction 
dNTP 0.15µl 
RNase Inhibitor 0.19µl 
Reverse Transcriptase enzyme 1.00µl 
10x RT Buffer 1.50µl 
Nuclease Free Water (NFW) 4.16µl 
5x RT SnoRNA202 Primers 3.00µl 
RNA 10ng 
Table	  2.18	  Components	  of	  the	  reverse	  transcription	  reaction	  required	  for	  the	  
endogenous	  control	  SnoRNA202.	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The reverse transcription of microRNAs was then conducted using the following thermal 
program: 
 
Time Temperature 
30minutes 16oC 
30minutes 42oC 
5minutes 85oC 
∞ 4 oC 
Table	   2.19	   Thermal	   profile	   for	   reverse	   transcription	   of	   microRNAs	   using	  
Reverses	  Transcription	  microRNA	  kit	  (Applied	  Biosystems).	  
 
 The q-RT PCR analysis of microRNAs in serum required the running of both the 
specific miR106B sample and SnoRNA202 in singleplex reactions. The MiR106B and 
SnoRNA202 reverse transcribed products were placed into a PCR reaction with their 
specific PCR primer and probe combinations (Applied Biosystems) in the quantities 
described below. 
Component (n=1) per 10 µ l reaction 
Master Mix 5µl 
MiR106B Primer & Probe Mix 0.5µl 
Nuclease Free Water (NFW) 3.5µl 
cDNA MiR106B 1µl 
Table	   2.20	   Components	   of	   the	   q-­Real-­Time	   PCR	   reaction	   required	   for	  
miR106B.	  
 
 
Component (n=1) per 10 µ l reaction 
Master Mix 5µl 
SnoRNA202 Primer & Probe Mix 0.5µl 
Nuclease Free Water (NFW) 3.5µl 
cDNA SnoRNA202 1µl 
Table	   2.21	   Components	   of	   the	   q-­Real-­Time	   PCR	   reaction	   required	   for	   the	  
endogenous	  control	  SnoRNA202.	  
 
An ABI 7500 fast real time PCR system was used under the following cycle conditions:  
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Time	   Temperature	  (oc)	   Cycles	  2	  minutes	   50	   1	  10	  minutes	   95	   1	  15	  seconds	   95	   40	  1	  minute	   60	   40	  30	  seconds	   72	   40	  
Table	  2.22	  Thermocycling	  conditions	  for	  the	  amplification	  of	  MiR106B	  and	  the	  
endogenous	  control	  SnoRNA202	  .	  
 
Final measurements were an average of a minimum of three independent 
experiments, in triplicate wells for each condition. Assessment of statistical significance 
was performed using fold chances of gene expression was conducted by applying the 
unpaired t-test. 
Upon analysis of the q-RT PCR data it was found that SnoRNA 202 was not 
present in the serum samples of TRAMP murine model. Therefore, it was necessary to 
explore alternative endogenous controls. The endogenous control used for analysis of 
human cell lines is the ribosomal 18s. Mouse 18s is homologous to human 18s and so it 
was decided that 18s levels of the TRAMP mouse cDNA should be assessed in serum. As 
shown in table 2.22 the levels of MiR-16 and MiR-143 were measured. Serum samples 
showed a high Ct of 18s and therefore two additional endogenous control alternatives 
were examined. These have been identified as potentially useful endogenous controls in 
serum analysis [171] and were assed for their level of expression. MiR-16 provided the 
highest level of expression (lowest Ct) and so was chosen as the endogenous control in 
serum q-RT PCR samples.  
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Endogenous 
control SNO202 18s MiR-16 MiR-143 
Mean Ct Undet. 27.37 25.46 31.61 
STD Dev Undet. 2.85 1.77 1.49 
SEM Undet. 0.42 0.26 0.22 
Table	   2.23	   Comparison	   of	   the	   different	   endogenous	   controls	   used	   in	   the	  
analysis	  of	  MiR-­106B	  levels.	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Chapter 3: Pre-receptor manipulation of 
PPARγ  signalling  
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3.1 Introduction 
 Nuclear Receptors (NRs) regulate gene targets that control cell growth and 
differentiation in prostate epithelial cells. The ability of NRs to exert these gene regulatory 
effects is intimately controlled by numerous factors including epigenetic mechanisms 
(reviewed in [172, 173]). However, NR activity is also governed by ligand availability.  
 Targeting of the AR by androgen deprivation therapy (ADT) forms the current 
treatment mainstay for CaP that has escaped the local prostate environment. However, 
recurrence of CaP in a castrate recurrent form, so called ADT-R CaP is predominantly lethal 
[174]. CaP in both early and late stage disease remains an attractive target for anticancer 
therapies that target NRs such as VDR, RARs/RXRs and PPARα/γ. However, de novo and 
acquired receptor resistance has limited these applications.  
 Expression of PPARγ is sustained in CaP and is able to exert a range of tumour 
repressive effects. Through induction of anti-proliferative and pro-differentiating gene targets 
PPARγ receptor has been the target of a phase II clinical study with Troglitazone, suggesting 
that this NR is a promising potential target for prostate cancer therapy [175]. Deregulated co-
repressor functions appear to be an important component for this resistance [176] with similar 
events disrupting AR signalling [177, 178] (reviewed in [85]). In an attempt to restore and 
enhance growth restraint a number of studies have targeted enzymes involved in androgen 
synthesis.  
 As a mechanism to restore PPARγ signaling we have considered the regulatory actions 
of aldoketoreductase 1C3 (AKR1C3), a type 2 3α-Hydroxysteroid dehydrogenase or 17-beta-
HSD type 5. This is involved in the metabolism of androgen, converting androstenedione to 
testosterone [139]. However, AKR1C3 is a highly promiscuous, multi-functioning enzyme 
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that is able to convert many different substrates. The lack of primary substrate may result in 
the enzyme acting on alternative substrates, among which are the arachadonate derived 
prostaglandins that act as de novo ligands for PPARγ. Perhaps reflecting this ambiguity the 
other substrate choice for AKR1C3 is overexpressed in prostate cancer tissue samples and cell 
lines [179], but also is detected in cell lines with absent or low levels of AR. These findings 
suggest that 5α-Dihydrotestosterone may not be the primary substrate of AKR1C3 [137, 138].    
AKR1C3 may therefore utilise prostaglandin D2 (PGD2), converting it into the 9α,11β 
prostaglandin F2 [141] and preventing the generation of PGJ2 which is a potent, endogenous 
PPARγ ligand. Medroxyprogesterone acetate (MPA) is a sex hormone that has been 
demonstrated to be a potent inhibitor of AKR1C3 and other metabolic enzymes [180]. In 
leukemic systems a synergistic effect on cell death occurs in combination with PPARγ ligand 
bezafibrate, as a result of elevation of PGD2 concentrations [181]. Combinatorial treatments of 
MPA and PGD2 have been shown in other cancer disease models and samples to induce 
apoptosis and cell cycle arrest through PPARγ mediated activation pathways [182]. These 
findings suggest that elevated AKR1C3 may provide two key CaP benefits; namely to 
promote AR signalling and to limit anti-proliferative actions of PPARγ signalling. This study 
examined the effect of reducing AKR1C3 levels in prostate cell lines and thus elucidating its 
role in ADT-R CaP. ADT-R CaP cells stably expressing a short hairpin RNA sequence to 
AKR1C3 were investigated for the impact of the response to treatment with PGD2.  
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3.2 Results 
3.2.1 Characterisation of ShAKR1C3 clones. 
The transfected short hairpin mRNA sequence is processed in the nucleus by 
DROSHA and exported into the cytoplasm where it is bound by the RISC complex and 
cleaved. The resulting short nucleotide sequence, complementary to AKR1C3 mRNA 
(shAKR1C3) is able to detect AKR1C3 transcript targeting it for degradation. Thus cell 
lines stably expressing reduced AKR1C3 mRNA and protein are produced. The clones 
transfected with shAKR1C3 sequence were measured against an empty vector control.  
PC-3 and DU 145 cells containing the short hairpin sequences showed significant 
reduction in AKR1C3 mRNA in comparison to the vector only (VO) control transfection 
data (shown in Figure 3.1).  
Figure 3.1 Stably expressing shAKR1C3 achieved significant AKR1C3 knock-down 
in prostate cancer cell lines. PC-3 and DU 145 cells were seeded with of 5x105 per well 
in a 6 well plate and left to adhere overnight. The following day mRNA was extracted, 
reverse transcribed and Q-RT-PCR performed. VO = Vector only. Each data point 
represents the mean of four separate mRNA isolates amplified in triplicate wells ±SEM. 
Statistical significance assessed using t-test ( *=p-value <0.05, **=p-value <0.01). 
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PC-3 short hairpin clone #1 demonstrated 13.08% (±4.00 SEM) and clone #2 
demonstrated 15.21% (±6.50 SEM) expression in comparison to the vector only control. 
DU 145 shAKR1C3 also show reduced transcript measured at (33.56% (±12.21 SEM) 
and 48.91% (±7.52 SEM) for clone #1 and clone #2 respectively.) 
To examine further the extent of AKR1C3 knockdown Western immunoblot 
analysis was conducted using an antibody specific for the AKR1C3 protein. The 
shAKR1C3 transfected cell lines demonstrated reduced AKR1C3 at a protein level 
(Figure 3.2).  
Figure 3.2 Protein levels in ShRNA AKR1C3 Clones. PC-3 and DU 145 cells (two 
Vector only (VO) and two shAKR1C3 clones) were plated at 1x106 into T75 flask and 
left overnight to adhere. The following day cells were harvested and proteins extracted. 
Analysis of AKR1C3 was determined using Western immunoblot. Representative image 
shown of three independent experiments. β-actin used as a loading control. 	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To examine the functional consequence of reduced AKR1C3 mRNA and protein 
and to test the hypothesis that AKR1C3 contributes to impaired PPARγ activity the 
actions of PPARγ in the absence of AKR1C3 were investigated. 
3.2.2 Effect of PGD2 addition on growth rate in the reduced 
AKR1C3 environment. 
 Given that prostaglandin D2 is the biological precursor of PGJ2, exogenous 
addition would prompt either the conversion into PGF2 or hypothetically in the 
shAKR1C3 cells permit non-enzymatic conversion to the PPARγ ligand PGJ2. Therefore 
a dose response of PGD2 was conducted to establish any dose dependent effect that varies 
between the two cell lines. Data obtained from this experiment are shown in Figure 3.3. 
Exposure to PGD2 (5.0µM) in PC-3 shAKR1C3 clone 1 produced no significant decrease 
in proliferation, an effect similar to that seen in DU 145 knockdown cells. In addition, 
lower concentrations of PGD2 (2.50µM, 1.25µM and 0.625µM) also produced no 
significant change in proliferation response in comparison to vector only controls.  
Therefore, exogenous addition of PGD2 did not induce a significant decrease in 
proliferation. In an attempt to enhance to action of PPARγ treatment in the presence of 
the HDAC inhibitor Suberoylanilide hydroxamic acid (SAHA) was conducted. It was 
hypothesized that the use of SAHA in this study would overcome aberrant levels of 
HDAC activity present in malignant cell lines that may limit PGD2 signalling via PPARγ.  
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Figure	  3.3	  Cell	  proliferation	  is	  not	  altered	  in	  cells	  with	  AKR1C3	  knockdown	  in	  
response	  to	  PGD2.	  Cells	  were	  plated	  in	  a	  96-­‐well	  plate	  at	  2x103	  cells	  per	  well.	  PC-­‐3	  shAK1C3	   #1	   and	   DU	   145	   shAKR1C3	   #1	   dose	   response	   to	   PGD2	   was	   measured.	  Ligand	  exposure	  time	  was	  96	  hours	  with	  retreatment	  at	  48	  hours.	  VO=Vector only. Each	   data	   point	   represents	   the	   mean	   of	   four	   independent	   experiments	   each	   in	  triplicate	  wells	  ±	  SEM.	  
 
3.2.3 Cell proliferation in response to the HDACi SAHA in PC-3 
and DU 145 ShAKR1C3 transfected cells.    
Prostate cancer tissue and cell lines have been shown previously to have a 
decreased level of acetylated lysine residues in their core histones [151, 183]. A reduction 
in the overall level of HDAC activity is proposed to increase in lysine acetylation and 
induce an open chromatin context. In agreement with this, previous studies have shown 
this to facilitate PPARγ mediated actions [181, 184]. Therefore, it was hypothesized that 
HDACi in combination with the exogenous PGD2 may activate PPARγ target genes 
within ShAKR1C3 cells.  
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Figure	  3.4	  PC-­3	  and	  DU	  145	  proliferation	  response	  of	  malignant	  prostate	  cell	  
lines	  in	  response	  to	  the	  PGJ2	  precursor	  (PGD2)	  alone	  and	  in	  combination	  with	  
the	  HDAC	   inhibitor	  SAHA.	  Cells	  were	  plated	   in	  a	  96-­‐well	  plate	  at	  2x103	  cells	  per	  well	  and	  left	  overnight	  to	  adhere	  to	  the	  plate.	  Treatments	  commenced	  the	  following	  day	   and	  wells	  were	   retreated	   after	   48	   hours,	   total	   treatment	   time	  was	   96	   hours.	  	  Each	  data	  point	  represents	  the	  mean	  of	  three	  separate	  mRNA	  isolates	  amplified	   in	  triplicate	  wells	  ±SEM.	  VO=Vector only. Statistical	  significance	  assessed	  using	  t-­‐test	  in	  comparison	  to	  vehicle	  treated	  controls	  (*=p-­‐value	  <0.05,	  **=p-­‐value	  <0.01). 
 
Figure 3.4 shows PC-3 shAKR1C3 #1, DU 145 shAKR1C3 #1  and empty vector 
control responses to SAHA (0.5µM), PGD2 (2.50µM) alone and both in combination. 
SAHA inhibited proliferation in PC-3 and DU 145 cells containing the shAKR1C3 
sequence. PC-3 shAKR1C3 #1 showed no additive response when under the co-treatment 
conditions. Surprisingly, this experiment suggests that attenuating the level of AKR1C3 
may increase the sensitivity of the cell to HDAC inhibitors. The effect was measured in 
DU 145 shAKR1C3 #1 when compared to the empty vector control of the same treatment 
and trended toward to same response in PC-3 shAKR1C3 #1.  
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3.2.4 Cell proliferation in response to PPARγ antagonist GW9662 
in PC-3 and DU 145 ShAKR1C3 transfected cells.    
To investigate if this effect is mediated by PPARγ, a potent antagonist (GW9662) 
was used. This experiment was designed to investigate whether inhibition of PPARγ 
alone and in combination with SAHA will impact the proliferation rate of cells with 
reduced AKR1C3. 	  
Figure	   3.5	   Proliferation	   response	   of	   malignant	   prostate	   cancer	   cell	   lines	   in	  
response	  to	  the	  PPARγ 	  antagonist	  GW9662	  and	  the	  HDAC	  inhibitor.	  Cells	  were	  plated	  in	  a	  96-­‐well	  plate	  at	  2x103	  cells	  per	  well	  and	  left	  overnight	  to	  adhere	  to	  the	  plate.	  Treatments	  commenced	  the	  following	  day	  and	  wells	  were	  retreated	  after	  48	  hours,	  total	  treatment	  time	  was	  96	  hours.	  	  Each	  data	  point	  represent	  s	  the	  mean	  of	  three	   separate	   mRNA	   isolates	   amplified	   in	   triplicate	   wells	   ±SEM.	   Statistical	  significance	   assessed	   using	   t-­‐test	   in	   comparison	   to	   vehicle	   treated	   controls	   (*=p-­‐value	  <0.05).	  
  
 Figure 3.5 shows response of shAKR1C3 transfected clones and empty vector 
controls treated with SAHA, GW9662 and both in combination. DU 145 cells showed an 
increased sensitivity to SAHA in the presence of reduced AKR1C3 levels. Demonstrated 
also is that the potency of this response is diminished upon combined treatment with 
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GW9662, though this was not statistically significant. These experiments indicate that 
PPARγ maybe exerting minimal anti-proliferative responses upon cells with reduced 
AKR1C3 levels. 
3.2.5 Multi-targeted micro-fluidic Q-RT-PCR analysis of 
shAKR1C3 PC-3 cells.  
A microfluidic Q-RT-PCR approach was used to further this study and examine 
the impact of reduced AKR1C3 levels. Gene targets on the micro-fluidic card were 
selected to reflect the nuclear receptor role in the prostate environment including fatty 
acid regulatory factors, nuclear receptors (broad and low affinity), cell surface 
transporters, cell cycle regulators, and transcriptional coregulators.  
Figure	   3.6	   AKR1C3	   knockdown	   influences	   a	   network	   of	   genes	   involved	   in	  
transcriptional	   regulation.	   Untreated	   PC-­‐3	   vector	   only	   controls	   and	   untreated	  shAKR1C3	  PC-­‐3	  Clone	  #1	  samples	  were	  used.	  Total	  mRNA	  was	  added	  to	  the	  micro-­‐fluidic	   reverse	   transcription	  Q-­‐RT-­‐PCR	   two	   step	   reaction.	   Primer	   sets	   on	   the	   card	  were	  selected	  for	  their	  nuclear	  receptor	  prostate	  specific	  context	  consisting	  of	  nine	  groups	   listed	   in	   the	   materials	   and	   methods	   section.	   Downregulated	   genes	   were	  grouped	  according	  to	  their	  cellular	  actions.	  Histone	  deactylases	  (red	  box),	  NR	  CoAs	  (green	  box),	   (PPAR	  and	  PPAR	  specific	  CoAs)	   (blue	  box)	  and	  NRs	  (black	  box).	  Data	  are	  the	  mean	  of	  three	  biological	  experiments	  performed	  in	  technical	  duplicate.	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   The	   data	   shown	   in	   Figure	   3.6	   illustrates	   the	   genes	   with	   deregulated	   basal	  levels	   in	   PC-­‐3	   shAKR1C3	   clone	   #1. These were then grouped according to their 
biological function. Reduction in AKR1C3 levels was able to decrease the levels of 
expression of histone deactylases, nuclear receptor coactivators and PPARα and PPARγ. 
Importantly, the shAKR1C3 environment not only reduced the levels of these PPARs but 
also their specific coactivator PPARGC1A. A reduction of AKR1C3 levels was found to 
increase the basal expression of other nuclear receptors including ESR2 and THRβ.	  
3.3 Discussion 
 Previous studies show elevated AKR1C3 deprives the cell of J-series 
prostaglandins that are responsible for multiple cascade signals and ligands for NR 
mediated transcription. Further, it has recently been demonstrated [185] that stable 
expression of AKR1C3 in hormone dependent MCF-7 breast cancer cell lines has a 
negative impact upon the anti-proliferative actions of PGD2. It has been therefore 
hypothesised that silencing AKR1C3 within hormone independent disease may result in 
the pathway reverting to the non-enzymatic conversion to 15-PGJ2 a ligand for PPARγ 
initiating potentially apoptotic and differentiating actions.  
 PPARγ ligands have been investigated for the treatment of various cancer types 
for example neuroblastomas [186], colorectal [187] breast and prostate cancers [188, 
189]. Metastatic prostate cancer cells overexpressing AKR1C3 have been suggested to 
deprive PPARγ of its natural ligand 15Δ-PGJ2, driving the available PGD2 towards the 
formation of the proliferative 9α,11β-PGF2.   
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 Some CaP cell lines overexpress AKR1C3 mRNA and primary prostate tissue 
tumours are shown to have significantly increased AKR1C3 levels. Successful 
knockdown of AKR1C3 in PC-3 and DU 145 cells has been demonstrated using short 
hairpin sequences. Examination of the shAKR1C3 cells response to PGD2 was assessed 
as found not to produce significant changes in comparison to control (Vector only) cells. 
NR resistance has been previously measured in many CaP cells and is demonstrated 
herein. Epigenetically enforced repression of NR target genes has been previously 
demonstrated. In this study SAHA was utilised to increase levels of acetylation at PPARγ 
target genesin an attempt to reinitiate PPARγ functioning. Treatment of DU 145 
shAKR1C3 #1 cells with a combination of PGD2 and SAHA significantly reduced 
proliferation to a similar extent of SAHA alone. This suggests that overexpression of 
AKR1C3 maybe not be responsible for the maintenance of increased proliferation.  
 PC-3 and DU 145 are ADT-R CaP cell lines exposed to PPARγ antagonist 
GW9662 both isolated and in combination with PGD2 were not found to produce any 
significant response in proliferation. This indicates that the role of PPARγ signalling in 
cancer cell growth in these cell lines may be minimal, indeed the physiological relevance 
and consequence of the achieved AKR1C3 knockdown in ADT-R cells remain 
ambiguous. 
 Analysis of NR prostate specific gene alterations using the Q-RT-PCR indicates 
that reducing AKR1C3 level produces marginal changes within the NR networks. Down 
regulation of HDACs supports the hypothesis that AKR1C3 mediates repression of anti-
proliferative genes. Further, downregulation of coactivators and the NCOR1 corepressor 
(not shown) shows AKR1C3 may have some influence upon gene regulatory 
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mechanisms. Interestingly, the upregulation of IKBKB correlates with previous findings 
suggesting a link between AKR1C3 and regulation of NF-kB signalling pathways. The 
actions of elevated AKR1C3 in cancer have been classified in a cancer contributory 
context in many cell types such as leukaemia, CLL. By depriving the anti-proliferative 
PPARγ nuclear receptor of a high affinity ligand it can induce the pro-growth actions of 
9α,11β prostaglandin F2. The role of AKR1C3 overexpression in ADT-R CaP remains 
unclear. However, an epigenetic mis-regulation previously observed in NR signalling is 
recapitulated here. Furthermore, this is shown to be more susceptible to HDAC inhibition 
in the reduced AKR1C3 environment. Therefore, AKR1C3 is implicated in the 
mechanism of NR resistance observed in cancer from various tissue types.  Perhaps most 
importantly the levels of both PPARγ and PPARGC1A are down regulated with 
AKR1C3. PARGC1A is a specific coactivator to PPARγ that facilitates the recruitment 
of factors such as the CREB (cAMP Response Element Binding Protein) and its 
transcriptional response. Thus a decreased level of not only PPARγ but also its specific 
coactivator may have impinged on the NRs activation. The molecular pathways by which 
reduced AKR1C3 impact upon PPAR expression levels are unclear. However, it is clear 
that this promiscuous steroid converting enzyme is linked to many process involved in 
the regulation of NR transcription.  
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4.1 Introduction 
 Sirtuins are nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases 
that have become heavily researched with respect to both ageing and cancer. They are 
unique in their HDAC activity, as they require NAD+ for their action.  
Several NRs have been demonstrated to be regulated by sirtuin mediated 
deactlyation and additionally NR coregulators have also been shown to alter their activity 
in the presence of sirtuins. Sirtuin 1 (SIRT1) has been demonstrated to enhance 
transcriptional repressive activity shown by NCOR1 when inhibiting the PPARγ [190]. 
The direct interaction of sirtuins has also been shown to affect other NRs such as the AR 
whose activity is inhibited by its deacetylation [155]. In addition the ER has been 
impaired by SIRT1 action [191]. Though not prostate orientated these findings 
demonstrate that the sirtuins act as both direct and indirect regulators of NR activity.  
Previous studies have indicated that there is an overexpression in the level of 
sirtuins within the malignant environment. Their reduction may also be associated with 
decreased tumour growth [146, 192, 193]. However, the action of sirtuins within the 
prostate is poorly understood with a publication indicated SIRT1 is overexpressed in CaP 
patients compared to healthy controls [146]. 
Therefore, the expression levels of selected sirtuin family members will be 
examined and the effect of a selective chemical inhibitor upon their ability to impair 
nuclear receptor signaling will be investigated. Current understanding suggests sirtuin 
overexpression may mediate epigenetic silencing of NR target genes. Therefore 
inhibition of their action may restore NR signaling capability.  
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4.2 Results  
4.2.1 Examination of Sirt2 and Sirt6 levels within CaP cell lines. 
To investigate if sirtuins are overexpressed in CaP mRNA was extracted from a 
panel of prostate cancer cell lines and subjected to traditional q-RT-PCR using specific 
primers for SIRT2 and SIRT6. These members of the family have been previously 
indicated to be elevated in malignant CaP models (data not shown). RWPE-2, PC-3 cells, 
LNCaP and LNCaP C-42s were also utilized to establish how sirtuin expression changes 
in malignancy. Amplification of SIRT2 and SIRT6 was compared to those in RWPE-1 
cells. Figure 4.1 shows significant elevation in SIRT2 levels occur in PC-3 and LNCaP 
prostate cells (2.39 ± 0.36 SEM and 3.27 ± 0.60 SEM respectively), whereas SIRT6 
levels did not significantly vary when compared to RWPE-1.  
	  
Figure	  4.1	  Assessment	  of	  mRNA	  levels	  of	  SIRT2	  and	  SIRT6	  in	  prostate	  cell	  lines.	  Reverse	  transcription	  and	  Q-­‐RT-­‐PCR	  was	  conducted	  using	  primers	  specific	  for	  SIRT2	  and	   SIRT6.	   All	   results	   shown	   are	   the	   mean	   of	   three	   independent	   experiments	  performed	   in	   triplicate	   ±	   SEM.	   Statistical	   significance	   was	   assessed	   using	   t-­‐test	  where	  	  *=p-­‐value	  <0.05.	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Q-RT-PCR indicated that SIRT2 was elevated in PC-3 cells. Western immunoblot 
analysis revealed the increased SIRT2 protein levels in the malignant PC-3 cells (Figure 
4.2). Therefore, malignant cells often overexpress the SIRT2 protein, this may contribute 
to the increased proliferative activity of CaP cells.  
 
	  
	  
	  
	  
	  
	  
	  
	  
Figure	   4.2	   PC-­3	   show	  basaly	   elevated	   SIRT2	   in	   comparison	   to	  RWPE-­1	   cells.	  Analysis	  of	  SIRT2	  protein	  levels	  were	  detected	  using	  Western	  analysis,	  β-­‐actin	  levels	  are	  shown	  as	  a	  loading	  control.	  	  
 
4.2.2 Impact of the sirtuin inhibitor Sirtinol upon proliferation of 
RWPE-1 and PC-3 cells 
To examine the impact of elevated SIRT2 a sirtuin inhibitor (Sirtinol) was used to 
produce a dose response curve in RWPE-1 and PC-3 cells. This assay was performed to 
find an effective dose for treatment of cells with Sirtinol. Figure 4.3 shows PC-3 cells to 
be more resistant to the actions of Sirtinol in comparison to RWPE-1 cells. RWPE-1 cells 
showed a significant decrease in proliferation at 0.01µM (89.94% ±3.0% of controls), 
10µM 58.88% (±9.62 SEM) and 50µM 8.86 (±4.12 SEM). PC-3 cells are more resistant 
to the inhibitory effects with only 50µM achieving significant decrease in proliferation 
(59.34 (± 29.23 SEM). RWPE-1 exposure to Sirtinol at 10µM produced close to ED50 
response and the ED50 for PC3 was approximately 50µM.  
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Figure	  4.3	  Resistance	  to	  sirtuin	  inihbitor	  Sirtinol.	  Cells	  were	  plated	  into	  96	  well	  plates	   and	   left	   overnight	   to	   adhere.	   Treatments	   comenced	   the	   following	   day.	   All	  points	   are	   mean	   of	   three	   independent	   experiments	   performed	   in	   triplicate	   wells	  shown	  ±	  SEM.	  Statistical	  analysis	  was	  performed	  using	  t-­‐test.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	  
 
4.2.3 Response of RWPE-1 cells treated with Sirtinol and 
Bezafibrate alone and in combination.  
In order to establish the mechanism behind RWPE-1 growth inhibition and PC-3 
resistance to Sirtinol cells were exposed the sirtuin inhibitor (10µM) alone and in 
combination with the PPARγ ligand Bezafibrate (0.5µM & 5.0µM). Cells were treated 
for 0.5 and 4 hours before mRNA collection. Reverse transcription was performed and 
cDNA analysed by Q-RT-PCR for the PTGS2 and CDKN1A transcript levels. Bezafibrate 
has been demonstrated to decrease the levels of PTGS2 whilst also increasing the level of 
CDKN1A [176].  
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Figure	   4.4	   Sirtinol	   alone	   and	   in	   combination	   with	   the	   PPARγ 	   ligand	  
Bezafibrate	   in	   RWPE-­1	   cells.	   RWPE-­‐1	   cells	   were	   plated	   at	   1x105	   left	   overnight	  before	   treatment	   with	   Sirtinol,	   Bezafibrate	   or	   both	   in	   combination.	   Control	   cells	  were	   normalised	   to	   1.0.	   All	   bars	   are	   the	  mean	   of	   three	   independent	   experiments	  performed	  in	  triplicate	  PCR	  wells	  ±	  SEM.	  	  
 
Figure 4.4 illustrates the RWPE-1 response to Bezafibrate and Sirtinol alone and 
in combination. Sirtinol treatment in RWPE-1 cells was able to induce expression of the 
CDKN1A and PTGS2 mRNA after 4 hours of exposure. These data suggest sirtuins have 
some role in suppressing PPARγ mediated expression and their inhibition can partially 
restore sensitivity. To investigate how this role is altered in malignancy the same 
experiment was conducted using sirtinol resistant PC-3 cells. 
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4.2.4 Response of PC-3 cells treated with Sirtinol and 
Bezafibrate alone and in combination.  
Figure	   4.5	   Sirtinol	   alone	   and	   in	   combination	   with	   the	   PPARγ 	   ligand	  
Bezafibrate	   in	   PC-­3	   cells.	   PC-­‐3	   cells	   were	   plated	   at	   5x104	   left	   overnight	   before	  treatment	   with	   Sirtinol,	   Bezafibrate	   or	   both	   in	   combination.	   Control	   cells	   were	  normalised	   to	   1.0.	   All	   bars	   are	   the	   mean	   of	   three	   independent	   experiments	  performed	  in	  triplicate	  PCR	  wells	  ±	  SEM.	  	  
 
 Figure 4.5 shows the response of PC-3 cells to the Sirtinol and Bezafibrate 
treatment conditions. Bezafibrate exposure was unable to induce CDKN1A but in 
combination with Sirtinol produce an upward trend greater than Sirtinol alone. 
Combination of Bezafibrate (0.5µM) and Sirtinol produced significant mRNA 
accumulation. Again PC-3 cells demonstrate a level of resistance toward Sirtinol with 
pronounced induction. In addition, expression of CDKN1A is not restored with combined 
treatment.  
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4.3 Discussion 
 Restoration of NR signaling remains a key target for cancer research. The 
prospect of therapy that can overcome the phenomenon of NRs resistance and restore 
activation is compelling. Sirtuin mediated deregulation of NR signaling has been 
demonstrated to occur both at a direct (deacetylation of the estrogen receptor enhances its 
transcriptional activity) [194] and an epigenetic level (histone deacetylation reduces that 
transcriptional output of target genes) [195]. Currently the impact of sirtuins upon NR 
activity within CaP is ambiguous. This study attempts to reveal the extent of silencing 
mediated through Sirtuins in ART-R CaP. 
A previous study compared the prostate gene expression network during the cell 
cycle and showed SIRT2 and SIRT6 to be continually upregulated [195]. Analysis of a 
panel of CaP cell lines demonstrated that SIRT2 is elevated in PC-3 and LNCaP cells 
when compared to RWPE-1 cells. Therefore, to challenge the NR silencing activity of 
sirtuins cells were exposed to a range of concentrations of Sirtinol. This revealed PC-3 
cells have increased resistance to Sirtinol in comparison to RWPE-1 cells.  
The reduced activity of PC-3 cells to NR stimulation compared to RWPE-1 is in 
correlation with previous studies [68, 74, 196]. In addition, selective loss of PPARγ target 
gene mediated through NCOR1 action has been investigated [176], this study adds 
further insight to the loss of NR actions. The data herein find an upregulation of SIRT2 in 
malignancy to play a contributory role in PPARγ silencing with particular respect to the 
target gene CDKN1A. Ongoing studies should target both the action of SIRT2 and 
possible interaction with NCOR1 in an attempt to achieve sustained NR potency.  
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Chapter 5: Regulation of VDR target 
genes in non-malignant and malignant 
prostate cells 
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5.1 Introduction 
 Published findings have demonstrated a loss in anti-proliferative response to 
vitamin D receptor (VDR) ligands [197, 198] in many malignancies including CaP. The 
mechanisms behind this loss of sensitivity have been previously investigated in PC-3 and 
DU 145 cells. These studies have demonstrated that elevated levels of NCOR1 and 
NCOR2/SMRT are able to contribute to gene repression via increased HDAC3 
recruitment [131]. This mechanism results in aberrant deactylation at the local chromatin 
environment repressing transcription.     
In addition, studies have also demonstrated NR mediated gene transcription to 
occur in a cyclical fashion. This process involves sequential recruitment and release of 
both CoR and CoA complexes bound to the NR. Consequently changes in the chromatin 
PTMs placed around the gene affect its level of transcription. However, these studies 
have not examined how the VDR regulates target genes within the normal epithelial state. 
All previous studies have used derivations of breast or prostate cancer cell lines to 
examine transcriptional regulatory events. Therefore, the following work examined the 
ability of VDR to regulate genes in the normal prostate epithelial model RWPE-1. By 
using a non-malignant cell system this work investigated a transcriptional response that 
equates to in-situ epithelial prostate cells. This served to establish a baseline of VDR 
mediated activity in the non-transformed state. Bulk cell populations were treated with 
vitamin D receptor ligand (1α,25(OH)2D3 ) and VDR target gene dynamics were 
observed over 24 hours.  
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 It was hypothesized that comparison of RWPE-1 VDR target gene expression to 
transformed malignant cell lines PC-3 and the isogenic RWPE-2 these experiments may 
unveil the extent of misregulation underlying the progression of CaP.  
 Many NRs including AR have also been demonstrated to influence expression of 
microRNAs (miRNAs) as a regulatory components of their transcription networks [199]. 
Genome wide analysis of malignant tissues has revealed the full extent of miRNA 
deregulation within tumours [200, 201]. Altered miRNA levels have been associated with 
many hormonally mediated malignancies including the CaP [202, 203]. Previous work by 
this laboratory (unpublished data) has identified that 1α,25(OH)2D3 activation of VDR 
induced the DNA replicative helicase MCM7. The MCM7 gene sequence contains a 
miRNA sequence within the 3’UTR located on intron 13 that produces the miRNA 
named MiR106b [204]. MiR106b has been shown previously to target CDKN1A 
transcript for degradation [205]. Therefore, VDR regulation of MiR106b produces a 
negative feedforward loop, and further distortion of this loop may be a key contributory 
factor to NR resistance often observed in CaP.  
 To test this hypothesis the levels of MCM7 and MiR106b expression were 
observed in both RWPE-1 and PC-3 cell lines. In addition the VDR feedforward loop 
containing MiR106b was examined for its relationship to tumour progression within the 
TRAMP murine model.  
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5.2 Results 
5.2.1 The effect of growth media upon VDR target genes in CaP 
cell lines. 
 The RWPE-1, RWPE-2 and PC-3 cell lines used in this experiment were 
maintained in different media conditions. RWPE-2 cells were a derivative of RWPE-1 
and were maintained in the KSF complete medium. However, PC-3 cells were 
maintained in RPMI1640 complete medium. Therefore, to investigate the effect of each 
media and its supplements upon each cell line the following experiment was conducted 
using variations in the growth conditions. RWPE-1 cells were plated in three conditions 
to examine the impact of the components on cell growth: 
              1) KSF complete (including BPE and EGF)  
            2) KSF and BPE without EGF 
            3) KSF complete overnight and replaced with RMPI (+FBS). 
The malignant cell line model PC-3 was also investigated for the influence of 
their recommended media upon the transcription of the VDR target genes (CYP24A1 and 
CDKN1A). PC-3 cells are grown in RPMI 1640 medium supplemented with Fetal Bovine 
Serum (FBS). Since FBS contains many growth factors that may influence the 
transcriptional outcome of these two VDR genes it was important to assess their effect. 
PC-3 cells were plated in either: 
1) RPMI 1640 (+FBS)  
2) RPMI 1640 (+FBS) + EGF  
3) KSF complete   
Upon completion of treatment, the cells mRNA was isolated, extracted, reverse 
transcribed and Q-RT-PCR performed for VDR target genes CYP24A1 and CDKN1A.  
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Figure	  5.1	  Variations	  in	  medium	  componants	  have	  minimal	  impact	  upon	  VDR	  
target	  gene	  expression.	  RWPE-­‐1	  (1x105)	  and	  PC-­‐3	  (5x104)	  cells	  were	  plated	  in	  to	  6	  well	  plates	  and	  treated	  with	  either	  vehicle	  control	  or	  1α,25(OH)2D3	  (100nm)	  for	  6	  hours.	  mRNA	  was	   assessed	   for	  CDKN1A	   and	  CYP24A1	   transcript	   levels.	   All	   results	  are	  mean	  of	  at	  least	  three	  independent	  experiments	  ±	  SEM.	  Statistical	  analysis	  was	  performed	  using	  t-­‐test,	  **=p-­‐value	  0.01.	  
 
Exposure to 1α,25(OH)2D3 (100nm) for 6 hours induced expression of the 
CYP24A1 gene in both RWPE-1 and PC-3 cells. However, the PC-3 cells showed a lower 
level of induction (approximately 10 fold) than that observed in RWPE-1 cells (1000 
fold). In addition CYP24A1 remained inducible in the cell populations plated in 
alternative media conditions. The data showed a lack of induction of CDKN1A in both 
RWPE-1 and PC-3 cells that in RWPE-1 maybe due to the selected treatment time (6 
hours). Such a selection provides evidence of the importance in timepoint used to 
measure ligand response. Withdrawal of EGF from RWPE-1 cells causes a statistically 
significant basal increase (3.64 ± 0.51% fold change) in the CYP24A1 transcript level. All 
other media modifications used produced no statistical change in either CYP24A1 or 
CDKN1A transcript levels. Interestingly, treatment of RWPE-1 cells with 1α,25(OH)2D3 
(100nm) for 6 hours produced a downward trend in CYP24A1 induction. CDKN1A 
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mRNA response in either untreated, or 1α,25(OH)2D3 (100nm) treated cells was not 
significantly altered by the media variations examined in this experiment.   
Changing the media PC-3 cells are grown in also had little effect upon the VDR 
target gene expression as there was no statistical significance between treated or 
untreated controls. This supported the use of the recommended media as it shows their 
gene expression is not altered its absence.  
5.2.2 Comparison of the effect of 1α,25(OH)2D3 upon the cell 
cycle in non-malignant and malignant CaP cells.   
 
 Inhibition of the cell cycle contributes to anti-tumourigenic action of 
1α,25(OH)2D3 and was investigated by FACS analysis. To investigate the response VDR 
stimulation has upon the cell cycle RWPE-1 and PC-3 cells were treated with two 
different doses of 1α,25(OH)2D3 (10nm and 100nm) for 24 hours before FACS analysis.  
Figure 5.2 demonstrates exposure over 24 hours was able to induce cell cycle arrest in 
RWPE-1 cells. This response appeared to be dose-dependent as 1α,25(OH)2D3 (10nm) 
induced a marginal but statistical increase in G1 phase (73.8 ±0.8% fold change) where 
as 100nm treatment lead to an increase in G1 phase of the cell cycle (87.9 ±0.5% fold 
change) with a corresponding decrease of cells in S phase and G2/M. 
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Figure	  5.2	  Cell	  cycle	  arrest	  induced	  by	  1α ,25(OH)2D3	  in	  RWPE-­1	  cells	  is	  lost	  in	  
PC-­3	  cells.	  RWPE-­‐1	  and	  PC-­‐3	  cells	  were	  seeded	  at	  1x106	  and	  5x105	  cells	  per	  well	  respectively.	  Treatment	  was	  with	  1α,25(OH)2D3	  (10nm)	  and	  (100nm)	  for	  24	  hours.	  Cells	   were	   stained	   with	   propidium	   idodide	   and	   analysed	   for	   cell	   cycle	   status	   by	  FACS.	   Each	   data	   bar	   represents	   the	   mean	   (±	   SEM)	   of	   at	   least	   three	   independent	  experiments.	   Statistical	   analysis	  was	   performed	  using	   t-­‐test.	   *=p-­‐value	   0.05,	   **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	  
 
 These results are in agreement with previously published data [206, 207]. Similar 
FACS analysis of PC-3 cells in response to 1α,25(OH)2D3 (10nm and 100nm) failed to 
produce cell cycle arrest as observed in RWPE-1 cells. Interestingly, treatment of PC-3 
cells produced marginal increases of cells in S and G2 phase, although this is not found to 
be significant when challenged with t-test assessment.   
5.2.3 VDR target gene dynamics within RWPE-1 cells.   
 Vitamin D response elements (VDREs) are found within gene promoters of the 
VDR target genes. Past studies within this group have examined established target genes 
of the VDR and a panel of these were selected for further study. 
  The ALOX5 gene produces the 5-lipoxygenase enzyme. This is responsible for 
the conversion of cholesterol-derived phospholipids into the pro-inflammatory mediators 
called leukotrienes. Although ALOX5 expression has some correlation with tumour 
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tissues the first identification of ALOX5 being upregulated by 1α,25(OH)2D3 came in 
1995 [208].  
More recently, investigations of the ALOX5 gene demonstrated that although 
there are various VDREs within its promoter these are non-functional when analysed 
using reporter gene constructs. Furthermore, it was hypothesised that the VDREs within 
the 10kb promoter required VDREs at more distal sequence to exert significant 
transcriptional regulation [209]. In correlation, detailed analysis by the same research 
group showed that VDREs outside of the ALOX5 promoter region are strongly influenced 
by VDR ligand exposure. From the 84kb surrounding the ALOX5 gene it was discovered 
that the most potent VDRE was approximately 42kb upstream of the transcription start 
site of the gene [210].  
Thus, VDR activation is able to produce activation of the ALOX5 gene, 
contributing to the regulation of the inflammatory response. In conjunction with this 
action are reports indicating that VDR also has the PTGS2 gene as a target [184]. PTGS2 
encodes the Cyclooxygenase 2 (COX-2) protein and has a strong association with pro-
tumourigenic inflammatory effects within the prostate. Upregulation of COX-2 promotes 
prostagladin catabolism contributing to inflammation.  
Additional to this, VDR target genes for study were selected including the G1-G0 
switch gene (G0S2). This gene is thought to regulate the movement of cells in and out of 
the cell cycle thus controlling the cells rate of division. Since the discovery of G0S2 it has 
exhibited regulation through the PPAR and the RAR nuclear receptor families [211, 212]. 
Also identified in previous work by this group to be a VDR target gene [184] and was 
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chosen alongside the ESR1 (encodes ERα) and MAPK4 that were also identified being 
VDR regulated. 
 
  
 
 
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  5.3	  VDR	  regulates	  target	  genes	  with	  sustained	  mRNA	  output.	  RWPE-­1	  cells	  
were	   plated	   into	   6	   well	   plates	   at	   a	   density	   of	   1x105	   and	   treated	  with	   1α25(OH)2D3	  
(100nm).	   mRNA	   was	   isolated	   and	   reverse	   transcribed.	   Levels	   of	   transcript	   were	  
analysed	  by	  Q-­RT-­PCR.	  Each	  data	  bar	   represents	   the	  mean	  (±	  SEM)	  of	  at	   least	   three	  
independent	  experiments.	  *=p-­value	  0.05,	  **=p-­value	  0.01,	  ***=p-­value	  0.001. 
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 Figure 5.3 illustrates that the kinetics of CYP24A1, G0S2 and ALOX5 show 
similar aspects. For example, these all displayed a common significant mRNA 
accumulation throughout the timecourse. However, their magnitude of response varied.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Figure	  5.4	  VDR	  selectively	  regulates	  ESR1	  and	  PTGS2	  target	  genes	  with	  short	  
term	  mRNA	  output.	  RWPE-­‐1	  cells	  were	  plated	  into	  6	  well	  plates	  at	  1x105	  cells	  per	  well	   and	   treated	   with	   1α25(OH)2D3	   (100nm).	   mRNA	   was	   isolated	   and	   reverse	  transcribed.	   Total	   mRNA	   levels	   were	   analysed	   by	   Q-­‐RT-­‐PCR.	   Each	   data	   bar	  represents	  the	  mean	  (±	  SEM)	  of	  at	  least	  three	  independent	  experiments.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001. 
 
The kinetic profile produced by PTGS2, ESR1 and MAPK4 (Figure 5.4) did not 
resemble the initial fluctuation and sustained increased mRNA transcription observed 
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with the previous genes (CYP24A1, ALOX5 or G0S2). There were no statistically 
significant increases in mRNA production beyond 8 hours treatment. Similar to those 
previously observed in ALOX5 and G0S2 there is a sustained repressive period that in 
PTGS2 is extended and runs from 70 minutes to 110 minutes. This is followed by an 
increase at 8 hours. In a comparable manner to that of PTGS2, ESR1 shows fluctuation in 
mRNA followed by upregulated gene expression. This elevation was not sustained but 
terminates at 6 hours.  
 To investigate how VDR regulated epigenetic events control target gene 
expression histone modifications associated with active or repressive roles in gene 
transcription were measured at target gene transcription start sites. Illustrated in Figure 
5.5 are the data from analysis of the G0S2, ALOX5 and PTGS2 TSS and the fold changes 
of selected histone marks present. From the mRNA expression profiles both G0S2 and 
ALOX5 were shown to produce sustained transcriptional output over the 24 hour time-
period. In contrast the PTGS2 gene produced significant mRNA accumulation up until 8 
hours post VDR activation. Therefore, analysis of differential histone modification 
recruitment between genes TSS may reveal a ‘short term’ histone code that retains 
instructions for gene expression dynamics observed in Figures 5.3 and 5.4.  
 H3K27me3 was shown to be higher at the TSS of sustained expression genes 
(ALOX5 and G0S2) upon treatment with 1α,25(OH)2D3 (100nm). G0S2 TSS has a 
significantly reduced level of H3K27me3 mark at 0.5, 1, 4 and 24 hours post treatment. 
ALOX5 demonstrated a loss of H3K27me3 that remained significantly reduced 
throughout, with high levels but declining at 0.5, 4, 12 and 24 hours treatment 
1α,25(OH)2D3 (100nm). 
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Figure	   5.5	   Oscillation	   of	   activating	   and	   repressing	   histone	   modifications	  
during	  gene	  transcription.	  RWPE-­‐1	  DNA	  recovered	  by	  nChIP	  was	  analysed	  by	  q-­‐RT-­‐PCR.	  H3K4me3	  and	  H3K9ac	  are	  activation	  marks	  (contained	  within	  a	  green	  box)	  and	   H3K27me3	   ad	   K3K9me2	   are	   assicated	   with	   repressed	   gene	   expression	  (contained	  within	   red	   box).	   Each	   data	   bar	   represents	   the	  mean	   (±	   SEM)	   of	   three	  independent	  experiments.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	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 PTGS2 shows no significant change in the enrichment levels of H3K27me3 until 
24 hours post treatment (0.036 ±0.182% fold enrichment). H3K9me2 is also associated 
with repression of transcription. Observation of this mark over the TSS of ALOX5, G0S2 
and PTGS2 resulted in significant changes in ALOX5 (1.62 ± 0.22% fold enrichment) and 
PTGS2 treatment at 24 hours (0.016 ±0.002% fold enrichment).  
 H3K4me3 became enriched at genomic regions containing active genes. This 
study compared the changes in this histone mark in response to VDR activation and 
found the TSS of different genes show differential levels of H3K4me3. The G0S2 gene 
shows a significantly reduced level after 24 hours 1α,25(OH)2D3 (100nm). However, the 
TSS of ALOX5 demonstrates rapid loss and restoration of this mark in response to 
activation. Therefore, genes exhibiting sustained mRNA expression may utilise 
H3K4me3 release to induce transcription. Furthermore, the level of this mark may 
influence the rate of transcription. H3K9ac was significantly reduced at 0.5 h at the TSS 
of G0S2, ALOX5 and PTGS2. Later time points demonstrated that H3K9ac levels were 
upregulated on all three genes reflecting the positive mRNA regulation. Together these 
findings suggest that H3K9ac enrichment at the TSS and mRNA accumulation were 
closely coordinated. This is the first time these histone modifications have been shown to 
fluctuate with VDR target gene activation, in addition it is also demonstrated that these 
post translational marks have levels of accumulation unique to each target gene.  
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5.2.4 Protein production in response to 1α,25(OH)2D3 (100nm) 
over time. 
 
To examine the productivity of the mRNA kinetics observed Western 
immunoblotting was conducted and Figure 5.6 shows the response of ALOX5 in RWPE-
1 cells treated with 1α,25(OH)2D3 (100nm). This revealed a fluctuating protein response, 
indicating dynamic regulation of ALOX5 in response to VDR activity.  
 
 
 
 
 
 
 
 
 
 
 
	  
Figure	   5.6	   1α ,25(OH)2D3	   periodically	   induces	   ALOX5	   and	   COX-­2	   protein	   in	  
RWPE-­1	  cells.	   	  RWPE-­‐1	  cells	  were	  plated	  into	  T75	  flasks	  at	  a	  density	  of	  1x106	  and	  treated	   with	   	   1α,25(OH)2D3	   (100nm).	   Cells	   were	   harvested	   and	   protein	   lysates	  recovered	   and	   subject	   to	   western	   imunnobloting.	   Quantification	   was	   by	   Image-­‐J	  software	  and	  relative	  to	  β-­‐actin	  (n=1).	  	  
	  
Analysis at the protein level (Figure 5.6) showed elevated protein levels of COX-
2 reached a maximum two hours after treatment, this then decreased but remains above 
basal levels for the duration of the timecourse. Therefore, the activation of VDR is 
producing productive transcriptional variations that are translated into protein. Further, 
these two target genes exhibit similar protein dynamics in comparison to differing mRNA 
kinetics.  
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5.2.5 Basal levels of novel and established VDR target genes 
within RWPE-1 and PC-3 cells.  
As discussed previously mis-regulation of NR signaling capacity in malignancy is 
frequently reported [68, 213-216]. Disturbance of the VDR activity in CaP has also been 
established. Observation of the basal expression of VDR target genes relative to basal 
VDR expression itself may suggest the target genes ability to respond to activation. 
Furthermore, comparing the basal levels of these genes between normal and malignant 
cells may provide further elucidation of VDR signaling network deregulation in prostate 
carcinogenesis.  
Figure	   5.7	   Basal	   expression	   of	   VDR	   target	   genes	   suggests	   their	   responsive	  
capacity	   to	   1α,25(OH)2D3.	  Untreated	  RWPE-­1	   (1x105)	   and	   PC-­3	   cells	   (5x104)	  were	  
plated	   and	   left	   overnight.	   The	   following	   day	   mRNA	   was	   isolated	   and	   reverse	  
transcribed.	   Basal	   gene	   levels	  were	   assessed	   using	   Q-­RT-­PCR	   and	   normalised	   to	   the	  
VDR	  from	  each	  cell	  line.	  Bars	  shown	  are	  mean	  of	  at	  least	  two	  independent	  experiments	  
(±	  SEM)	  and	  performed	  in	  triplicate.	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CYP24A1 showed a basal level of expression not significantly different from that 
of VDR (3.21 (±3.12 SEM) fold change), this is an example of how normal prostate 
epithelium is enriched for 1α,25(OH)2D3 response genes. Genes that respond rapidly to 
VDR stimulation (such as PTGS2) have levels of basal expression approximately 10 fold 
below that of VDR. This was in comparison to the late responding genes (Figure 5.7) 
G0S2 and ALOX5 have levels of enrichment approximately 100 fold lower than VDR. 
However, the expression of ALOX5 is not altered in PC-3 cells.  
 Conducting a similar experiment in PC-3 cells unveils a skewed relationship 
between the level of basal VDR expression and its target genes. These data show the 
enrichment of VDR was lost in PC-3 cells and this distortion in basal expression may 
contribute to NR resistance.   
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 5.2.6 VDR target gene expression in PC-3 cells   
 To reveal the extent of VDR signaling deregulation in ADT-R CaP detailed 
timecourse investigations were conducted in PC-3 cells. Figure 5.8 demonstrates that the 
VDR target gene CDKN1A became unresponsive to ligand stimulation.  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  5.8	  VDR	  mediated	  response	  of	  CDKN1A	  mRNA	  is	  lost	  in	  prostate	  cancer	  
cell	   line	  PC-­3.	  Cells	  were	  plated	   into	  6	  well	  plates	  at	  a	  number	  of	  5x104	  cells	  per	  well	   and	   left	   overnight.	   Treatment	   commenced	   the	   following	   day	   1α,25(OH)2D3	  (100nm).	  mRNA	  was	   isolated	   and	   expression	   levels	  were	  determined	  using	   q-­‐RT-­‐CPR.	   Each	   data	   bar	   represents	   the	   mean	   (±	   SEM)	   of	   at	   least	   three	   independent	  experiments.	  
 
Analysis of the total mRNA for the CDKN1A transcript reveled that these cells 
are insensitive to the action of the VDR. There was no statistically significant change in 
the mRNA output in comparison to the vehicle only controls.  
CDKN1A mRNA is processed and translated into the protein p21(waf1/cip1). This 
protein contributes directly to the cell cycle arrest through inhibition of cyclin dependent 
kinases (CDKs), an effect measured in RWPE-1 cell by G1 cell cycle arrest (Figure 5.2).  
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Figure	  5.9	  VDR	  stimulation	   is	  unable	   to	   induce	  p21(waf1/cip1)	  protein	   levels	   in	  
PC-­3	  cells.	  PC-­‐3	  cells	  were	  plated	  into	  T75	  flasks	  at	  a	  density	  of	  5x105	  and	  treated	  with	   	   1α,25(OH)2D3	   (100nm).	   Cells	  were	   harvested	   and	  protein	   lysates	   recovered	  and	  subject	  to	  western	  immunobloting.	  Quantification	  was	  by	  Image-­‐J	  software	  and	  relative	  to	  β-­‐actin.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	  
 
 
 The loss of VDR sensitivity shown by the PC-3 cells was also measured at a 
protein level (Figure 5.9). Quantification of the image demonstrated the p21(waf1/cip1) 
protein was not induced upon addition of 1α,25(OH)2D3 (100nm).Whether the specificity 
of NR insensitivity was limited to growth regulatory genes or global targets of the NR in 
question had not been addressed. Therefore, to establish the extent of VDR signaling 
deregulation a panel of target genes was examined. Each gene has previously 
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demonstrated to be responsive in the non-malignant model (RWPE-1), but was shown to 
be transcriptionally unresponsive in ADT-R CaP (Figure 5.10). There were visible 
fluctuations in the kinetics of PTGS2 and ALOX5 mRNA of PC-3 cells. However, these 
were not statistically significant when subjected to t-test.  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  5.10	  VDR	  regulated	  genes	  are	  unresponsive	  to	  ligand	  treatment	  in	  PC-­3	  
cell	  line.	  PC-­‐3	  cells	  were	  plated	  into	  6	  well	  plates	  at	  5x104	  cells	  per	  well	  and	  treated	  with	   1α25(OH)2D3	   (100nm).	   RNA	   was	   isolated	   and	   reverse	   transcribed.	   mRNA	  levels	  were	  analysed	  by	  Q-­‐RT-­‐PCR.	  Each	  data	  bar	  represents	  the	  mean	  (±	  SEM)	  of	  at	  least	   three	   independent	   experiments.	   *=p-­‐value	  0.05,	   **=p-­‐value	  0.01,	   ***=p-­‐value	  0.001.	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5.2.7 Distortion of VDR signalling within an isogenic cell line.  
 How or when cells acquire NR resistance is not known but VDR insensitivity has 
been demonstrated in ADT-R CaP. The following experiment used RWPE-2 cells to 
assess the progression of VDR deregulation within a genetic background similar to 
RWPE-1. Figure 5.11 illustrates the data obtained from Q-RT-PCR analysis of the 
CDKN1A gene within RWPE-2 cells. Though there is an initial peak of mRNA occurring 
at 0.5 hours it is not statistically significant and throughout the timecourse there was no 
significant accumulation of CDKN1A mRNA.  
 
Figure	   5.11	   RWPE-­2	   cells	   exhibit	   differential	   VDR	   target	   gene	   regulation	   in	  
response	  to	  1α ,25(OH)2D3	  (100nm).	  Total	  mRNA	  was	  collected	  from	  cells	  (1x105	  per	  
well)	   and	   reverse	   transcribed	   Q-­RT-­PCR	   analysis	   of	   cells	   exposed	   to	   1α,25(OH)2D3	  
(100nm)	  over	  time	  using	  primers	  specific	  for	  CDKN1A.	  The	  fold	  change	  to	  vehicle	  only	  
control	   was	   calculated.	   Points	   shown	   are	   the	   mean	   of	   at	   least	   three	   independent	  
experiments	  ±	  SEM.	  	  Data	  was	  subject	  to	  t-­test	  using	  Welch	  Correction	  to	  account	  for	  
unequal	  population	  variances.	  *=p-­value	  0.05,	  **=p-­value	  0.01,	  ***=p-­value	  0.001.	  
	  
	  
	   As insensitivity was demonstrated in the CDKN1A gene in RWPE-2 other VDR 
regulated genes were examined.	   Figure 5.12 shows the CYP24A1, PTGS2, VDR and 
GADD45α genes. PTGS2, VDR and GADD45α show no significant induction in response 
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to ligand. RWPE-2 cells produce a similar of CYP24A1 induction in comparison to 
RWPE-1. 	  
Figure	   5.12	   RWPE-­2	   cells	   exhibit	   selective	   VDR	   insensitivity	   in	   response	   to	  
1α ,25(OH)2D3.	   Total	   mRNA	   was	   collected	   from	   cells	   (1x105	   per	   well)	   and	   reverse	  
transcribed	  Q-­RT-­PCR	   analysis	   of	   cells	   exposed	   to	   1α,25(OH)2D3	   (100nm)	   over	   time.	  	  
mRNA	  was	  measured	  and	  the	  fold	  change	  to	  vehicle	  only	  control	  was	  calculated.	  Points	  
shown	  are	  the	  mean	  of	  at	  least	  three	  independent	  experiments	  ±	  SEM.	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5.2.8 MCM7 expression in response to 1α,25(OH)2D3 in RWPE-1 
and PC-3 cells.  
  To further understand VDR regulation within a physiological signaling response 
the MCM7 gene, a target of S-phase transcription factors was examined. RWPE-1 cells 
treated with 1α,25(OH)2D3 (100nM) produced a down regulation of the MCM7 protein.  
 
 
 
 
 
 
 
 
Figure	  5.13	  1α,25(OH)2D3	  induced	  MCM7	  protein	  level	  changes	  in	  RWPE-­1	  and	  
PC-­3	   cells.	  RWPE-­‐1	   and	   PC-­‐3	   cells	  were	   plated	   in	   T75	   flasks	   at	   1x106	   and	   5x105	  cells	   per	   well	   respectively.	   Treatment	   commenced	   the	   following	   day	   with	  1α,25(OH)2D3	   (100nm)	   controls	   were	   treated	   with	   ethanol	   vehicle	   only.	   Protein	  lysates	   were	   harvested	   and	   analysed	   by	   Western	   with	   MCM7	   specific	   antibody.	  Quantification	  conducted	  by	  Image-­‐J	  software	  and	  MCM7	  bands	  were	  normalized	  to	  respective	  β-­‐actin	  loading	  controls.	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Conducting the same experiment in PC-3 cells showed that the magnitude of this 
response is diminished in ADT-R CaP. This demonstrates that VDR insensitivity may 
enhance the replicative potential of the malignant cell (Figure 5.13). Elevated MCM7 
expression is associated with an increased cellular proliferation potential within the cell 
and it has been shown that this protein is overexpressed in ADT-R CaP [217]. Analysis of 
basal protein levels in RWPE-1 and PC-3 cells shown in Figure 5.14 showed PC-3 cells 
overexpress MCM7 protein with a 3.6 fold increase in levels in comparison to RWPE-1 
cells.   
 
 
 
 
 
 
	  
	  
Figure	  5.14	  Replicative	  helicase	  MCM7	  is	  overexpressed	  in	  PC-­3	  cells.	  RWPE-­‐1	  and	   PC-­‐3	   cells	   were	   plated	   in	   T75	   flasks	   at	   1x106	   and	   5x105	   cells	   per	   well	  respectively.	  Protein	  lysates	  were	  harvested	  and	  analysed	  by	  Western	  Immunoblot	  with	   MCM7	   specific	   antibody.	   Quantification	   conducted	   by	   Image-­‐J	   software	   and	  MCM7	  bands	  were	  normalized	  to	  respective	  β-­‐actin	  loading	  controls.	  	  
 
 Elevation in the level of the MCM7 protein suggested that the levels of MiR106b 
are also elevated within malignancy. Such accumulation would lead to increased 
targeting of CDKN1A transcript reducing protein levels within transformed cells. This 
may establish a novel VDR dependent mechanism that becomes deregulated in CaP. 
Therefore to understand this response during prostate tumourigenesis TRAMP mouse 
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model mRNA at differing stages of tumour growth was examined for differential 
expression within the VDR-MCM7-CDKN1A feedforward loop.  
5.2.9 Disruption of a VDR feed forward loop in CaP. 
 Components of the VDR feed forward loop become significantly altered within 
the TRAMP model of CaP (Figure 5.15). Primary TRAMP tumours show significant 
increases in cdkn1a mRNA (197.20 fold ± 30.99 SEM) levels. Analysis of metastatic 
tissue also demonstrated a significant increase in cdkn1a message (91.55 fold increase 
±6.47 SEM). TRAMP levels of mcm7 were found to be elevated in comparison to wild 
type with both primary and metastatic tumours showing a significant elevation in 
message (168.30 ±34.63 SEM and 417.9 ±103.3 SEM respectively). Furthermore, 
comparison between the two tumour types shows that metastatic tumours have a higher 
level of mcm7 than primary tumours (p-value 0.009).  
 
 
 
 
 
	  
	  
	  
Figure	   5.15	   cdkn1a,	   mcm7	   and	   mir106b	   are	   elevated	   in	   primary	   and	  
metastatic	   TRAMP	   tissue	   in	   comparison	   to	   wild	   type	   tissue.	   Tissue	   samples	  were	  taken	  from	  the	  TRAMP	  model	  and	  mRNA	  analysed	  for	  cdkn1a,	  mcm7,	  vdr	  and	  mir106b	   transcripts.	   Each	   points	   represents	   a	   tumour	   taken	   from	   an	   individual	  mouse	  (N=at	   least	  3)	  ±	  SEM.	  Data	  was	  subject	   to	   t-­‐test.	   *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	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The mir106b transcript was also found to be overexpressed in both primary and 
metastatic tumours (26.50 ± 3.09 SEM and 67.02 ± 36.80 SEM respectively). In 
conjunction with metastatic tumours demonstrating increased mcm7 there is a statistically 
higher expression of mir106b in comparison to the primary tissue tumours (p-value 
0.036). Expression of VDR within primary tumours was shown to be significantly lower 
in comparison to wild type mice with a fold reduction of 0.29 (± 0.13 SEM). There was 
no significant change in the VDR transcript abundance in the metastatic TRAMP tissue 
samples (0.73 ± 0.47% fold change of VDR). From these data is it evident the governing 
nuclear receptor, VDR and the motifs within the feedforward loop become deregulated. 
Furthermore, both mcm7 and mir106b were significantly elevated in the metastatic 
samples in comparison to primary tumours, suggesting a differential modulation of the 
feed forward circuitry.   
 To examine this further TRAMP tumour samples from castrated mice were 
selected for analysis. These represent an ADT-R model of prostate disease and were 
extracted and analysed alongside the androgen dependent tissue samples. Such hormone 
refractory tumours have been previously demonstrated to exhibit NR deregulation. 
Analysis of the manner of deregulation may reveal the role of androgen sensitivity as 
being a key mechanism by which malignancy produces a VDR insensitive phenotype, 
and facilitating a bypass of the p21(waf1/cip1) cell cycle arrest response between the two 
diseases.   
 The data presented in Figure 5.16 show that elements of the VDR-MCM7-
CDKN1A feed-forward loop are deregulated within ADT-R disease but are also altered 
in prostate malignancy that is not representative of recurrent disease. Elevation of 
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Cdkn1a was observed in both the primary tumour and malignant tumour samples from 
the castrated mice (3482.05 fold change ±1894.00 SEM and 315.04 fold change ±83.02 
SEM respectively.  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	   5.16	   cdkn1a,	   mcm7	   and	   mir106b	   are	   elevated	   in	   primary	   and	  
metastatic	   TRAMP	   tissue	   taken	   from	   castrated	   mice	   in	   comparison	   to	   wild	  
type	  tissue.	  Tissue	  samples	  were	  taken	  from	  the	  TRAMP	  mice.	  	  mRNA	  was	  analysed	  for	   cdkn1a,	  mcm7,	   vdr	   and	  mir106b	   transcripts.	   Each	   point	   represents	   a	   tumour	  taken	   from	  an	   individual	  mouse	   (N=	  at	   least	  3)	  ±	   SEM.	  Data	  was	   subject	   to	   t-­‐test.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	  
 
 Reflective of the findings in the non-castrated samples (both primary and 
metastiatic) both mcm7 and mir106b transcripts are also elevated in TRAMP based 
malignancy. Furthermore, the vdr transcript abundance was not altered in castrated 
tumour tissue in comparison to wild type. This suggests that the mechanism of 
deregulation of the incoherent feedforward loop in androgen independent primary tissue 
may be similar to metastatic disease.  
 The disruption of miR106b within CaP is in corroboration with many studies that 
conclude miR expression is important in tumourigenesis (reviewed in [218]). Emerging 
literature also supports the hypothesis that miRNA overexpression can be detected within 
Androgen independent 
Primary tumours 
Androgen independent 
Metastatic tumours 
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the serum of patients [219]. This has potential to become a new area of diagnostic 
biomarkers for cancer. Therefore, it was hypothesised that elevated miR106b within the 
circulating serum of individuals may be an important indicator of VDR responsiveness 
and of tumour progression. The test this serum was collected from TRAMP mice used in 
the tissue mRNA study and the level of miR106b were assessed.   
 
 
 
 
 
 
 
	  
	  
	  
Figure	  5.17	  mir106b	  is	  elevated	  in	  the	  serum	  of	  TRAMP	  mice	  in	  comparison	  to	  
wild	  type	  tissue.	  Serum	  samples	  were	  taken	  from	  the	  TRAMP	  model	  core	  facility	  in	  Roswell	   Park	   Cancer	   Institute	   and	  mRNA	  was	   extracted,	   reverse	   transcribed	   and	  analysed	   for	  mir106b	   transcripts	   and	  made	   relative	   to	  miR-­‐16	   as	   an	   endogenous	  control.	   Each	   points	   represents	   a	   tumour	   taken	   from	   an	   individual	  mouse	   (N=	   at	  least	   3)	   ±	   SEM.	  Data	  was	   subject	   to	   t-­‐test.	   *=p-­‐value	   0.05,	   **=p-­‐value	   0.01,	   ***=p-­‐value	  0.001.	  
 
 The data illustrated in Figure 5.17 shows miR106b was significantly elevated in 
the serum of TRAMP tumour mouse models (3.84 fold change ±1.01 SEM). This finding 
supports the hypothesis that serum expression of VDR regulated microRNA within 
cancer may be useful to define molecular phenotypes such as aggressiveness or resistance 
to VDR ligands. 
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5.3 Discussion	  
This investigation addressed the dynamic regulation of the VDR within a non-
transformed prostate epithelial cell line (RWPE-1). Using this model of prostate epithelial 
cell status the functional role of NR target genes was observed. Data showing the 
regulation of VDR target genes was compared to models of prostate malignancy (PC-3 
and RWPE-2). Both isogenic and non-derivative cell lines showed levels of VDR 
insensitivity, however, the corruption of VDR signaling is pronounced in PC-3 cells. 
Before studying gene expression within the VDR network it was also critical to evaluate 
the effects of media components upon the cells growth characteristics. This study found 
that the addition of growth stimulatory EGF to medium of RWPE-1 cells had no 
significant impact upon the levels of VDR target gene expression. This demonstrated 
VDR regulated actions are suitably observed within the RWPE-1 and PC-3 cell lines. 
 Activation of VDR was able to induce varying mRNA dynamic profiles within 
RWPE-1 cells. The kinetics of these responses allowed genes to be divided into two 
groups of sustained elevated mRNA (CYP24A1, ALOX-5, G0S2) or short-term induction 
over the first 8 hours treatment (ESR1 and PTGS2).   
 Non-transformed prostate cells were shown to exhibit enriched VDR and basal 
levels of target genes that are proportional to their VDR responsiveness. Further, the 
malignant cells lose their enriched basal levels of VDR in comparison to VDR target 
genes. This may reflect the inability of these cells to respond to VDR in the presence of 
ligand. 
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 Studies have demonstrated that an epigenetic lesion within malignant disease 
contributes to loss of VDR sensitivity [129]. In particular, deregulated NCOR1 has been 
shown to play are role in this process [176].  
From the data herein it is proposed that the prostate VDR network contains an 
incoherent feedforward loop (FFL) that modulates the expression of CDKN1A mRNA. 
Activation of VDR directly induces CDKN1A expression, in addition there is activation 
of MiR106B that is able to target and degrade the CDKN1A message thus producing an 
incoherent FFL.  
Both coherent and incoherant FFLs have been implicated in temporal waves of 
response [220] and serve to regulate the level of mRNA output modulating signal 
strength and preventing inappropriate mRNA accumulation whilst at the same time 
permitting accumulation of message at levels greater than background noise.  However, 
we observe that malignancy renders the prostate cells selectively unresponsive to VDR 
ligand mediated activation.  The presence of 1α,25(OH)2D3 in PC-3 cells does not 
activate the CDKN1A response but does activate MCM7 and MiR106B (although there is 
observable change in magnitude and timing). This suggests that the present incoherent 
FFL becomes altered in disease allowing accumulation of the CDKN1A repressive 
element whilst impeding the CDKN1A activating element. Such selective aberrance is not 
uncommon in cancer and has been observed in other FFLs of both a coherent [221] and 
incoherent [222] nature. 
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Figure	   5.18	   Incoherent	   feedforward	   loop	   (IFFL)	   implemented	   by	   VDR	  
activation	  becomes	  deregulated	  in	  cancer	  models.	  Demonstrated	  above	  in	  non-­‐transformed	  cells	  VDR	  activation	  stimulates	  CDKN1A	  but	   in	  combination	  is	  able	  to	  indirectly	  decrease	  p21(waf1/cip1)	  	  levels	  through	  MiR-­‐106B	  induction.	  Deregulation	  of	  the	   IFFL	   in	   prostate	   cancer	   models	   is	   shown	   only	   at	   the	   direct	   level,	   indirect	  regulation	  by	  MiR106B	  induction	  remains	  unaltered.	  	  
 
Of further interest is the deregulation of MCM7 at the protein level observed in 
the malignant disease model, VDR ligand was successful at inducing the degradation of 
the MCM7 protein levels not previously observed (however, the molecular mechanism 
behind this response is unclear). However, in disease the effect of VDR activation upon 
MCM7 level is not replicated and MCM7 levels were sustained. 
Members of the MCM family have been demonstrated previously to be targeted 
and degraded by the MiR-1296 [223], in addition it has been shown that the miRNA 
MiR-1296 is lost in CaP. Therefore, it is hypothesised that during CaP development the 
cell loses the ability to express MiR-1296 resulting in aberrant and sustained activation of 
MCM7. This demonstrates another level of transcriptional deregulation present in 
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malignant disease. Additionally, the MiR-1296 sequence is located on chromosome 10 
within the second intron of the histone demethylase JMJD1c (originally named TRIP8) 
suggesting that activation of VDR is responsible for up-regulation of both a histone 
modifying demethylase and a microRNA. Upon validation this would exemplify the 
existence of another incoherent feedforward loop that becomes deregulated in CaP.  
 This study found detectable levels of MiR106b present within the serum samples 
from TRAMP model mice. Furthermore, the study demonstrated elevated levels of 
MiR106B present in CaP serum samples. Current screening for prostate cancer utilises 
the expression levels of PSA that are linked to androgen receptor levels. Indeed, since the 
introduction of the PSA test 25 million are performed yearly in the USA [224]. Current 
guidelines state a PSA concentration of greater than 4.0ng/ml indicates the presence of 
cancer. However, there are many reported cases of prostate cancer occurring in patients 
with a PSA lower than the 4.0ng/ml cut off limit. Therefore, it is clear that whilst the PSA 
test has produced an increase in the levels of detection of prostate cancer, it is unable to 
distinguish between associated prostatic conditions such as benign prostate hyperplasia 
(BPH) and prostatic inflammation. The search for new biomarkers of prostate cancer is 
continuing with any potential serum biomarkers being of great value. Elevation of 
MiR106B in comparison to normal serum samples in TRAMP mice indicates that this 
miRNA is released into the serum and may be a new novel biomarker of prostate cancer 
pathology. In order to validate this finding further, serum samples from humans with 
differing grades of prostate cancer development should be assessed for their MiR106B 
content. 
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6.1 Introduction 
 Investigations into the mechanisms of inappropriate gene repression have 
demonstrated that epigenetic lesions are induced by elevated recruitment of CoRs and 
HDACs to target gene promoters [131]. Using RWPE-1 and PC-3 cells the following 
investigation examined how ligand stimulation of VDR governs the recruitment of 
nuclear corepressors (NCOR1, NCOR2/SMRT) and activated polymerase II 
(phosphorylated polymerase II) to the promoter of CDKN1A. Previous publications have 
focused on the significant role of the CoRs, and both NCOR1 and NCOR2/SMRT can 
interact with VDR to negatively regulate transcriptional responses [225, 226]. 
Specifically, CaP cells have been demonstrated to upregulate the expression and activity 
of the NCOR1 and NCOR2/SMRT proteins [213] that contribute to transcription 
silencing.  
 Analysis to examine the extent of CoR release and recapture by the VDR has not 
yet been conducted. Also not fully elucidated are the levels of preference (if any) that the 
VDR demonstrates either towards NCOR1 or NCOR2/SMRT. Earlier investigations 
indicate that the VDR uses both NCOR1 and NCOR2/SMRT to modulate of mRNA 
production. Repression of transcriptional response through the interaction of corepressors 
may produce variations in mRNA kinetics. Therefore, it was hypothesised that their 
analysis may reveal the rate of interaction of NRs with CoRs and how they work in 
tandem with epigenetic marks to facilitate polymerase activation. In addition to this the 
binding status of the same elements in the malignant prostate cell line PC-3 was also 
investigated. This may allow identification of molecular deregulations present in ADT-R 
forms of CaP.  
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6.2 Results 
6.2.1 Re-ChIP in RWPE-1 cells to reveal VDR-CoR interactions. 
 To understand how corepressors influence the action of 1α25(OH)2D3 treated 
VDR in normal prostate environment re-chip studies were conducted. In response to 
ligand activation VDR bound NCOR1 and VDR bound NCOR2/SMRT were 
immunoprecipitated to examine the role of corepressor recapture and release upon 
CDKN1A transcription. Measurement of VDR in the presence of NCOR1 unveiled 
significant release of this CoR at each response element and the TSS 0.5 hours post 
treatment in comparison to vehicle only controls (VDRE-3 0.191 ± 0.058 SEM, VDRE-2 
0.317 ±0.137 SEM, VDRE-1 0.273 ±0.092 and TSS 0.156 ± 0.081 SEM) (Figure 6.1). 
These events occurred at 1 and 4 hours post 1α,25(OH)2D3 (100nm) exposure.  VDRE-2 
showed a 3.199 fold change (±0.659 SEM) in NCOR1 bound VDR at 1 hour and 3.971 
(±0.804 SEM) at 4 hours. These indicated significant enrichment of NCOR1 associating 
with the ligand activated VDR at 1 and 4 hours at VDRE-2. There was no statistically 
significant change in the level of NCOR2/SMRT associated with VDR. However, there 
were trends shown at VDRE-2 at 0.5, 1 and 4 hours treatment. In addition there were 
increases in the level of NCOR2/SMRT found bound to VDR at the TSS at 4 and 12 
hours, suggesting some recruitment for this CoR. Thus, as found previously VDR can 
interact with both NCOR1 and NCOR2/SMRT. However, here it has been demonstrated 
that ligand stimulation produced significant shifts in the enrichment of VDR bound to 
NCOR1. These data therefore suggest that NCOR1 holds a greater influence over VDR 
target gene regulation than NCOR2/SMRT.  
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Figure	   6.1	   Interactions	   of	   VDR	   with	   transcriptional	   corepressors	   on	   the	  
CDKN1A	  gene	  promoter.	  RWPE-­‐1	  cells	  were	  treated	  with	  1α,25(OH)2D3	  (100nm)	  for	  0.5,	  1,	  4	  or	  12	  hours,	   chromatin	  was	  extracted	  and	  subject	   to	  Re-­‐Chip	  analysis	  with	  either	  VDR	  and	  NCOR1	  antibodies	  or	  VDR	  and	  SMRT	  antibodies.	  Levels	  of	  DNA	  recovered	  from	  the	  sequential	  ChIP	  experiments	  at	  the	  VDREs	  and	  TSS	  of	  CDKN1A	  were	  analysed.	  Data	  was	  normalized	  and	  calculated	  as	  fold	  enrichment	  over	   input.	  Experiments	   were	   performed	   on	   three	   independent	   occasions	   and	   statistical	  significance	   was	   assessed	   using	   t-­‐test	   analysis.	   *=p-­‐value	   0.05,	   **=p-­‐value	   0.01,	  ***=p-­‐value	  0.001.	  
VDR-NCOR1 
VDR-NCOR2/SMRT 
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6.2.2 VDR regulated binding events on the CDKN1A promoter in 
RWPE-1 and PC-3 cells. 
Current consensus on the procedure of gene transcription is that it is a highly 
dynamic process conducted by numerous interacting factors. To help reveal how factors 
interact with a single gene upon transcriptional activation, recruitment of VDR, NCOR1 
and phosphorylated polymerase 2 (p-POL II) was measured for their presence at the 
CDKN1A promoter and TSS in RWPE-1 cells. Additionally, to identify deregulation 
contributing to transcriptional resistance exhibited in ADT-R CaP PC-3 cells were 
analysed for their CDKN1A recruitment dynamics and compared to the RWPE-1 
findings.   
  The response element most distal from the CDKN1A TSS is located -7056 to  
-7036 base pairs upstream VDRE3 (Figure 1.15). Examination by xChIP suggested a 
higher level of VDR enrichment within RWPE-1 cells and significant increases over PC-
3 cells were measured at 2 and 12 hours post treatment (Figure 6.2). Generally there is a 
depletion of VDR binding at this VDRE demonstrating eviction of the VDR in PC-3 cells 
upon ligand addition. This is in opposition to the sustained levels measured in RWPE-1 
cells. NCOR1 association at this region indicates that there was CoR depletion of the 
RWPE-1 cells, with a sustained level of NCOR1 in the PC-3 cells. There was clear early 
enrichment in both cell types (0.25 hours for RWPE-1 and 0.50 hours for PC-3 cells) of 
CoR. However this was followed a protracted loss in levels that was greater in the 
RWPE-1 cells again demonstrating elevated CoR presence in PC-3. There were no 
significant changes in the level of phosphorylated polymerase 2 recorded in either cell 
line. This indicated that transcriptional machinery has limited role upon gene activity at 
this distal location.  
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Figure	   6.2	   Recruitment	   and	   loss	   of	   factors	   at	   VDRE3.	   RWPE-­‐1	   and	   PC-­‐3	   cells	  were	   plated	   at	   1x107	   and	   5x106	   cells	   per	   flask	   respectively.	   Treatment	   was	   with	  1α,25(OH)2D3	  (100nm)	  for	  the	  described	  time	  periods.	  Crosslinked	  chromatin	  was	  harvested	  and	  sonicated	  to	  an	  average	  of	  500bp	  in	  length.	  Specific	  antibodies	  were	  used	  to	  pull	  down	  proteins	  bound	  to	  DNA.	  Levels	  of	  immunoprecipitated	  DNA	  were	  measured	  using	  Q-­‐RT-­‐PCR.	  Data	  was	  normalized	   and	   calculate	   as	   fold	   enrichment	  over	   input.	   Bars	   indicate	   the	   mean	   of	   at	   least	   three	   independent	   experiments	  analysed	  in	  triplicate	  PCR	  well	  ±	  SEM.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	  
Chapter 6 VDR governed control of gene transcription and epigenetic components within CDKN1A  
 
166 
Figure 6.3 shows the data from the VDRE located -4505 to -4489 base pairs 
upstream of the CDKN1A TSS. These data indicate there was accumulation of NCOR1 at 
specific times post treatment. Furthermore, NCOR1 was found to become significantly 
enriched in the PC-3 cells at 0.5 hours. This supports the hypothesis that aberrant 
corepressor recruitment may act as a molecular brake upon transcriptional activation. 
Levels of VDR and p-POL II enrichment between the two cell lines showed little 
significant variation. Only enrichment of VDR at 1 hour was shown in RWPE-1 cells 
indicating some activity at this region. Taking into consideration the histone modification 
changes occurring upon VDR activation revealed parallel epigenetic regulation. The 
enrichment of VDR shown at 0.5 and 1 hour not only occurred with a release of NCOR1 
but also correlated to increases in H3K9ac and depletion of the repressive H3K9me2 
mark. However, the modifications at H3K9 reverted back to a repressive signature by 1 
hour (Figure 1.18). This suggests a tightly controlled response to ligand addition 
programmed to activate transcription.  
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Figure	  6.3	  Recruitment	  and	  loss	  of	  factors	  at	  the	  VDRE2.	  RWPE-­‐1	  and	  PC-­‐3	  cells	  were	   plated	   at	   1x107	   and	   5x106	   cells	   per	   flask	   respectively.	   Treatment	   was	   with	  1α,25(OH)2D3	  (100nm)	  for	  the	  described	  time	  periods.	  Crosslinked	  chromatin	  was	  harvested	  and	  sonicated	  to	  an	  average	  of	  500bp	  in	  length.	  Specific	  antibodies	  were	  used	  to	  pull	  down	  proteins	  bound	  to	  DNA.	  Levels	  of	  immunoprecipitated	  DNA	  were	  measured	  using	  Q-­‐RT-­‐PCR.	  Data	  was	  normalized	   and	   calculate	   as	   fold	   enrichment	  over	   input.	   Bars	   indicate	   the	   mean	   of	   at	   least	   three	   independent	   experiments	  analysed	  in	  triplicate	  PCR	  well	  ±	  SEM.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	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Located 2146–2129 base pairs upstream of the CDKN1A TSS is a VDRE (VDRE1). 
Binding characteristics in both RWPE-1 and PC-3 cells at this functioning VDRE were 
measured in response to ligand and are shown in Figure 6.4.  
 VDR enrichment at VDRE1 was demonstrated to be more persistent in RWPE-1 
cells with significantly higher levels at 1 and 24 hours in comparison to PC-3 cells. These 
data suggest a depletion of VDR presence in PC-3 cells. Measurement of NCOR1 activity 
showed no statistically significant difference between the two cell lines. However, there 
was an upward trend of NCOR1 within PC-3 cells at 4 and 6 hours suggesting a role in 
‘late’ transcriptional events. Accumulation of p-POL II was highly active in the RWPE-1 
cells and is significantly elevated above PC-3 cells. This was consistent with the regions 
proximity to the TSS of an active gene in comparison the CDKN1A in PC-3 cells 
demonstrated not to be activated by VDR stimulation. Analysis using phosphorylated 
POL II antibody serves as an indication for transcriptional activity, and p-POL II levels 
were significantly enriched in RWPE-1 cells compared to PC-3 cells. This finding alludes 
to the lack of transcriptional response in malignant cells, prevention of VDR recruitment 
to this region inturn impacts upon the enrichment of p-POL II.  
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Figure	  6.4	  Recruitment	  and	  loss	  of	  factors	  at	  the	  VDRE1.	  RWPE-­‐1	  and	  PC-­‐3	  cells	  were	   plated	   at	   1x107	   and	   5x106	   cells	   per	   flask	   respectively.	   Treatment	   was	   with	  1α,25(OH)2D3	  (100nm)	  for	  the	  described	  time	  periods.	  Crosslinked	  chromatin	  was	  harvested	  and	  sonicated	  to	  an	  average	  of	  500bp	  in	  length.	  Specific	  antibodies	  were	  used	  to	  pull	  down	  proteins	  bound	  to	  DNA.	  Levels	  of	  immunoprecipitated	  DNA	  were	  measured	  using	  Q-­‐RT-­‐PCR.	  Data	  was	  normalized	   and	   calculate	   as	   fold	   enrichment	  over	   input.	   Bars	   indicate	   the	   mean	   of	   at	   least	   three	   independent	   experiments	  analysed	  in	  triplicate	  PCR	  well	  ±	  SEM.	  *=p-­‐value	  0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	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Recruitment at the CDKN1A TSS is shown in Figure 6.5. VDR binding at the TSS 
showed significant enrichment in RWPE-1 cells at 0.75 hours (1.75 fold change ±0.21 
SEM) when compared to PC-3 cells (0.30 fold change ±0.04 SEM).  
Furthermore, PC-3 cells demonstrated an elevation of NCOR1 levels to the 
CDKN1A TSS in response to VDR activation. This is in contrast to RWPE-1 cells, which 
show a rapid depletion of NCOR1 upon VDR activation. These become statistically 
significant at 0.75, 1, 4, 6 and 24 hours suggesting that VDR in untransformed prostate 
epithelial cells are able to release NCOR1 upon ligand binding. Moreover, these data also 
suggest that this becomes corrupt in malignancy preventing the release of NCOR1 from 
the TSS. The analysis of p-POL II levels indicates PC-3 cells show enrichment greater 
than RWPE-1 cells with significant accumulations measured at 0.75 and 2 hours post 
treatment.      
 Taken together, the xChIP analysis confirms that RWPE-1 and PC-3 cells exhibit 
differential recruitment of factors to the VDREs encoded within the CDKN1A promoter. 
Furthermore, the enrichment of the factors observed varied in a time dependent fashion 
and each region demonstrates individual binding patterns of VDR, NCOR1 and p-POL II. 
This establishment of recruitment and loss of these factors in non-transformed cell lines 
provides integral understanding of the mechanisms behind transcriptional activation. For 
example,	   1α,25(OH)2D3 treatment induced depletion of NCOR1 from the TSS, 
presumably to allow CoA recruitment. An additional key finding shown at the TSS the 
persistent NCOR1 levels at the TSS in PC-3 cells in contrast to the accumulation of p-
POL II.    
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Figure	  6.5.	   	  Recruitment	  and	   loss	  of	   factors	  at	   the	  CDKN1A	   transcription	   start	  
site	   (TSS).	  RWPE-­‐1	   and	  PC-­‐3	   cells	  were	   plated	   at	   1x107	   and	  5x106	   cells	   per	   flask	  respectively.	   Treatment	   was	   with	   1α,25(OH)2D3	   (100nm)	   for	   the	   described	   time	  periods.	  Crosslinked	  chromatin	  was	  harvested	  and	  sonicated	  to	  an	  average	  of	  500bp	  in	  length.	  Specific	  antibodies	  were	  used	  to	  pull	  down	  proteins	  bound	  to	  DNA.	  Levels	  of	  immunoprecipitated	  DNA	  were	  measured	  using	  Q-­‐RT-­‐PCR.	  Data	  was	  normalized	  and	  calculate	  as	  fold	  enrichment	  over	  input.	  Bars	  indicate	  the	  mean	  of	  at	  least	  three	  independent	   experiments	   analysed	   in	   triplicate	   PCR	   well	   ±	   SEM.	   *=p-­‐value	   0.05,	  **=p-­‐value	  0.01,	  ***=p-­‐value	  0.001.	  
Chapter 6 VDR governed control of gene transcription and epigenetic components within CDKN1A  
 
172 
6.3 Discussion 
 These data established that the VDR target gene CDKN1A exhibits fluctuations in 
the dynamics of NR and CoR exchanges that occur in a unique manner at each response 
element. These changes have been reflected further by the recently demonstrated 
chromatin looping of these VDREs toward the CDKN1A TSS [126]. 
As previously discussed this laboratory and others have purported NCOR1 as the 
pertinent corepressor in VDR mediated target gene regulation [129, 131, 227].  However, 
the importance of NCOR2/SMRT within VDR activation until now had not been fully 
investigated. To address this Re-ChIP analysis of VDR bound with NCOR2/SMRT and 
VDR bound with NCOR1 was conducted. Analysis by Re-ChIP demonstrated that VDR 
favorably interacts with NCOR1 in preference to NCOR2/SMRT (Figure 6.1). The 
significant release of NCOR1 observed at 0.5 hours from VDR also suggests this may be 
a major contributor early mRNA peak observed in Chapter 1 Figure 1.16. Furthermore, 
an increased level of NCOR1 associated with VDR at the VDRE1 at 1 and 4 hours and 
this may serve to temper the transcriptional output of the CDKN1A gene. Therefore, this 
demonstrated this VDRE to have a specific role in the transcriptional regulation of 
CDKN1A.  
Through xChIP analysis of the CDKN1A promoter it was found that RWPE-1 
cells recruit VDR to the TSS upon ligand activation. In addition TSS bound VDR was 
found to be depleted for NCOR1 in a time dependent manner. This loss of CoR is in 
corroboration with the classical view of transcriptional studies and a reduction in NCOR1 
indicates there may be enrichment of CoAs (such as CBP, SRC and TRAP220 which 
have been previously shown to become enriched at the CDKN1A VDREs [75]). 
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Concordant with these findings there is a general increase in the levels of p-POL II at the 
TSS emphasising transcriptional activation.  
Characterisation of the binding patterns in RWPE-1 at the VDREs showed 
individual accumulation and loss patterns isolated to each region. It is hypothesised that 
each region contributes through DNA bound VDR looping of the response element to the 
TSS (Reviewed in [228, 229]). These events can occur regardless of their physical 
proximity and investigations conducted that show the looping of VDREs to exhibit an 
irregular cyclical quality [126].  
Therefore, it is postulated that cyclical looping of VDREs to the CDKN1A TSS 
maybe reflected by the recruitment of VDR, coeffectors and phosphorylation of 
Polymerase II in order to drive transcriptional activation. This yields a specific mRNA 
profile characteristic of the gene’s VDREs and epigenetic status. 
The altered VDR target gene expression patterns in Chapter 5 were reflected by 
changes in the patterns of NCOR1 recruitment in RWPE-1 and PC-3 cells. Also both 
CoRs associate on the CDKN1A promoter in a highly dynamic manner in response to 
VDR activation, however, only NCOR1 was able to show statistical significance. These 
data also show NCOR1 clearly associated on the CDKN1A promoter in PC-3 in a more 
dominant manner in comparison to RWPE-1 cells. Thus, instead of inducing co-repressor 
release, NCOR1 was actively enriched at all three response elements and reflected the 
transcriptional repression. The molecular mechanisms behind vitamin D insensitivity in 
PC-3 cells in Chapter 5 is not fully clear. This study finds in PC-3 cells there are 
differential recruitment patterns most notably resulting in accumulation of NCOR1 at the 
TSS. This represents deregulation of the switch model leading to corepressor/activator 
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exchange [230]. In PC-3 cells there is an inability of VDR to release the NCOR1 leading 
to maintenance of transcriptional status, preventing activation. Future studies should be 
conducted into the molecular basis regulating NCOR1 binding, including its ubiquination 
that governs its clearance from ligand bound NR complexes [231].  
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 Identifying the mechanisms behind dietary and hormone signaling and their 
impact upon cancer progression is an important goal of research. Nuclear receptors 
respond directly and indirectly to modulate target gene expression producing essential 
physiological process such as differentiation and cellular growth. However, their activity 
appears impeded in various malignancies. Furthermore, this NR resistance is heavily 
implicated within breast and prostate cancer progression (reviewed by [232]).   
7.1 Pre-receptor regulation of NR activity in ADT-R CaP. 
 Prereceptor ligand metabolism has been previously demonstrated as an important 
factor in the regulation of nuclear receptor activity. Networks of signaling pathways can 
therefore influence the levels of NR ligand available to the receptor. During progression, 
CaP cells acquire the ability to upregulate the formation of AKR1C3 [233]. This enzyme 
is able to convert the naturally occurring ligand for PPARγ into a compound with pro-
growth effects of PGF2, thus hypothetically depriving the anti-proliferative pathways 
normally activated by PPARγ. This study attempted to restore the actions of this anti-
tumourigenic nuclear receptor through reduction in the levels of AKR1C3. This may 
increase the levels of ligand available for PPARγ activation. Such experiments have 
previously shown knocking down AKR1C3 has proved successful in various leukemic 
and breast cell lines [185, 234]. Therefore, this investigation used PC-3 and DU 145 
(both models of ADT-R disease) and found that reducing the levels of AKR1C3 and co-
treatment with PGD2 and SAHA was unable to restore activation of this NR. To address 
these findings further it is suggested that interventionist studies of the following nature 
should be conducted; Upregulation of HAT enzymes may enhance the responsiveness 
shown by these results. It is hypothesized that exogenous exposure of HATs would aid 
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the placement of acetyl groups increasing expression. Knocking down AKR1C3 is shown 
to have a profound effect upon various elements important to transcriptional activation. 
These effects may be specific to ADT-R CaP cells and inhibiting any elevation in PPARγ 
activity. In addition quantification in the levels of PGJ2 being produced within 
shAKR1C3 cells would serve to verify increased presence of NR ligand. 
7.2 Elevated sirtuin levels produce aberrant HDAC activity 
 Insensitivity toward VDR and PPARγ ligands in CaP has been associated with 
increased CoR and HDAC expression. Furthermore, inhibition of HDACs has been 
demonstrated to enhance to responsiveness of NR ligands [184]. Here investigations 
found a member of the sirtuin family SIRT2 to be overexpressed in some but not all CaP 
cell lines. Thus, the hypothesis was formed that increased levels of SIRT2 led to targeting 
histone hypoacetylation, and repression of NR target gene expression. To test this 
RWPE-1 and PC-3 cell lines were exposed to a sirtuin inhibitor (Sirtinol) in an attempt to 
reduce levels of deacetylation. It was found PC-3 cells were resistant to the inhibitory 
effects of Sirtinol in comparison with RWPE-1 cells.  
 Previous work has also shown that knocking down NCOR1 reduced the ED50 of 
HDAC inhibitors needed to reduce PC-3 growth [184]. Therefore, it is suggested that NR 
target gene repression is maintained through CoRs. As there is minimal evidence for 
sirtuins interacting directly with the CoRs this possibility was explored through 
observation of NR target gene activity. Therefore, combined treatment of Sirtinol in 
conjunction with NR activation was performed. Addition of both VDR and PPARγ 
ligands in the presence of sirtinol were found to be unable to restore signaling of the 
nuclear receptors within the malignant cell environment. These findings indicate that 
Chapter 7                                                                                                              Conclusions and future work  
 
178 
although prostate cancer cells contain upregulated levels of SIRT2 these have limited 
significance upon the NR silencing response observed within the PC-3 cell line which is a 
model of prostate malignancy. 
7.3 VDR gene regulation within CaP progression 
 Regulation of genes in response to hormonal and dietary signals manifests from 
NRs, these activate networks of genes producing a physiological response. The VDR has 
been demonstrated to activate anti-tumourigeneic genes capable of slowing growth rates 
of cells. This work finds sub-sets of VDR regulated genes hold similarities in their 
pattern of expression independent of the physiological action they are associated with. 
This thesis, consistent with previous findings describes malignant metastatic prostate 
tumour cell lines to be insensitive to the biologically active form of vitamin D [235]. 
Several genes regulated by VDR in RWPE-1 cells become unresponsive in the PC-3 
malignant cell line. Furthermore, the disruption is also shown to be present in the 
isogenic RWPE-2 cell line suggesting that deregulation occurs prior to ADT-R in NR 
activity. This study also demonstrated that the regulation of VDR regulated genes is 
highly dynamic and the magnitude of target gene expression varies in timing and 
magnitude. Furthermore, these genes can be grouped according to the kinetics and level 
of transcriptional response to 1α,25(OH)2D3.  
 During cancer development cells become increasingly aggressive in their growth 
characteristics and develop insensitivity to the vitamin D ligand. Insensitivity is shown in 
Chapter 5 of this work with PC-3 cells unable to be regulated by the nuclear receptor 
VDR. In accordance with this the basal levels of the VDR in PC-3 cells become altered. 
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Levels of VDR expression is lost in correlation to its target genes, this reflects the ability 
of VDR to exert its actions in cells which have become transformed.  
 The incoherent feedforward reponse observed within VDR-MCM7 signalling 
contains a microRNA (MiR106b) whose activity becomes disrupted in cancer. Therefore, 
it is evident that selective upregulation of the MCM7 promoter provides a growth 
advantage to the transformed cell. Not only does the proliferative MCM7 protein become 
upregulated but also the miR106b that targets CDKN1A transcript becomes upregulated. 
Similar deregulations of microRNAs in CaP are common (reviewed in [236]), the 
microRNA identified here not only is regulated by VDR but also targets a VDR target 
gene essential to growth control for degradation. Therefore, the hypothesis is put forward 
that MiR106b is a proto-oncogene capable of indicating the VDR resistant status of CaP. 
In relation, strong evidence is now emerging that microRNA expression of tumours are 
related to their levels of serum expression [237]. This makes them an exciting potential 
biomarker for the responses which they are involved in. To continue this work it is 
suggested that the serum analysis of human patients with various stages of prostate 
disease should be analysed and compared alongside normal control groups. The nature 
and consequence of the elevated MCM7 protein levels observed in malignancy are not 
clear. The hypothesis that increased MCM7 directly contributes in increased DNA 
replication of these cells needs to be further examined. In parallel the mechanism by 
which 1α,25(OH)2D3 is able to profoundly downregulate MCM7 protein levels in 
RWPE-1 and the loss of this in PC-3 needs deeper analysis.  
 Furthermore, previous evidence has suggested that the elevated expression of 
CoR and their increased deacetylation effect is able to selectively target specific genes. 
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For example partial correlation analysis showed NCOR1, PPARγ, C/EBPα, PTGS2 and 
ALOX5 cluster together separately from NCOR2/SMRT, AR and CDH1 [184]. This 
reveals that each CoR plays distinct roles in gene regulation for different subsets of target 
genes.  
7.4 Regulation of CDKN1A transcription 
 
 Within the VDR network the nuclear corepressor NCOR1 has been shown to be a 
key regulator of transcriptional repression. Furthermore, previous studies have shown 
various cancer cells lines and tissues to contain elevated levels of corepressors [184]. 
ReChIP analysis in this work demonstrated that VDR bound to the CDKN1A gene 
promoter contains either NCOR1 or NCOR2/SMRT. This is in line with previous 
findings that have shown inducible knockdown models of NCOR1 to increase NR 
mediated gene expression [184]. However, not shown previously was the level of 
interaction over time in response to ligand. Additionally, although ADT-R CaP disease 
shows elevated CoR levels, examination of NCOR1 and NCOR2/SMRT activity at bound 
NRs within non-transformed cells has not been studied. This thesis reveals that 
fluctuations occur in the levels of NCOR1 and NCOR2/SMRT bound to VDR upon 
ligand stimulation. However, these changes only become significantly altered when 
measuring the VDR-NCOR1 levels. Such findings show that although VDR-
NCOR2/SMRT is present at the CDKN1A VDREs and TSS they appear to play a 
minimal role in regulating transcription. The level of VDR-NCOR1 interaction is has 
been demonstrated to dramatically change over time. The rapid decrease in NCOR1 
levels associated with VDR demonstrates a coordinated release of this CoR. Furthermore, 
there is recruitment of NCOR1 occurring over the later timepoints (4 and 12 hours). This 
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finding provides further evidence of NCOR1 being preferentially recruited by VDR. The 
continuity of this response between isoforms of both NCOR1 and NCOR2/SMRT is not 
known. As the affinity exhibited toward them by VDR may alter. Truncations in the 
receptor interacting domains of these CoRs may produce differing levels of activity not 
yet investigated.  
 Epigenetic inheritance indicates that there maybe transmission of gene regulatory 
information through placement of histone modifications from one generation of cell to 
the next [238]. However, not all marks contribute to such a cellular memory and it has 
become apparent that some marks may be used for short-term regulation of a genes 
transcription. Thus, aberrant epigenetic marks or their absence can lead to a disease state 
through aberrant gene expression or repression [239] Such modifications to the histone 
tails can regulate the extent of access transcription factors have the DNA by increasing or 
decreasing the level of chromatin compaction. However, in addition, histone marks have 
also been shown to have the ability to ‘flag’ specific DNA sequences. For example H3K4 
monomethylation has been demonstrated to mark enhancer regions and H3K4 tri-
methylation associated with enhancers and TSS [240]. This indicates the potential 
existence of an ‘epigenomic map’ with levels of various histone marks being used to 
indicate the presence of specific regions coded within the genome. These marks can be 
used to recruit transcriptionaly repressive regulators such as HDACs.  
 As part of this investigation the well-studied CDKN1A gene was examined for 
responses mediated by the VDR ligand dependent transcription factor. These data show 
upon treatment with 1α,25(OH)2D3 there was depletion and enrichment of the NR at the 
response elements encoded within its promoter. In addition the pattern of response 
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observed differed at each response element. The CDKN1A transcription start site also 
showed high levels of VDR interaction and was consistent with of high levels of 
chromatin looping from VDREs to the TSS. These effects were measured over a 
prolonged time period in order to obtain an extended view of the transcriptional 
activation process. Chromatin immunoprecipitation gives a snapshot of interactions on a 
scale of minutes. This helps monitor the measurement of stochastic interactions that have 
also been previously shown to occur in transcription factors including the GR receptor 
and NF-kB [241, 242]. Analysis of CDKN1A mRNA over the same time periods yielded 
a fluctuating profile of transcription, of particular interest it the early peak of production 
after 0.5 hours 1α,25(OH)2D3 (100nm) stimulation. This was shown to be a productive to 
a protein level and examination of the xChIP data suggested that a loss of NCOR1 from 
the CDKN1A TSS may be an important factor in the rapidity of the mRNA transcription. 
This was further supported by the accumulation of NCOR1 at the CDKN1A TSS in PC-3 
cells. Thus aberrant accumulation of CoRs at TSS may be a key change acquired by 
cancer cells to attain insensitivity to nuclear receptor transcription.  
 Future studies should be focused on establishing the nature of NCOR1 bound 
complex recruitment to the CDKN1A TSS. Particular attention should be paid to the 
ubiquitination mechanisms that mediate corepressor release from NR heterodimers such 
as the examination of the transducin β-like1 (TBL1) transducin β-like related 1 (TBLR1) 
proteins responsible for the recruitment of the 19s proteosome that induces release and 
degradation of NCOR1. Phosphorylation of the TBL1 and TBLR1 has been demonstrated 
to modulate their actions toward CoRs [243]. Therefore, inhibition of this post-
translational modification may prevent the molecular activity of the TBL1 and TBLR1. 
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Consequently, it is hypothesized that foci of deregulated/impaired TBL1 and/or TBLR1 
activity, whose placement is dictated by specific histone marks, may permit the 
accumulation of CoR at a normally transcriptionally active region. It is also suggested 
that such marks may include those indicating transcription start sites such as the H3K9ac 
and H3K4me3, increased presence of these marks may hold dual consequences for the 
cell. In non-transformed cells they indicate TSS positions and active chromatin. 
However, in malignancy their position may remain but additional deregulations such as 
impaired TBL1 and TBLR1 activity may exist.  Such investigations may reveal how 
epigenetic modifications can contribute to the activity of NRs and importantly how their 
deregulation impacts upon NR target gene expression. In the future these investigations 
will be used to design new therapeutic compounds capable of specifically targeting 
aberrantly placed histone modifications or the enzymes responsible for their placement or 
‘reading’.  
Collectively these data suggest there are progressive epigenetic distortions to NR 
signaling in CaP. NCOR1 levels are elevated, and preferentially change in response to 
VDR activation. In addition it is increasingly recruited to target gene promoters in 
response to VDR ligand presence. The net result of increased NCOR1 and 
NCOR2/SMRT association at VDR target genes is the loss of H3K9ac and accumulation 
of H3K9me2. In turn this epigenetic mark is recognised by the CpG methylation 
machinery and allows for the potential for DNA methylation at adjacent CpG regions for 
example through the recruitment of DNMT associated complexes include 
heterochromatin binding protein 1 (HP1)[244] (reviewed in [245]). Further links exist 
between NCOR1 and DNA methylation through its interaction with KAISO, to regulate 
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DNA methylation [246]. Jointly this elevation of CoR action thereby converts a transient 
epigenetic silencing process that is part of the normal NR-transcriptional cycle into a 
stable and heritable event. In this manner the ability of the VDR to regulate key anti-
proliferative target genes is altered into a process that leads to their the stable silencing. 
As a consequence this may release the burden for elevated NCOR1 and NCOR2/SMRT 
requirement.  
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 Section A: Full list of genes contain on the 
microfluidic gene card.  
Gene Symbol Common name Function 
ABCA1 ABCA1 ATP-binding cassette (ABC) transporter 
ABCB8 ABCB8 ATP-binding cassette (ABC) transporter 
ABCC3 ABCC3 ATP-binding cassette (ABC) transporter 
ABCG2 ABCG2 ATP-binding cassette (ABC) transporter 
ACADM ACADM Oxidoreductase 
AKR1C1/2 AKR1C1/2 Oxidoreductase 
AKR1C3 AKR1C3 Oxidoreductase 
ALOX5 ALOX5 Oxidoreductase 
AOF2 LSD1/KIAA Oxidoreductase 
APOA1 APOA1 Transfer/carrier protein 
AR AR Nuclear hormone receptor 
BAX BAX Apoptotic regulator 
CARM1 CARM Methyltransferase 
CASP4 CASP4 Cysteine protease 
CCNB1 Cyclin B1 Kinase modulator 
CCND1 Cyclin D1 Kinase modulator 
CCNE1 Cyclin E1 Kinase modulator 
CDC2 CDC2 Serine/threonine protein kinase 
CDH1 Arc-1/CDH1 Cell adhesion molecule 
CDK5 CDK5 Serine/threonine protein kinase 
CDKN1A p21/cip/waf Kinase modulator 
CDKN1B p27 Kinase modulator 
CDKN2A p16 Kinase modulator 
CEBPA C/EBPa Transcription factor 
COPS2 ALIEN/TRIP15 Transcription factor corepressor 
CREBBP CREBBP Transcription cofactor 
CRSP2 DRIP150/TRAP170 Transcription factor 
CRSP6 TRAP80/DRIP80 Transcription factor 
CYP24A1 Cyp24 Oxidoreductase 
CYP27B1 Cyp27 Oxidoreductase 
CYP3A4 Cyp3A4 Oxidoreductase 
EGFR EGFR Tyrosine protein kinase receptor 
ESR1 ESR1 Nuclear hormone receptor 
ESR2 ESR2 Nuclear hormone receptor 
G0S2 G0S2 Cell cycle regulator 
GADD45A GADD45a Cell cycle regulator 
GATA3 GATA3 Zinc finger transcription factor 
HDAC1 HDAC1 Histone Deacetylase 
HDAC10 HDAC10 Histone Deacetylase 
HDAC2 HDAC2 Histone Deacetylase 
HDAC3 HDAC3 Histone Deacetylase 
HDAC4 HDAC4 Histone Deacetylase 
HDAC5 HDAC5 Histone Deacetylase 
HDAC6 HDAC6 Histone Deacetylase 
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HDAC7A HDAC7 Hydrolase,Deacetylase 
ID1 ID1 Transcription factor 
IGFBP1 IGFBP1 Growth factor binding protein 
IGFBP3 IGFBP3 Growth factor binding protein 
IGFBP5 IGFBP5 Growth factor binding protein 
IKBKB IKKB Protein kinase 
IKBKG IKKG Protein kinase 
MAPK4 MAPK4 Non-receptor serine/threonine protein kinase 
MAPKAPK2 MAPKAP2 Protein kinase 
MAPKAPK5 MAPKAPK5 Protein kinase 
MYB MYB Other transcription factor 
NCOA1 NCoA1/RIP160 Transcription cofactor 
NCOA2 NCo-A2 Transcription factor,Transcription cofactor 
NCOA3 NCOA3 Transcription factor,Transcription cofactor 
NCOA4 NCoA4 Transcription factor,Transcription cofactor 
NCOR1 NCOR1 Transcription factor corepressor 
NCOR2 SMRT/NCOR2 Transcription factor corepressor 
NR0B1 DAX1 Nuclear hormone receptor 
NR1H2 LXRb Nuclear hormone receptor 
NR1H3 LXRa Nuclear hormone receptor 
NR1H4 FXR Nuclear hormone receptor 
NR1I2 PXR Nuclear hormone receptor 
NR1I3 CAR Nuclear hormone receptor 
NR3C1 GR Nuclear hormone receptor 
PADI4 PADI4 Hydrolase 
PPARA PPARa Nuclear hormone receptor 
PPARBP DRIP/TRAP220 Transcription cofactor 
PPARD PPARd Nuclear hormone receptor 
PPARG PPARg Nuclear hormone receptor 
PPARGC1A PPARGC1 Transcription cofactor 
PTGS1 COX-1 Oxidoreductase 
PTGS2 COX-2 Oxidoreductase 
RARA RARa Nuclear hormone receptor 
RARB, RARb Nuclear hormone receptor 
RARG RARg Nuclear hormone receptor 
RBBP4 RBBP4 Chromatin-binding protein 
RXRA RXRa Nuclear hormone receptor 
RXRB RXRb Nuclear hormone receptor 
SET7 SET7/KIAA Chromatin-binding protein 
SIN3A SIN3A/KIAA Chromatin-binding protein 
SIRT2 SIRT2 Chromatin-binding protein 
SIRT6 SIRT6 Chromatin-binding protein 
SNAI1 SNAI1 Zinc finger transcription factor 
SULT2A1 SULT2A Transferase 
SUV39H1 SUV39A Chromatin-binding protein 
TGFB2 TGFB2 Growth factor 
TGIF TGIF Homeobox transcription factor 
THRB THRB Nuclear hormone receptor 
TP53 p53 Transcription factor 
VDR VDR Nuclear hormone receptor 
YY1 YY1 Zinc finger transcription factor 
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